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Summary  
Mast cells are well known effector cells in allergic disorders. In the recent years, however, 
mast cells were demonstrated to play pivotal roles in initiating and modulating innate and 
adaptive immune responses. The animal models available until today for the investigation 
of mast cell functions are primarily the Kit-mutant KitW/Wv and KitWsh/Wsh mouse strains. 
These mice are devoid of mast cells and can be reconstituted with mast cells from gene 
deficient mice. The phenotypic abnormalities, apart from mast cell deficiency, e.g. the 
profound perturbation of the hematopoietic system, however, limit the utility of these 
strains. Aiming at new models of mast cell-specific gene inactivation in vivo and of mast 
cell-deficiency, the Cre/loxP system was applied to allow Cre-mediated mutagenesis 
selectively in mast cells. BAC (bacterial artificial chromosome) transgenic animals were 
successfully generated that display Cre expression under the control of either the Mcpt5 
or Mcpt6 promoter. Cre-mediated recombination as assessed by reporter gene expression 
in Mcpt5-Cre or Mcpt6-Cre R26R-EYFP double positive mice was found to be highly 
efficient in peritoneal and skin mast cells, but was not found in hematopoietic cell 
populations other than mast cells. Thus, the new mast cell-specific Cre transgenic mouse 
lines will provide useful tools for the investigation of mast cell-specific functions of 
individual genes. 
Furthermore, the Mcpt5-Cre strain was used to establish a new model for inducible 
ablation of mast cells in adult mice. By crossing this line to the iDTR strain, which 
expresses the high affinity diphtheria toxin receptor (DTR) after Cre-mediated deletion of a 
stop element, mast cells were rendered diphtheria toxin (DT) sensitive. DT treatment of 
Mcpt5-Cre iDTR double positive mice resulted in successful ablation of connective tissue 
type mast cells (CTMC), but not of mucosal mast cells (MMC). The depletion of CTMC 
resulted in significant reduction of a passive, systemic anaphylactic response 
demonstrating that this system for mast cell ablation represents a useful model for the 
investigation of mast cell functions during immune responses. Interestingly, the 
repopulation of the peritoneal cavity and the skin with mast cells after DT-mediated mast 
cell depletion followed a very slow kinetic with a noteworthy recurrence of peritoneal mast 
cells three months after DT treatment. Skin mast cells do not return significantly within a 
period of four months. Thus, the long persistence of the mast cell-depleted state allows 
the application of this system for long-term experiments and should provide new insights 
into the mechanisms of mast cell homeostasis and recruitment.  
 
 
 
  
Zusammenfassung 
Mastzellen sind vor allem bekannt als Effektorzellen allergischer Erkrankungen. In den 
letzten Jahren wurde jedoch gezeigt, dass Mastzellen entscheidend zu der Mobilisierung 
und Modellierung von angeborenen und adaptiven Immunantworten beitragen. Die 
derzeitig verfügbaren Modelle für die in vivo-Analyse von Mastzellfunktionen, sind 
vorwiegend die Kit-mutierten, Mastzell-defizienten KitW/Wv und KitWsh/Wsh Mäuse, die mit in 
vitro differenzierten Mastzellen von Gen-defizienten Mäusen rekonstituiert werden 
können. Phänotypische Abnormitäten zusätzlich zu der Mastzell-Defizienz, z. B. 
Störungen des hämatopoietischen Systems, erschweren jedoch das Experimentieren und 
die Interpretation der Daten. Aus diesem Grund wurde hier das Cre/loxP-System 
herangezogen, um in vivo Gene gezielt in Mastzellen zu inaktivieren und um neue 
Modelle für Mastzell-Defizienz zu generieren. BAC (bacterial artificial chromosome) 
transgene Mauslinien wurden erfolgreich hergestellt, die die Cre-Rekombinase unter der 
Kontrolle des Mcpt5- bzw. Mcpt6-Promotors ausprägen. In Mcpt5-Cre bzw. Mcpt6-Cre 
R26R-EYFP doppelt positiven Mäusen konnte eine höchst effiziente, Cre-mediierte 
Rekombination in Mastzellen der Peritonealhöhle und der Haut, jedoch nicht in anderen 
Zellpopulationen, nachgewiesen werden. Die neuen Mastzell-spezifischen Cre-
transgenen Mauslinien werden daher in Zukunft die Untersuchung Mastzell-spezifischer 
Funktionen einzelner Gene erheblich erleichtern. 
Des Weiteren wurde die Mcpt5-Cre Linie für die Etablierung eines neuen Models für 
induzierbare Ablation von Mastzellen in vivo verwendet. Die Kreuzung dieser Linie mit 
dem iDTR Mausstamm, der den hoch affinen Diphtherietoxin Rezeptor (DTR) nach Cre-
mediierter Deletion eines Stop-Elements ausprägt, führt zu einer Sensibilisierung von 
Mastzellen gegenüber dem Diphtherietoxin (DT) in Mcpt5-Cre iDTR doppelt positiven 
Tieren. Die Behandlung mit DT resultierte in einer effizienten Depletion von Bindegewebs-
mastzellen (CTMC), jedoch nicht von mukosalen Mastzellen (MMC). Die Ablation der 
CTMC reichte aus, eine passive, systemische anaphylaktische Reaktion signifikant zu 
reduzieren, was demonstriert, dass das System der induzierbaren Mastzell-Ablation ein 
geeignetes Modell für die Erforschung von Mastzell-Funktionen darstellt. Interessanter-
weise folgte die Repopulation der Bauchhöhle und der Haut mit Mastzellen einer höchst 
langsamen Kinetik. Ein signifikanter Anstieg der Mastzell-Zahlen in der Bauchhöhle zeigte 
sich erst drei Monate nach Depletion. Eine deutliche Rückkehr der Hautmastzellen war 
auch nach vier Monaten noch nicht zu beobachten. Folglich erlaubt die langfristige 
Depletion der Mastzellen die Anwendung dieses Systems in Langzeitexperimenten und 
kann, des Weiteren, neue Einblicke in die Mechanismen der Homöostase und 
Rekrutierung von Mastzellpopulationen gewähren. 
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1 Introduction 
1.1 Mast cells 
Mast cells are highly granulated immune cells that reside in tissues and serosal cavities 
throughout the body but predominantly at inner and outer body surfaces, like the skin, the 
airways and the intestinal tract and also in close vicinity to blood vessels and nerves 
(Galli, 1990). At these locations they are well placed to serve as the first line of defense.  
Mast cells were first described by Paul Ehrlich in the late 19th century based on the 
metachromatic staining properties of the large cytoplasmic granules (Ehrlich, 1878). The 
“well-fed appearance” led him to designate these cells as mast cells. Today we know that 
the granule content does not originate from an uptake but from the synthesis and storage 
of high amounts of proteoglycans, proteases and other mediators.  
Mast cells are widely recognized as major effectors in allergic disorders and in responses 
to parasites. But in the last decade, it turned out that mast cells also serve other important 
functions. The essential role of mast cells in the immune system is also reflected by the 
fact that no human individual has been identified until today that lacks mast cells (Stevens 
and Adachi, 2007).   
1.1.1 Mast cell development and heterogeneity  
Mast cells originate from multipotent hematopoietic precursors in the bone marrow. 
Differentiated to committed mast cell progenitors (MCP), they are released to the blood 
and circulate until they extravasate into the tissue and serosal cavities where they finally 
differentiate to the mature tissue resident mast cells (Hallgren and Gurish, 2007; 
Rodewald et al., 1996). The spleen has also been demonstrated to be a source of MCPs 
in the adult mouse (Arinobu et al., 2005; Khalil et al., 1996). The earliest murine 
committed MCP has been identified in fetal blood at day 15.5 of gestation (Rodewald et 
al., 1996). In contrast, the direct identification of MCPs in the circulation of adult mice has 
not been accomplished by reason of their low frequency, i.e. 0.001% of mononuclear cells 
as determined by mast cell colony formation by blood cells ex vivo (Hallgren and Gurish, 
2007). A sequential increase of MCPs first in the bone marrow, then in the blood and 
finally in the intestine, could be observed in worm infected mice demonstrating the 
recruitment of mast cells from the bone marrow to the site of infection (Pennock and 
Grencis, 2004). The development of MCPs to mature mast cells is strongly dependent on 
the microenvironment and, thus, on the production of growth factors at the site of 
differentiation. The most important factor for mast cell growth, differentiation, proliferation 
and survival is the stem cell factor (SCF) that binds to the receptor tyrosine kinase c-Kit 
and is expressed by stromal cells as a soluble or a membrane bound molecule in various 
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tissues (Galli et al., 1994; Longley et al., 1997). The Kit gene is a proto-oncogene 
originally discovered as the cellular homolog (c-Kit) of the feline sarcoma virus oncogene 
v-Kit (Besmer et al., 1986). The Kit receptor is expressed on hematopoietic progenitor 
cells but is down regulated upon differentiation in all lineages except mast cells which 
express Kit and remain SCF responsive throughout their entire differentiation and life span 
(Metcalfe et al., 1997). The critical role of c-Kit/SCF interaction was demonstrated in mice 
with spontaneous mutations in the c-Kit locus (also known as white spotting locus (W)), 
e.g. in KitW/W-v and KitWsh/Wsh mice (Grimbaldeston et al., 2005; Kitamura et al., 1978) or in 
mice with mutations of the SCF locus, (SI/SId mice (Kitamura and Go, 1979), see also 
section 1.1.5). In addition to SCF, the mediators Interleukin (IL)-3, IL-4, IL-9, IL-10 and 
nerve growth factor (NGF) contribute to mast cell growth and differentiation (Okayama 
and Kawakami, 2006).  
Mast cells that reside in various tissues differ in their phenotypes. This heterogeneity 
among mast cells is due to the diverse microenvironments and the presence of various 
combinations of the above mentioned growth factors at these sites where the precursor 
cells differentiate into mature mast cells (Okayama and Kawakami, 2006). Histochemical 
differences among mast cells described by Enerbäck et al. led to the classification of two 
distinct mast cell subpopulations in rodents, i.e. connective tissue mast cells (CTMC) and 
mucosal mast cells (MMC) (Enerbäck et al., 1985). These mast cell phenotypes differ in 
their localization and secretory granule content. CTMCs are found predominantly in the 
subepithelial strata of the skin and the peritoneal cavity but also in the submucosal layers 
of the intestine. Characteristically, CTMCs store abundant heparin sulfate proteoglycan, 
chymases, tryptases and mast cell carboxypeptidase A (MC-CPA). In contrast, MMCs 
reside predominantly within the epithelia in the intestinal and respiratory tract, i.e. they are 
located above the basement membrane between the epithelial cells. They are smaller 
than CTMCs and have fewer granules. The MMC granules contain chonodroitin sulfate 
proteoglycan and chymases, but not tryptases (Metcalfe et al., 1997). An important finding 
was that the MMC population remarkably expands in T cell-dependent responses to 
certain intestinal parasites and that, in athymic mice, MMC numbers are reduced, while 
CTMC numbers are not, revealing a T cell dependence of MMCs, but not of CTMCs 
(Metcalfe et al., 1997). The intestine harbors a large reservoir of mast cell progenitors. 
Helminth infections cause a rapid expansion of the MMC population, likely facilitated by 
the presence of these intestinal precursors and by de novo production of mast cell 
progenitors in the bone marrow that are committed to enter the intestine from the blood 
(Gurish and Boyce, 2006; Pennock and Grencis, 2004). Within three weeks after 
expulsion of the pathogen, the number of intestinal mast cells decreases again suggesting 
a life span of most MMCs of only one to two weeks. On the contrary, an extraordinarily 
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long life span, i.e. probably more than one year, has been reported for CTMCs in the skin 
and peritoneal cavity (Kitamura, 1989).  
Also in humans, two mast cell subpopulations, distinguished by their granule content, 
were described. The MCT subpopulation contains only tryptases, whereas the MCTC 
contain tryptase and chymase as well as cathepsin G-like protease and MC-CPA 
(Metcalfe et al., 1997). In terms of localization, MCT correspond most closely to the MMC 
phenotype in rodents as they reside predominantly in the lung septa and small intestine 
mucosa. In contrast, the MCTC, localized particularly in the skin and intestinal submucosa, 
resemble most closely the rodent CTMC population (Metcalfe et al., 1997). 
1.1.2 Mast cell granules and proteases 
The mast cell granules predominantly contain proteoglycans and proteases. The serglycin 
proteoglycans with heparin and chonodroitin sulfate site chains in the secretory granules 
are the most negatively charged molecules in the body (Huang et al., 1998b) and are the 
reason for the metachromatic staining properties of mast cells that can readily be detected 
with cationic dyes like Toluidine blue or Giemsa. The neutral proteases, which are active 
at a neutral pH, are synthesized as inactive zymogens containing a hydrophobic signal 
peptide for the translation into the endoplasmic reticulum followed by a propeptide. In the 
mature secretory granules the proteases are stored in their enzymatically active form that 
results from proteolytic cleavage of the propeptide and are ionically bound to the serglycin 
proteoglycans (Huang et al., 1998b). About 50% of the weight of a mature mast cell 
consists of the proteases/serglycin complexes (Thakurdas et al., 2007). The three major 
families of mast cell proteases are tryptases, chymases and mast cell carboxypeptidase A 
(MC-CPA) (Reynolds et al., 1989). Both, tryptases and chymases, belong to the family of 
serine proteases with endopeptidase activity whereas CPA is a metalloproteinase with 
exopeptidase activity.  
In mice, two mast cell tryptases, mMCP-6 and mMCP-7 (McNeil et al., 1992b; Reynolds et 
al., 1991), and five chymases, mMCP-1, -2, -4, -5 and -9 (Hunt et al., 1997; McNeil et al., 
1991; Serafin et al., 1990; Serafin et al., 1991; Trong et al., 1989), were described. In 
contrast to the MC-CPA, encoded on chromosome 3, the genes for the tryptases, Mcpt6 
and Mcpt7, are located in a 1.5 Mb complex on chromosome 17, which is a cluster of 
genes encoding for 13 mouse proteases all belonging to the serine protease superfamily. 
Among these, mMCP-6 and mMCP-7 are selectively expressed in mast cells (Wong et al., 
2004). Like the tryptase genes, the genes encoding for the chymases, Mcpt1, 2, 4, 5 and 
9, are organized in a gene cluster which is located on chromosome 14 (Gurish et al., 
1993). This cluster also includes the genes that encode cathepsin G and numerous 
granzymes (Huang et al., 1998b).  
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The mast cell proteases are differentially expressed in the mast cell subpopulations. 
CTMCs display abundant mMCP-4, -5 and -6 as well as MC-CPA expression whereas 
MMC express preferentially mMCP-1 and -2 (Pejler et al., 2007). The expression pattern 
of mast cell proteases shows that even the subpopulation of MMCs and CTMCs are not 
homogenous. MMCP-9, for instance, is preferentially expressed in uterine CTMCs (Hunt 
et al., 1997). Stevens and coworkers demonstrated that perivascular mast cells in BALB/c 
mice express mMCP-2 and high steady state levels of mMCP-7 in addition to mMCP-4, -
5, -6 and MC-CPA (Stevens et al., 1994). Furthermore, a strain specific difference has 
been detected for mMCP-7. This protease is not expressed in C57BL/6 mice due to a 
point mutation leading to differential splicing and, thus, to an introduction of on additional 
stop codon (Hunt et al., 1996). The mast cell protease phenotype seems to be plastic 
during immune responses since Friend and coworkers showed that in Trichinella spiralis-
infected BALB/c mice the phenotype of mast cells changed in respect to their protease 
content. Dependent on the time after infection and on the intestinal tissue layer they 
detected, in addition to mast cells expressing either mMCP-5 or mMCP-1/mMCP-2, 
transitional phenotypes that express either mMCP-5/mMCP-2 without mMCP-1, or only 
mMCP-2 (Friend et al., 1996).  
The functions of mast cell proteases are versatile. Results of in vitro studies implicated 
mast cell proteases in the activation of matrix metalloproteases, cleavage of angiotensin I 
to angiotensin II and extracellular matrix remodeling by cleavage of fibronectin (Pejler et 
al., 2007). In vivo, the tryptase mMCP-6 was demonstrated to be essential for the 
clearance of a Klebsiella pneumonia infection. By inducing IL-8 production from 
endothelial cells mMCP-6 indirectly mediates neutrophil extravasation and accumulation 
in the tissue (Thakurdas et al., 2007). The disruption of the Mcpt1 gene, usually 
expressed in MMCs, leads to an impaired expulsion of the nematode Trichinella spiralis 
(Knight et al., 2000). Using mMCP-5 deficient mice, Abonia et al. demonstrated a critical 
role of mMCP-5 in ischemic tissue injury (Abonia et al., 2005). Furthermore, the CTMC 
proteases mMCP-4 and -6 were implicated in mast cell-mediated upregulation of 
angiogenesis in a model of epithelial cancer (Coussens et al., 1999). Interestingly, 
chymase-heparin complexes exocytosed into the dermal tissue seem to regulate mast cell 
numbers in the skin by converting membrane bound SCF expressed by keratinocytes to 
its soluble form. In addition these complexes mediate the accumulation of eosinophils in a 
model of dermatitis (Tomimori et al., 2002a; Tomimori et al., 2002b). Finally, using an mc-
cpa mutant Schneider and coworkers could demonstrate the critical role of MC-CPA in the 
regulation of endothelin effects and in the protection against snake venom sarafotoxins 
(Schneider et al., 2007). 
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1.1.3 From mast cell activation to effector functions 
Mast cells were widely recognized as key effector cells in type I hypersensitivity reactions 
or in responses to parasites. Especially in countries where parasite infections play a minor 
role, mast cells were primarily regarded as potentially harmful cells causing allergic 
disorders. Today it is well accepted that mast cells exert various other physiological 
functions. The strategical location close to the inner and outer body surfaces and their 
location close to blood vessels enable mast cells to quickly react to invading pathogens 
and to initiate immune responses by producing and secreting a broad spectrum of factors 
and by recruiting other effector cells from the circulation.  
Mast cells are equipped with a multitude of receptors serving directly or indirectly as 
sensors of pathogen invasion. Many of these belong to the large family of pattern 
recognition receptors (PRR) that bind directly to pathogen associated molecular patterns 
(PAMPs) shared by distinct groups of pathogens. Toll-like receptors (TLR) are an 
important group of the PRR family. Via the TLR2/6 heterodimer, the TLR4 and via the 
intracellular TLR9 they are able to recognize gram positive bacteria (peptidoglycans), 
gram negative bacteria (lipopolysaccharide, LPS) and bacterial DNA containing CpG 
motives, respectively (Matsushima et al., 2004; McCurdy et al., 2001; Supajatura et al., 
2002). Furthermore, mast cells release proinflammatory cytokines like type I interferons 
(IFN) when activated by dsRNA (Poly I:C, a mimic of viral infection) via TLR3 and ssRNA 
via TLR7 indicating a role of mast cells in anti-viral responses (Kulka et al., 2004; 
Matsushima et al., 2004).  
The activation of mast cells via FcεRI was investigated extensively (Kinet, 1999). This 
receptor is constitutively expressed on mast cells and constantly loaded with IgE due to its 
high affinity to the invariable chain of this immunoglobulin class (Benoist and Mathis, 
2002). The crosslinking of FcεRI bound IgE by multivalent antigens results in 
degranulation. In the presence of SCF and IFNγ mast cells additionally express the 
FcγRIII and FcγRI, respectively (Tkaczyk et al., 2004). The crosslinking of these receptors 
by IgG immune complexes can also induce degranulation. Beside these activating 
receptors, mast cells also express the inhibitory receptor FcγRIIB. Coaggregation of 
FcγRIIB with FcεRI or FcγRIII by IgG immune complexes results in downregulation of the 
secretory response (Ott and Cambier, 2000; Tkaczyk et al., 2004). Also the interaction of 
complement components or their cleavage products (C3a and C5a) with complement 
receptors on mast cells results in activation and release of mast cell mediators (Marshall, 
2004). 
Mast cells can be regarded as factories of a huge variety of mediators. Three major 
classes of mediators are produced by mast cells (Marshall, 2004): (1) The preformed and 
granule-associated mediators like histamine, serotonin, mast cell proteases as well as the 
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factors TNF, VEGF and FGF2; (2) the newly synthesized lipid mediators like leukotriene 
(LT)C4, LTB4, prostaglandin 
chemokines. The cytokines 
and immunomodulatory cytokines. 
potential functions are listed in T
Responses To Pathogens” by Jean S. Marshall 
 
Table 1.1 Mediators synthesized by mast cells. Table is taken from the review of Marshall, 2004 
“Mast-Cell Responses To Pathogens”. CCL, CC
ligand; FGF2, fibroblast growth factor 2; GM
factor; IFN, interferon; IL, interleukin; LIF, leukemia inhibitory factor; LT, leukotriene; PG, 
prostaglandin; TGF-β, transforming growth factor
endothelial growth factor.  
 
Dependent on the mode of activation, mast cell
mediator profiles thereby enabling mast cells to initiate and modulate immune responses
in a way appropriate to meet the pathogenic challenge
 
(PG)D2 and PGE2 and (3) do novo-synthesized cytokines and 
produced by mast cells can be grouped in
The huge variety of mast cell-mediators as well as their 
able 1.1 which was taken from the review “Mast
(Marshall, 2004).  
-chemokine ligand; CXCL, 
-CSF, granulocyte/macrophage colony
-β; TNF, tumor-necrosis factor; VEGF, vascular 
s can release distinct
. 
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The importance of mast cells for host defense against bacterial infection was 
demonstrated by studies of Klebsiella pneumonia infection and of a peritonitis model of 
cecal ligation and puncture (CLP) (Echtenacher et al., 1996; Malaviya et al., 1996). Using 
genetically mast cell-deficient mice (Kit-mutant mice, see below) it was shown that the 
rapid release of TNF from mast cells facilitated neutrophil recruitment necessary for 
clearance of infection. Mast cells are the only cells known to prestore TNF in their 
secretory granules, which can be immediately released upon activation (Gordon and Galli, 
1990a), stressing the potential role of mast cell-derived TNF in the initiation of 
inflammatory responses. In addition to TNF, other mediators secreted by mast cells 
promote the recruitment of effector cells. These mediators include histamine that 
increases vascular permeability and enhances the expression of adhesion molecules on 
endothelial cells (Marshall and Jawdat, 2004), as well as mast cell proteases which play a 
critical role in the recruitment of neutrophils and eosinophils (Huang et al., 1998a; 
Schmidlin et al., 2002). In vitro studies showed that mast cells are capable of 
phagocytosing pathogens and that mast cells produce antimicrobial peptides suggesting 
also direct effector functions of mast cells in host defense (Abraham and Malaviya, 1997; 
Di Nardo et al., 2003). These data were confirmed by a report that revealed a mechanism 
used by mast cells to kill bacteria extracellularly. This study demonstrated in vitro that, 
upon exposure to Streptococcus pyogenes, mast cells released extracellular structures 
composed of DNA, histones, tryptase and antimicrobial peptides. This process was 
mediated by reactive oxygen species (ROS)-dependent cell death (von Köckritz-
Blickwede et al., 2008). In addition to their critical role in host defense, several reports 
implicated mast cells in wound healing and tissue remodeling (Trautmann et al., 2000; 
Weller et al., 2006).  
The data discussed so far illustrates that mast cells are the cells responsible for the 
immediate innate response to invading pathogens. There are many indications that mast 
cells also set the stage for adaptive immune responses and exert modulatory functions on 
T and B cell responses. Accordingly, mast cells can influence the migration, maturation 
and function of dendritic cells and in this line indirectly induce the polarization of naïve T 
cells towards TH2 effector cells (Galli et al., 2005). McLachlan et al. could show that the T 
cell recruitment to lymph nodes draining at site of infection and the hypertrophy of these 
lymph nodes was substantially increased by mast cell-derived TNF (McLachlan et al., 
2003). In addition, a recent study by McLachlan and coworkers suggested mast cells as 
the sensory arm of the adaptive immune system. They could show that small-molecule 
mast cell activators, administered together with vaccine antigen, evoked substantial 
increases of antigen-specific serum IgG, highlighting mast cell activators as a new class of 
adjuvants (McLachlan et al., 2008). Surprisingly, mast cells, best known as 
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immunostimulatory cells and promoters of inflammation, have recently been implicated in 
immunosuppression, based on experiments with Kit-mutant, mast cell-deficient mice. The 
immunosuppressive function of regulatory T cells in a model of transplant tolerance was 
found to be dependent on mast cells (Lu et al., 2006). Another study demonstrated that 
mast cell-derived IL-10 limits skin pathology during allergic contact dermatitis and chronic 
irradiation with UVB (Grimbaldeston et al., 2007).  
1.1.4 Mast cell associated disorders 
The most extensively studied disorder associated with mast cells is the type I 
hypersensitivity. Because of the extremely high affinity of the Fc receptor for IgE (FcεRI), 
mast cells are constantly coated with IgE (Benoist and Mathis, 2002). Crosslinking of the 
surface IgE molecules by multivalent antigens leads to degranulation and release of 
preformed mediators like histamine, prostaglandins, leukotrienes and TNF causing the 
immediate allergic response. Furthermore, mast cells have an important role in the 
manifestation of chronic allergic disorders like asthma, allergic rhinitis and atopic 
dermatitis. In mice, it was shown that the development of the typical features of asthma, 
i.e. excessive production of mucus, airway hyperresponsiveness, bronchoconstriction, 
chronic inflammation of airway mucosa and recruitment of eosinophils and other 
leukocytes, was dependent on mast cells expressing the γ-chain of the FcεRI and FcγRIII 
receptors (Yu et al., 2006). Anaphylaxis is a life-threatening condition caused by the 
sudden release of mast cell- and basophil-derived mediators into the circulation. This 
severe form of an immediate hypersensitivity reaction is classically mediated by IgE and 
FcεRI. In rodents, however, an alternative mode of mast cell activation via IgG and FcγRIII 
was described (Grimbaldeston et al., 2006).  
In addition to antigen-specific IgE-mediated responses, antigen-nonspecific IgE can 
modulate mast cell functions as well. Mast cells and antigen-nonspecific IgE were both 
required for optimal sensitization in a model of contact hypersensitivity (CHS), a T cell-
mediated immune response. The TNF released by mast cells in this model was important 
for the optimal migration of dendritic cells to the draining lymph nodes which present the 
contact allergen to T cells (Grimbaldeston et al., 2006).  
Beside the IgE/FcεRI-mediated allergic disorders, a pathogenic role was suggested for 
mast cells in various other human diseases like multiple sclerosis, bullous pemphigoid and 
rheumatoid arthritis. Enhanced degranulation and accumulation of mast cells and their 
products at the affected sites in those patients indicated a contribution of mast cells to 
these diseases (Benoist and Mathis, 2002). The observations were supported by results 
obtained in mouse models for these disorders. Multiple sclerosis and the corresponding 
mouse model of experimental autoimmune encephalomyelitis (EAE) are both critically 
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dependent on proinflammatory TH1 cells. Interestingly, mast cell-deficient (Kit-mutant) 
mice develop an only milder form of the disease (Secor et al., 2000). Rheumatoid arthritis 
induced by antibodies against the enzyme glucose-6-phosphate isomerase (GPI) was 
also shown to be dependent on mast cells as mast cell-deficient mice were resistant to 
arthritis induction (Lee et al., 2002). The same was found in another model of collagen-
induced arthritis. The results have to be validated further since contradictory results were 
obtained with different mast cell-deficient mouse strains (see also section 1.1.5) (Zhou et 
al., 2007). The strong therapeutic effect of a β2-adrenergic agonist, that prevents mast cell 
degranulation, on experimental arthritis, however, supports a contribution of mast cells to 
this autoimmune disease (Malfait et al., 1999). Likewise, in a mouse model for bullous 
pemphigoid, mast cells were demonstrated to play a crucial role by recruiting neutrophils 
to the developing lesion (Chen et al., 2001).  
Recently, the involvement of mast cells in tumorigenesis is gaining increasing attention. 
Mast cells accumulate in the microenvironment of many tumors (Theoharides and Conti, 
2004). As mast cells can release mediators that are beneficial as well as mediators that 
are detrimental for the tumor, the overall effect of mast cells on tumorigenesis was not 
clear. Interestingly, in a model of adenomatous polyposis coli (APC), Khazaie and 
coworkers could show that the development of the polyps was mast cell dependent 
(Gounaris et al., 2007). Consistent with these results, mast cells accumulate around Myc-
induced pancreatic islet tumors. Reduced tumor growth after administration of inhibitors of 
mast cell degranulation and impaired tumor progression in Kit-mutant, mast cell-deficient 
mice provided evidence for an important function of mast cells in tumor progression 
(Soucek et al., 2007). In a model of epithelial carcinogenesis involving mast cell-
competent and mast cell-deficient (Kit-mutant) HPV16 transgenic mice, Coussens et al. 
demonstrated an implication of mast cells in the induction of premalignant 
neovascularization (Coussens et al., 1999).  
1.1.5 Models for the investigation of mast cells 
To investigate biochemistry and functions of mast cells ex vivo it is necessary to obtain 
pure suspensions of mast cells. The cultivation of primary mast cells isolated from mice 
was often hampered by the scarcity of mast cells in the various tissues. For in vitro 
studies, mast cell lines like the murine, growth factor-independent C57 or growth factor-
dependent MC/9 and PT18 lines (Burd et al., 1989) and human mast cell lines like the 
immature HMC-1 line (Butterfield et al., 1988) are available. These lines, however, might 
not reflect the mast cell phenotypes found in vivo. An improvement was the finding that 
mast cells can be derived from bone marrow cells in the presence of IL-3 (Kitamura, 
1989). These bone marrow-derived mast cells (BMMC) have a rather immature phenotype 
as judged by their production of chonodroitin sulfate and of the proteases mMCP-5 and -6 
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and MC-CPA but lack of mMCP-4 (Lunderius et al., 2000). The isolation and cultivation of 
fetal skin-derived mast cells (FSMC (Yamada et al., 2003)) and peritoneal cell-derived 
mast cells (PCMC (Malbec et al., 2007)) provided useful tools for the investigation of mast 
cells in vitro as these cultured mast cells closely resemble connective tissue type mast 
cells in vivo.  
To investigate mast cell functions in vivo, researchers utilized mouse strains carrying 
spontaneous mutations of either the c-Kit gene (white spotting locus, W) or of the steel 
locus (sl) encoding for the Kit ligand (stem cell factor, SCF) which result, among other 
phenotypic abnormalities, in profound mast cell-deficiency (Galli and Kitamura, 1987). The 
most commonly used mouse model for mast cell investigation is the WBB6F1-KitW/Wv 
mouse. W represents a point mutation at an exon-intron junction that causes an altered 
splicing of the mRNA, resulting in abrogation of surface Kit expression (Galli et al., 2005). 
Mice homozygous for the W allele are white and die before postnatal day ten. The W 
mutation is fixed to the WB background (W-spotted line B) due to a breeding program of 
continuous brother-sister matings of KitW/+ mice (Waskow et al., 2004). Wv is a loss-of-
function point mutation in the tyrosine kinase domain of c-Kit, that significantly reduce (but 
does not abolish) kinase activity upon ligand binding. The F1-hybrid of the KitW/+ and 
KitWv/+ mice (WBBL/6F1-KitW/Wv) is viable and profoundly lacks all mast cells with less than 
1% of wild-type levels of skin mast cells (Kitamura et al., 1978). In addition, these mice 
suffer from several other phenotypic abnormalities like macrocytic anemia, sterility, lack of 
melanocytes and interstitial cells of Cajal and a high incidence of spontaneous dermatitis, 
squamous papillomas of the fore-stomach, gastric ulcera and dilatation of the duodenum 
(Grimbaldeston et al., 2005). The same phenotype is present in Sl/Sld mice in which a 
mutation of the gene encoding for SCF results in mast cell deficiency (Galli and Kitamura, 
1987). Another mouse model that is gaining increasing popularity is the KitWsh/Wsh mouse. 
The “Wsash” (Wsh) mutation is an inversion mutation spanning 2.8 to 3.3 Mb (Nigrovic et 
al., 2008) in the region upstream of the transcription start of c-Kit that arose 
spontaneously in a cross between two inbred strains (C3H/HeH x 101/H) 23 years ago 
(Berrozpe et al., 2006; Grimbaldeston et al., 2005). Mast cells are present in newborn 
mice but their numbers decrease with age until, at the age of ten weeks, the mice are 
virtually mast cell-deficient (Wolters et al., 2005; Yamazaki et al., 1994). Grimbaldeston et 
al. detected in the back skin of ten to twelve week-old KitWsh/Wsh mice mast cell numbers 
that were about 1.2 to 7.2% of those observed in wild-type littermates. Surprisingly, it has 
been shown that after induction of chronic inflammatory responses, mast cell populations 
developed in KitWsh/Wsh but also in KitW/Wv mice at the affected sites (Metz et al., 2007). In 
contrast to the KitW/Wv mice, KitWsh/Wsh mice were considered to display less phenotypic 
abnormalities. They are viable and fertile but also lack the interstitial cells of Cajal and 
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demonstrated significant bile reflux into the stomach (Grimbaldeston et al., 2005). 
However, new data generated by Nigrovic et al. demonstrated hematopoietic 
abnormalities in KitWsh/Wsh mice (Nigrovic et al., 2008). Consistent with our own 
unpublished observations, they described significant splenomegaly in 12 week old mice 
along with expansion of the myeloid and megakaryocyte populations. In addition, the 
inversion mutation in KitWsh/Wsh mice disrupted the corin gene encoding for a serine 
protease that activates pro-atrial natriuretic peptide resulting in cardiac hypertrophy 
(Nigrovic et al., 2008).  
In order to demonstrate that phenotypic differences between mast cell-deficient and 
congenic wild-type mice are indeed due to the lack of mast cells, mast cell-deficient mice 
were reconstituted with either bone marrow cells or with BMMCs derived from congenic 
wild-type or gene deficient mice. While the adoptive transfer of hematopoietic cells into 
KitW/Wv and KitWsh/Wsh mice is possible, it is not in Sl/Sld mice because SCF is expressed 
predominantly by the microenvironment and not by the hematopoietic cells them self (Galli 
and Kitamura, 1987). For the reconstitution, the in vitro derived mast cells can be 
administered by intravenous, intraperitoneal, intradermal or by injection into the anterior 
wall of the stomach. The reconstituted mice were called “mast cell knock in mice” (Metz et 
al., 2007). Dependent on the anatomical site, the transferred BMMCs were reported to 
differentiate into mast cells resembling native mast cell populations at the corresponding 
site in wild type mice (Nakano et al., 1985). The reconstitution of mast cells in the different 
tissues is, dependent on the rout of administration, variable and mast cell numbers can 
differ from numbers in wild type mice. For example, more mast cells appear in the 
gastrointestinal tract when injected intravenously.  
These reconstitution models yielded important insights into functions of mast cells but 
inherent technical problems limit experimentation and interpretation of data obtained with 
these systems. These vagaries became especially apparent when Zhou et al. revealed a 
profound difference in the development of antibody-mediated arthritis in KitW/Wv and 
KitWsh/Wsh mice. While KitW/Wv mice were resistant, KitWsh/Wsh mice developed full arthritis 
(Zhou et al., 2007). These discrepant results illustrate that Kit-mutant mice are not ideal 
models for the study of mast cell functions and that new models of mast cell-deficiency 
are urgently needed, which are independent of Kit mutations.  
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1.2 Generation of mouse models 
The investigation of systems as complex as mammalian immune responses as well as the 
elucidation of the contributions of individual cell types to host defense, requires models 
that reflect in vivo situations. The mouse is such a suitable model since on the one hand 
murine immunology largely resembles the human situation and on the other hand there 
are enormous possibilities to manipulate the mouse genome. Gene-deficient mice as well 
as mice displaying a cell type specific gene knock out provide powerful tools to gain 
insights into immune functions.  
1.2.1 Classical gene “Knock out”  
To investigate gene functions in vivo, targeted mutations were introduced into the 
germline of the mouse in order to achieve inactivation of a gene of interest in all cell 
lineages in the mouse. For this purpose, the genome of embryonic stem (ES) cells was 
manipulated by homologous recombination. Injected into blastocysts, these ES cells can 
contribute to all cell lineages including germ cells, thus, resulting in heritable mutations 
(Capecchi, 1989; Koller and Smithies, 1992; Thomas and Capecchi, 1987).  
This classical gene knock out methodology is a valuable tool that provided important 
information. Germline mutations, however, can be lethal and complete gene inactivation in 
the entire mouse often does not allow conclusions on cell type-specific functions. 
Therefore, spatial and temporal control of mutagenesis in the mouse was desired.  
1.2.2 Conditional gene targeting 
1.2.2.1 Site specific recombination systems 
Conditional, i.e. cell type-specific or inducible mutagenesis in vivo, became possible by 
the introduction of site specific recombination (SSR) systems into the mouse. SSR relies 
on bacterial or yeast recombinases that cleave DNA at specific target sequences and 
ligate it to a second site (Kilby et al., 1993). The Cre/loxP recombination system proved 
particularly useful. The Cre recombinase (causes recombination) originates from the P1 
bacteriophage and catalyzes recombination between two recognition sites, designated 
loxP (locus of crossing (X)-over of P1). This 34 bp sequence contains an eight bp core 
spacer region that determines the orientation of the loxP site, and two flanking 13 bp 
palindromes, the binding sites for the recombinase. The Cre enzyme deletes sequences 
flanked by loxP sites of identical orientation leaving a single recognition site behind. In 
case of sites with opposite orientation, the loxP-flanked sequence is inverted. In addition, 
translocation between loxP sites located on different chromosomes can occur (Nagy, 
2000).  
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To achieve Cre-mediated mutagenesis in vivo, Cre transgenic lines are crossed to mouse 
strains containing loxP-flanked sequences. As shown by Vooijs et al., the success of Cre-
mediated recombination in vivo is dependent on the position of the loxP sites in the 
genome and on the cell type in which SSR is desired (Vooijs et al., 2001). Furthermore, 
the level of Cre expression is critical for efficiency of recombination. As the Cre 
recombinase is derived from a prokaryotic organism its expression is not optimal in 
eukaryotic cells. The high frequency of CpG motives, for instance, can lead to epigenetic 
silencing during mammalian development. In order to adapt Cre cDNA to the transcription 
and translation system in eukaryotic cells, Shimshek et al. generated a codon-improved 
Cre recombinase (iCre (Shimshek et al., 2002)). This mutated Cre sequence contains 
silent base mutations corresponding to human codon-usage preferences and a minimized 
CpG content. Putative cryptic splice sites were eliminated and an optimal Kozak 
consensus sequence was included.  
The temporal control of SSR in vivo was accomplished either using inducible promoters to 
drive Cre expression (Kuhn et al., 1995; St-Onge et al., 1996) or by chemically induced 
activation of an inactive form of the Cre protein. In the latter case, the Cre open reading 
frame was fused to the human estrogen receptor ligand binding domain (ER). The CreER 
fusion protein is trapped in the cytoplasm in an inactive state bound to the heat shock 
protein 90 (HSP 90) complex. Upon ligand binding, CreER is released from the complex 
and free to translocate into the nucleus where it can catalyze recombination. The estrogen 
binding domains used in this system are mutated (Cre-EBD (G521R) (Schwenk et al., 
1998), CreERT (G521R) (Feil et al., 1996)) and have a high affinity to the synthetic 
compound 4-OH-Tamoxifen (OHT), but not to endogenous 17β-estradiol. The affinity to 
OHT was further improved by mutation resulting in the CreERT1 and CreERT2 fusion 
proteins (Feil et al., 1997).   
Another site specific recombination system that has successfully been applied in mouse 
ES cells and gene targeting is the Flp/frt system derived from the yeast Saccharomyces 
cerevisiae (Dymecki, 1996b). The principle of Flp-mediated recombination resembles that 
of the Cre/loxP-system, although it is not as widely used as the Cre recombinase. The Flp 
recombinase is largely applied for the deletion of the selectable marker in ES cells after 
successful gene targeting (Kwan, 2002) or in vivo in combination with the Cre/loxP 
system.  
1.2.2.2 Applications of the Cre/loxP system 
To apply the Cre/loxP system to the mouse, genomic gene segments are flanked with 
loxP sites by classical gene targeting in ES cells. Conditional mutagenesis is then 
achieved by crossing the so called “floxed” mouse to a strain expressing the Cre 
recombinase under the control of a cell type-specific promoter. This binary system 
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represents a powerful tool to investigate gene functions by gene inactivation selectively in 
a cell population of interest. Since the first description of in vivo gene inactivation using 
the Cre/loxP system (Gu et al., 1994), an impressive number of floxed mouse lines have 
been generated as well as numerous tissue and cell type-specific Cre recombinase 
expressing strains, many of them listed on the webpage http://www.mshri.on.ca/nagy/.  
Furthermore, the Cre/loxP system can be used to activate gene expression in selected 
cell types. For this purpose, the open reading frame of a gene of interest is separated 
from a promoter by a loxP-flanked stop element containing polyadenylation sequences 
(Lakso et al., 1992). The expression of the gene is inhibited until Cre-mediated excision of 
the stop cassette. This principle of cell type-specific gene activation has found multiple 
applications. It is largely used in Cre excision reporter strains in order to demonstrate the 
functionality of a Cre transgenic line (Soriano, 1999; Srinivas et al., 2001). In these 
strains, the expression of indicator proteins, like β-glalactosidase or fluorescent proteins, 
under the control of a ubiquitously active promoter (e.g. ROSA26) indicates successful 
Cre-mediated deletion of the stop element. The same was applied with success for 
depletion of individual cell populations in vivo by Cre-mediated derepression of a 
diphtheria toxin fragment A (DTA) gene (Ivanova et al., 2005; Voehringer et al., 2008). 
Temporally controlled ablation of cell populations was achieved by Cre-mediated control 
of expression of the simian diphtheria toxin receptor (DTR) resulting in sensitization of the 
DTR-expressing cells to exogenous diphtheria toxin (Buch et al., 2005). Furthermore, the 
conditional expression of oncogenes (Lakso et al., 1992) and of mutated versions of 
genes (Forlino et al., 1999; Gerbaulet et al., submitted), allowed insides into 
tumorigenesis and the effect of loss or gain of function mutations on a given cell type.  
1.2.3 BAC transgene technology  
The introduction of foreign genes into the germ line of mice was achieved either by 
homologous recombination in ES cells resulting in the expression of the foreign gene 
under the control of an endogenous promoter (i.e. knock-in) or by pronucleus injection 
resulting in random integration of the construct into the genome. Thus, the construct for 
random integration must include the complete promoter in addition to the open reading 
frame.  
In the past, transgenes were limited in size and usually contained the cDNA of a gene of 
interest and a minimal promoter sequence. This restriction was due to the limited 
availability of DNA-engineering methods for large DNA molecules. Consequently, the lack 
of cis-regulatory elements in the promoter or intronic sequences could affect the 
expression level. Furthermore, small transgenes are notably prone to position effects 
exerted by regulatory elements present at the site of random integration. Effects of 
promoters, enhancers and silencers at the integration site may override those of the 
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transgenic promoter. Expression may also be hampered by integration into a 
heterochromatin rich site (Heaney and Bronson, 2006).  
To overcome these chromosomal position effects, the transgenes were either targeted to 
a certain site by homologous recombination in ES cells or, alternatively, the size of the 
randomly integrated transgenes was considerably increased, for instance, by using 
bacterial artificial chromosomes (BAC). These vectors can accommodate DNA fragments 
of up to 300 kb and are, therefore, used for the generation of mouse genomic BAC 
libraries (Osoegawa et al., 2000). Since large BAC clones can contain the entire genomic 
sequence of a gene including all cis-regulatory elements, BAC based transgenes are 
usually not affected by position effects (Giraldo and Montoliu, 2001). 
Conventional cloning methods, relying on the use of restriction endonucleases and DNA 
ligases, cannot routinely be applied for the manipulation of BAC clones as the size limits 
the availability of suitable (rare) restriction sites. Today, BAC modification is facilitated by 
homologous recombination in E. coli. A powerful tool applied for BAC recombineering is 
the Red®/ET® Recombination system (“ET-cloning”) (Muyrers et al., 1999; Zhang et al., 
1998). The process of recombination is catalyzed by one of the phage-derived enzyme 
pairs, either Redα and Redβ from the λ-phage or RecE and RecT derived from the Rac 
prophage. Redα and RecE are 5’-3’ exonucleases producing single-stranded overhangs 
at the 3’ end of double-strand breaks. Redβ and RecT are ssDNA-binding proteins with 
annealing and strand exchange activity. These equivalent enzyme pairs efficiently 
mediate recombination in E. coli BAC hosts between a circular BAC clone and a linear 
DNA fragment at homologous sequences shared by these two DNA molecules. Thus, this 
method is completely independent of restriction sites. Furthermore, as the regions of 
homology can be chosen freely, the BAC clone can precisely be modified at any desired 
position. Since only 50 bp are sufficient to serve as homology region, this short sequence 
can be included into oligonucleotide primers for amplification of a linear DNA fragment 
that is to be inserted into a BAC vector. The intrinsic recombination pathway in E. coli 
involves the strand invasion protein RecA and the RecBCD complex as the major cellular 
exonuclease. One function of the RecBCD is the destruction of foreign linear DNA and, 
thus, would render a recombination event between the BAC and linear DNA impossible. 
Therefore, the λ-derived Redγ protein, which inhibits the RecBCD exonuclease activity, is 
expressed along with Redα/Redβ or RecE/RecT (Zhang et al., 1998). The applications of 
this method are versatile. It allows the insertion and/or deletion of DNA and even single 
base changes. In addition, DNA can be subcloned from diverse sources, which can be 
BAC vectors, the E. coli chromosome or even mouse genomic DNA, into a minimal vector 
in one recombination step in E. coli (Zhang et al., 2000).   
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1.3 Objectives 
Recent research demonstrated that mast cells are not only central effectors of allergic 
disorders but play pivotal roles in orchestrating innate and adaptive immune responses by 
exerting immunostimulatory as well as immunosuppressive functions. Until today, most 
knowledge about mast cell functions was gained by in vitro studies or in vivo, using 
genetically mast cell-deficient mice, in particular the KitW/Wv and recently also the KitWsh/Wsh 
strain.  
The reconstitution of these mice with in vitro cultured mast cells derived from gene 
deficient mice provided valuable information about mast cell-specific gene functions. 
However, these models were not ideal since Kit-mutant mice, in addition to mast cell 
deficiency, are characterized by complex perturbation of the hematopoietic system. The 
vagaries of these models became in particular apparent when contradictory results were 
obtained from different mast cell-deficient strains. Thus, a new mouse model that allows 
mast cell-specific mutagenesis in vivo would represent an important improvement.  
The first aim of this thesis was, therefore, to generate a mouse line expressing Cre 
recombinase selectively in mast cells. This line should allow for selective inactivation but 
also activation of individual genes in mast cells in vivo.  
A second aim was to employ the new Cre expressing line to generate a new mouse model 
of mast cell deficiency. This is possible by Cre-mediated deletion of a stop element 
thereby derepressing the expression of the high affinity diphtheria toxin receptor (DTR) 
rendering Cre-expressing cells diphtheria toxin sensitive. In order to demonstrate 
biological effects of the induced mast cell-ablation in vivo, the impact of mast cell 
depletion on a typical mast cell-mediated immune response, i.e. systemic anaphylaxis, 
was investigated. Conditional expression of the DTR in mast cells should provide an 
alternative model to Kit-mutant mice, mentioned above, in which, apart from mast cell-
deficiency, no other phenotypic abnormalities perturb interpretation of the data.   
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2 Results 
2.1 Generation and analysis of mast cell-specific Cre 
transgenic mice 
2.1.1 Generation of the Mcpt5-Cre(ERT2) and Mcpt6-Cre gene 
constructs 
In order to express the Cre recombinase selectively in mouse mast cells in vivo we used 
the Mcpt5 and Mcpt6 promoters, respectively. The constructs were generated by 
modification of BAC vectors by homologous recombination. BAC clones encompassing 
either the entire Mcpt5 gene (clone RP23-284A14) or the Mcpt6 gene (clone RP23-
240F3) were identified using the NCBI tools “Map viewer” and “clone finder” of the mouse 
genome resources. Both clones are part of the mouse BAC library RPCI-23 (Roswell Park 
Cancer Institute (Osoegawa et al., 2000)) and consists of the pBACe3.6 vector backbone 
and a 210 kb and 173.2 kb large insert of C57BL/6 genomic DNA, respectively (Fig. 2.1 
and Fig. 2.2). The clones were purchased from the RZPD (Deutsches Ressourcen-
zentrum für Genomforschung GmbH, Berlin, Germany). 
 
 
Fig. 2.1 Scheme of a BAC clone of the 
RPCI-23 mouse BAC library. T7 and SP6 
are promoters located at the end of the 
BAC backbone of the pBACe3.6 vector 
(bold line). C57BL/6 genomic DNA 
fragments of about 150-300 kb were cloned 
into EcoRI sites of the pBACe3.6 vector. 
 
For transgene construction we used a modified improved Cre (iCre (Shimshek et al., 
2002)) gene cassette that consists of the coding sequence of iCre followed by an frt site-
flanked ERT2 cassette and a SV40 polyadenylation (PolyA) signal. The iCre-frt-ERT2-frt-
SV40-PolyA cassette was kindly provided by Dr. Giuseppe Testa, Milan. This cassette 
provides the option to induce Cre activity in adult mice by the application of tamoxifen but 
also the possibility to remove the ERT2 domain by Flp recombinase-mediated deletion 
either in E. coli or in the mouse in order to obtain constitutive Cre activity.  
All cloning steps were done by Red/ET recombination in E.coli. The primers containing the 
homology regions (HR) for each recombination step are listed in Table 2.1 and Table 2.2 
for construction of the Mcpt5-Cre and the Mcpt6-Cre construct, respectively. Clones which 
BAC clone model
3267 4 bp
SP6
T7
C57BL/6 genomic DNA
BAC backbone
EcoRI
EcoRI
NotI
NotI
RPCI-23 
clone
C57BL/6 genomic
DNA (150-300 kb)
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had undergone the desired recombination events during each of the cloning steps 
(described in section 2.1.1.1 and 0) were identified by PCR (data not shown). 
 
 
 
application/template primer name primer sequence 
shaving of the insert at T7 
end of the vector backbone 
 
template:  
pBluescript II KS+ 
T7HR-Amp-FOR 
5’GCTTGACATTGTAGGACTATATTGCT
CTAATAAATTTGCGGCCGCTAATAGGTC
TGACGCTCAGTGGAAC 
InsertRP23-284A14HR-
NotI-Amp-REV 
5’TGCCTGTTGGCCTGTGGGAGCCCAGC
GAGGTTGGGGCCAGCAGCGGGTGCGCGG
CCGCGTGCGCGGAACCCCTATTTG 
shaving of the insert at 
SP6 end of the vector 
backbone 
 
template:  
psiRNA-hH1zeo 
InsertRP23-284A14HR-
NotI-Zeo-FOR 
5’GGGCAGAAAGGCTCAGAAGTTGAGAC
TCAGCAGGGCCTCAGAAAGCTGGTGCGG
CCGCCTCCCTTGGAGCCTACCTAGACTC
A 
SP6HR-Zeo-REV 
5’TTTCTATCCTCCCGAATTGACTAGTG
GGTAGGCCTGGCGGCCGCCTGGCCAATG
CACTGACCTCCCACATTCCCTT 
subcloning of CreERT2 
 
template:  
pACYA184 
HR(3’End of 
Cre)subcloning-HR(last 
50bp of Mcpt5-exon1)-
NotI-minimal vector-FOR 
5’ACGCCTATTTTTATAGGTTAATGTCA
TGATAATAATGGTTTCTTAGACGTGTGA
GTGCTGGGGTCGCTCCCTCTCCAATCTG
CAGGGTCAGCTCCTAAAAGCGGCCGCGC
CCTGCACCATTATGTTCCGGA 
HR(5’End of 
Cre)subcloning-HR(50bp 
5’ of Mcpt5-ATG)-NotI-
minimal vector-REV 
5’ACAGGGAGGGCAGGCAGGTTTTGATG
CACAGTCAGCAGGTTGGACACCATATTT
GGGCCTTAGGCTTATTACTCCCAGCGGG
CAGGGGAGTGGCAGAGCTGCGGCCGCGC
CCGGCAGTACCGGCATAACCA 
insertion of Neo into the 
minimal vector between 
iCre and 3’HR of Mcpt5 
 
template:  
pPGK-gb2-neo 
HR(3’End of Cre)-loxm2-
NeoFOR 
5’ACGCCTATTTTTATAGGTTAATGTCA
TGATAATAATGGTTTCTTAGACGTATAA
CTTCGTATATGGTTTCTTATACGAAGTT
ATCGGCCGCATTCTACCGGGTAGG 
HR(last 50bp of Mcpt5-
Exon1)-loxm2-Neo-REV 
5’TTTTAGGAGCTGACCCTGCAGATTGG
AGAGGGAGCGACCCCAGCACTCACATAA
CTTCGTATAAGAAACCATATACGAAGTT
ATCGCGTTTAAACGGCGCGCCGCACACA
A 
 
Table 2.1 Primers used for Mcpt5-Cre(ERT2) transgene construction by Red/ET recombination. The 
respective 50 bp homology regions (HR) were included into the primers used for the amplification 
of selection markers or the minimal vector. 
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application/template primer name primer sequence 
shaving of the insert at T7 
end of the vector backbone 
 
template:  
pBluescript II KS+ 
T7HR-Amp-FOR 
5’GCTTGACATTGTAGGACTATATTGCT
CTAATAAATTTGCGGCCGCTAATAGGTC
TGACGCTCAGTGGAAC 
InsertRP23-240F3HR-
NotI-Amp-REV 
5’GGGGTCAGGATGAGGGGCGGGGCAC
ACCTGGTGCCCTCCTGCTCCTCCTCG
CGGCCGCGTGCGCGGAACCCCTATTTG 
shaving of the insert at 
SP6 end of the vector 
backbone 
 
template:  
psiRNA-hH1zeo 
InsertRP23-240F3HR-
NotI-Zeo-FOR 
5’AGCCCATCACCATCTCCCAGGAGCA
AGACCCCCCTAACATCAAATGGGGTG
CGGCCGCCTCCCTTGGAGCCTACCTAGA
CTCA 
SP6HR-Zeo-REV 
5’TTTCTATCCTCCCGAATTGACTAGTG
GGTAGGCCTGGCGGCCGCCTGGCCAATG
CACTGACCTCCCACATTCCCTT 
subcloning of CreERT2 
 
template:  
pACYA184 
HR(3’End of Cre) 
subcloning-HR(last 50bp 
of Mcpt6-exon1)-NotI-
minimal vector-FOR 
5’ACGCCTATTTTTATAGGTTAATGTCAT
GATAATAATGGTTTCTTAGACGTGTAAG
TTGTCTTGAGCCCTCCCTGTCTCTCC
CTCACCTTCACAGGCCACAGCGGCCGC
GCCCTGCACCATTATGTTCCGGA 
HR(5’End of Cre) 
subcloning-HR(50bp 5’ 
of Mcpt6-ATG)-NotI-
minimal vector-REV 
5’ACAGGGAGGGCAGGCAGGTTTTGATGC
ACAGTCAGCAGGTTGGACACCATCTGGA
AGCAGTGAGGAGCACAGCCTGAGTCC
AGCTAAAAGACAGGGCTAGGCGGCCGC
GCCCGGCAGTACCGGCATAACCA 
insertion of Neo into the 
minimal vector between 
iCre and 3’HR of Mcpt5 
 
template:  
pPGK-gb2-neo 
HR(3’End of Cre)-
loxm2-Neo-FOR 
5’ACGCCTATTTTTATAGGTTAATGTCA
TGATAATAATGGTTTCTTAGACGTATAA
CTTCGTATATGGTTTCTTATACGAAGTT
ATCGGCCGCATTCTACCGGGTAGG 
HR(last 50bp of Mcpt6-
Exon1)-loxm2-Neo-REV 
5’TGTGGCCTGTGAAGGTGAGGGAGAG
ACAGGGAGGGCTCAAGACAACTTACA
TAACTTCGTATAAGAAACCATATACGAA
GTTATCGCGTTTAAACGGCGCGCCGCAC
ACAA 
 
Table 2.2 Primers used for Mcpt6-Cre transgene construction by Red/ET recombination. The 
respective 50 bp HRs were included into the primers used for the amplification of selection markers 
or the minimal vector. 
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Fig. 2.2 Cloning strategy for the construction of the Mcpt5-CreERT2, Mcpt5-Cre and Mcpt6-Cre 
transgenes. (A) Scheme of the mouse BAC clones RP23-284A14 and RP23-240F3 containing the 
entire genomic sequences of the Mcpt5 and Mcpt6 gene, respectively. Both clones were shortened 
by replacing several kb at the T7 and at the SP6 end by an ampicillin (Amp) or a zeocin (Zeo) 
resistance cassette, respectively. Lengths of the replaced and remaining sequences are indicated. 
(B) Insertion of Cre into Mpct5/Mcpt6 genes by replacing the coding part of the first exon of the 
respective genes by an iCreERT2-loxm2-Neo-loxm2 cassette by homologous recombination and 
subsequent excision of Neo by Cre-mediated deletion. For constitutive Cre activity in transgenic 
mice, the ERT2 cassette was removed by Flp-mediated deletion in E. coli. Finally, the constructs 
Mcpt5-CreERT2, Mcpt5-Cre and Mcpt6-Cre were used for pronucleus injection. (N, NotI; E, EcoRI; 
shaded boxes, 5’ and 3’ untranslated region) 
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2.1.1.1 Shortening (“shaving”) of the BAC inserts 
Beside the Mcpt5 and Mcpt6 genes, the inserts of the BAC clones included many genes 
most of which encoded for other mast cell proteases. In order to avoid possible effects of 
altered gene dosages in the transgenic mice, these neighboring genes were excluded 
from the transgenic constructs by shortening the BAC inserts at both ends (Fig. 2.2, A). 
The Mcpt5 containing BAC was trimmed by replacing 51.3 kb of the T7 and 42.4 kb of the 
SP6 end of the genomic DNA insert by an ampicillin (Amp) and zeocin (Zeo) resistance 
cassette, respectively, leaving 67.4 kb upstream of the ATG start codon and 46.8 kb 
downstream of the 3’UTR of the Mcpt5 gene (Fig. 2.2, A). The Mcpt6 containing BAC was 
shortened by replacing 72 kb of the T7 and 31 kb of the SP6 end of the insert by Amp and 
Zeo cassettes, leaving 39 kb upstream of the translation start codon and 29.9 kb 
downstream of the 3’UTR of the Mcpt6 gene (Fig. 2.2, A). 
2.1.1.2 Assembly of CreERT2-Neo and insertion into the Mcpt5 and Mcpt6 
genes 
In order to assemble the CreERT2-Neo cassette and to attach the HRs for the insertion 
into the Mcpt5 or the Mcpt6 genes, the CreERT2 cassette was first subcloned from plasmid 
pCreERT2Amp (a gift from Giuseppe Testa, Milan) into a minimal vector (Fig. 2.3, A). This 
vector consists of an origin of replication and a chloramphenicol resistance cassette 
amplified from plasmid pACYA184. The primers used for the amplification contain the HRs 
for both, the subcloning of the CreERT2 cassette and for the insertion of CreERT2 into 
Mcpt5 or Mcpt6 (see Table 2.1 and Table 2.2). The subcloning step resulted in plasmid 
pMinCreERT2, which was modified by insertion of a loxm2-flanked PGK-gb2-Neo cassette 
(Neo) 3’ of CreERT2 and 5’ of the 3’Mcpt5/Mcpt6 HR (Fig. 2.3, B). The primers for the 
amplification of Neo contained the loxm2 sites in addition to the HRs for the 3’ end of Cre 
and the 3’Mcpt5/Mcpt6-HR. These mutated loxP sites can recombine with each other, but 
not with wild type loxP sites (Langer et al., 2002). Finally, the HR-CreERT2-loxm2-Neo-
loxm2-HR cassette was released from the minimal vector by NotI digestion and 
recombined into the BAC by replacing the coding part of exon 1 of the Mcpt5 gene or the 
Mcpt6 gene (Fig. 2.3, C and Fig. 2.2, B). The Neo cassette was subsequently removed by 
Cre-mediated deletion in E. coli resulting in the Mcpt5/Mcpt6-CreERT2 constructs that 
should allow for an induction of Cre activity in the adult mouse. The Mcpt5/Mcpt6-Cre 
constructs for constitutive Cre activity were generated by removing the ERT2 cassette by 
Flp-mediated recombination in E. coli (Fig. 2.2, B). 
 
Results  26 
 
Fig. 2.3 Assembly of the HR-CreERT2-loxm2-Neo-loxm2-HR cassette by subcloning of CreERT2 
and subsequent insertion of a loxm2-flanked Neo cassette. (A) In order to attach the Mcpt5/Mcpt6 
HRs to Cre, a minimal vector encompassing a chloramphenicol resistance cassette (Cm) and an 
origin of replication (ori) was amplified using primers containing both, the HRs for subcloning Cre 
(green line) and the HRs for the insertion into the Mcpt5/Mcpt6 gene (red line) and a NotI restriction 
site (N, blue line (B) The Neo cassette was inserted 3’ of Cre and 5’ of the 3’Mcpt5/Mcpt6-HR. (C) 
The HR-CreERT2-loxm2-Neo-loxm2-HR cassette, released from the minimal vector by NotI 
digestion, was ready for the replacement of the coding part of the first exon of Mcpt5/Mcpt6. 
 
2.1.1.3 Test for precision and fidelity of BAC modification 
During BAC modification by homologous recombination unwanted recombination events 
may occur in addition to the intended modification. To test for recombination events the 
modified BAC clones and the original unmodified clones are usually digested with 
restriction enzymes and the resulting DNA fragment patterns are compared. As the 
Mcpt5-Cre containing BAC was shortened by 94 kb and the Mcpt6-Cre BAC by 103 kb, 
the comparison with the unmodified clones was not meaningful. To ensure integrity of the 
promoter region, 4.5 kb upstream of the translation start codon of the original RP23-
284A14 and RP23-240F3 and of the respective modified BAC clones were sequenced. 
The comparison of the sequences revealed no mutations in these regions of the Mcpt5-
Cre and Mcpt6-Cre BAC clones (data not shown).  
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Fig. 2.4 Test for unwanted recombination events in the Mcpt5-Cre BAC construct by Southern blot 
analysis. (A) The scheme displays the Mcpt5 translation start, with the upstream region of the clone 
RP23-284A14. The start of the Amp cassette in the modified BAC followed by the T7 promoter of 
the BAC backbone is indicated. Six probes and the restriction sites for ApaI and KpnI as predicted 
from the database sequence of the unmodified BAC clone are indicated. (B) The expected DNA 
fragment sizes for each restriction enzyme are listed. (C and D) The original and Mcpt5-Cre BAC 
were either digested with ApaI or KpnI. The blots were hybridized with probe 1 to 6. The expected 
bands are marked by arrows. C, control RP23-284A14 BAC; M, modified BAC; *, additional signals 
due to unspecific binding of the probes or incomplete digest.  
 
In addition, 67 kb and 39 kb upstream of the translation start codon of the Mcpt5 and 
Mcpt6 genes, respectively, were tested for unwanted recombination events by Southern 
blot analysis. For this purpose, the Mcpt5-Cre construct and the respective unmodified 
BAC clone were digested either with ApaI or KpnI. The blots were hybridized with six 
different probes (Fig. 2.4, A) and the labeled DNA fragments of the original and the 
modified BAC were compared. The primers for the generation of the probes are listed in 
Table 4.3, section 4.3. As it is displayed in Fig. 2.4 C and D all DNA fragments of the 
modified BAC showed the expected sizes (Fig. 2.4, B), indicating that no major unwanted 
recombination events had occurred within this part of the construct. As the tested Mcpt5-
Cre construct was based on the Mcpt5-CreERT2 BAC, unwanted recombination in the 
latter construct can be excluded. The same strategy was pursued for the Mcpt6-Cre BAC 
using either SacI or EcoRV for the digestion. The blotted SacI digested DNA was 
hybridized with six and the EcoRV digested DNA with four probes. The comparison of the 
detected DNA fragments of the unmodified and modified BAC revealed no unwanted 
recombination events within the analyzed region (Fig. 2.5, A-D). 
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Fig. 2.5 Test for unwanted recombination events in the final Mcpt6-Cre BAC by Southern blot 
analysis. (A) The scheme displays the Mcpt6 translation start with the upstream region of clone 
RP23-240F3. The start of the Zeo cassette in the modified BAC followed by the SP6 promoter is 
indicated. Six probes and the restriction sites for SacI and EcoRV as predicted from the database 
sequence of the unmodified BAC clone are indicated. (B) The expected DNA fragment sizes for 
original and Mcpt6-Cre construct for each restriction enzyme are listed. (C and D) The original and 
Mcpt6-Cre BAC were either digested with SacI or EcoRV. The blots were hybridized with six and 
four probes, respectively. The expected bands are marked by arrows. C, control, RP23-240F3 BAC 
clone; M, modified BAC.  
 
 
Fig. 2.6 Alignment of the original coding sequence of the Cre recombinase with the Cre sequence 
in the final Mcpt5-Cre construct. Shown are the last 295 bp of the CreERT2 cassette. Both, the 
original Cre and the Mcpt5-Cre were sequenced. In the Mcpt5-Cre sequence, a single base pair 
insertion (red box) was found downstream of the SV40 polyadenylation signal (black box). Green 
box: part of the 3’ Mcpt5 homology region. 
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Finally the Cre cassettes of the Mcpt5-Cre and Mcpt6-Cre constructs and the ERT2 
cassette of Mcpt5-CreERT2 were analyzed for point mutations by sequencing overlapping 
PCR products (primers are listed in Table 4.3, section 4.3). No mutations were found in 
Mcpt6-Cre and in the ERT2 cassette of the Mcpt5-CreERT2 construct (data not shown). A 
single point mutation detected in the Mcpt5-Cre construct downstream of the PolyA signal 
was considered irrelevant (Fig. 2.6). This single base pair insertion is probably due to a 
mutation in the primer used for the subcloning of Cre. 
2.1.2 Generation of transgenic mice  
The constructs for constitutive and inducible Cre activity with Cre expression under the 
control of the Mcpt5 promoter were used for the generation of transgenic mice. The BAC 
inserts were separated from the vector backbone and from the ampicillin and zeocin 
resistance cassettes by NotI digestion and agarose gel electrophoresis. After further 
purification by electroelution and drop dialysis (see Material and Methods) the constructs 
were tested for the correct size and purity by pulsed-field gel electrophoresis (data not 
shown). The Mcpt5-CreERT2 and the Mcpt5-Cre constructs were finally pronucleus-
injected into fertilized C57BL/6 oocytes which were then transferred into foster mice. The 
pronucleus injections were performed by Ronald Naumann, Transgenic Core Facility, MPI 
of Molecular Cell Biology and Genetics, Dresden. 25 and 38 offspring were obtained for 
the Mcpt5-Cre and Mcpt5-CreERT2 constructs, respectively.  
In order to express the Cre recombinase under the control of the Mcpt6 promoter in vivo, 
only the construct for constitutive Cre activity was pronucleus-injected. The Mcpt6-Cre 
containing insert was separated from the BAC backbone by a double digestion with AscI 
and BspBI leaving the ampicillin and zeocin cassettes attached to the insert. These 
resistance cassettes can be detected by PCR in transgenic mice in order to test for full 
length integration of the transgene, which was not possible in case of the Mcpt5-Cre 
constructs. 34 offspring were obtained by pronucleus injection of the Mcpt6-Cre construct. 
Tail DNA of all offspring was tested for the presence of the transgenes by PCR. Primers 
for the detection of Cre and the ERT2 cassette are indicated in Fig. 2.7. The respective 
BAC constructs, which were diluted and mixed with wild type genomic tail DNA resulting in 
a molar ratio of BAC to genomic DNA of 1:1, served as positive control. Six animals were 
identified as Mcpt5-Cre and also six animals as Mcpt5-CreERT2 transgenic. The ID 
numbers of these founder animals are indicated in Fig. 2.7 (bold numbers). The Mcpt5-
CreERT2 transgenic founder 525624 died before the shipment to Cologne. In order to test 
for germ line transmission, all remaining founder mice were crossed to C57BL/6 wild type 
animals. As all Mcpt5-CreERT2 and Mcpt5-Cre founders had transgenic offspring, germline 
transmission was evident for eleven transgenic lines.  
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Fig. 2.7 Genotyping PCR for Mcpt5-Cre and Mcpt5-CreERT2 of animals generated by pronucleus 
injection of the respective constructs. Diluted BAC DNA served as positive control (P). Negative 
control reactions (N) did not contain DNA. Primers used for genotyping are indicated in the 
schemes representing the Mcpt5-Cre (A) and the Mcpt5-CreERT2 (B) constructs (arrows). Primer 
sequences are displayed in Table 4.3, section 4.3 under the respective numbers. (A) Genotyping of 
mice derived from the pronucleus injection of the Mcpt5-Cre construct. Cre-positive mice (bold 
numbers) were identified by a 558 bp product. No product was expected in wt animals. (B) 
Genotyping of mice derived from the Mcpt5-CreERT2 pronucleus injection. CreERT2-positive mice 
were identified by a 504 bp product. M, 100 bp DNA ladder, Fermentas life sciences. 
 
 
In case of the Mcpt6-Cre construct, ten transgenic animals were identified (Fig. 2.8, A), six 
of which carried a full length integration as demonstrated by PCR using primers specific 
for the ampicillin and zeocin resistance cassettes (Fig. 2.8, B). Mcpt6-Cre-specific 
amplification of tail DNA of founder 526844 repeatedly resulted in only very weak bands, 
most likely indicating that the transgene is found only in a fraction of the cells (Fig. 2.8, A, 
lane 526844 upper and lower panel). Therefore, this founder animal was not further 
analyzed. Germline transmission was evident for seven of the nine remaining founder 
lines after crossing them to C57BL/6 wild type animals.  
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Fig. 2.8 Genotyping PCR of mice generated by pronucleus injection of the Mcpt6-Cre construct. 
Primers for PCR are indicated in the schemes (arrows), the sequences can be found in Table 4.3, 
section 4.3 under the respective numbers. (A) The identification of positive founder animals (IDs 
are indicated) was done by PCR on genomic tail DNA resulting in a PCR product of 553 bp. (B) Full 
length integration of the transgene was tested by the amplification of the ampicillin (Amp) and 
zeocin (Zeo) resistance cassettes resulting in PCR products of 536 bp and 562 bp, respectively. M, 
100bp DNA ladder, Fermentas life sciences; N, negative control (without DNA); P, positive control 
(diluted BAC DNA mixed with genomic DNA resulting in molar ratio of BAC to genomic DNA of 
1:1). 
 
2.1.3 Screening of Mcpt5-Cre founder lines for Cre-mediated 
recombination  
In order to test for the efficiency and mast cell-specificity of Cre-mediated recombination, 
the six Mcpt5-Cre transgenic lines were mated to the R26R-EYFP reporter line (Srinivas 
et al., 2001). This reporter line expresses the enhanced yellow fluorescent protein (EYFP) 
under the control of the ubiquitously active ROSA26 promoter provided a loxP-flanked 
stop cassette is removed by Cre-mediated deletion (Fig. 2.9).  
Screening of the six lines was done by flow cytometric analysis of peritoneal mast cells for 
EYFP expression. In three lines, no or in less than 10% of mast cells EYFP expression 
could be detected (data not shown). One of the six lines showed EYFP expression in only 
80% of the peritoneal mast cells and was not further investigated (data not shown). In 
contrast, in two lines reporter gene expression could be detected in close to 100% of 
peritoneal mast cells (Mcpt5-Cre lines 525530 and 525537, for results see section 2.1.4). 
Because of autosomal inheritance of the transgene in the 525530 line and X-linked 
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inheritance in the 525537 line, these lines were designated A-Mcpt5-Cre and X-Mcpt5-
Cre, respectively. 
 
 
Fig. 2.9 Principle of reporter gene expression in Cre/R26R-EYFP double positive mice. Mcpt5-Cre 
mice were crossed to the R26R-EYFP reporter strain. EYFP is expressed under the control of the 
ubiquitously active ROSA26 promoter provided a loxP-flanked stop cassette is removed by Cre-
mediated deletion. 
 
 
2.1.4 Detailed analysis of A-Mcpt5-Cre and X-Mcpt5-Cre 
transgenic mice 
2.1.4.1 Efficient Cre-mediated recombination in mast cells 
Highly efficient Cre-mediated reporter gene expression in peritoneal mast cells, defined as 
CD117+FcεRIα+ cells, was detected in seven A-Mcpt5-Cre R26R-EYFP double positive 
mice (99.1±0.31%, Fig. 2.10, upper panel) but not in Cre-negative R26R-EYFP single 
transgenic control mice (littermates in most instances). In skin cell suspensions, mast cells 
were defined as CD117+CD45+ cells and were detected in low numbers, on average 
0.32% of total skin cells. (FcεRIα staining was not reliable likely due to loss of epitopes 
during enzymatic tissue dissociation.) In the five animals, for which this mast cell 
population was investigated, the majority of the few CD117+CD45+ cells gated was EYFP 
positive (43/47, 54/64, 32/39, 23/27 and 77/88 gated events, Fig. 2.10, lower panel). 
Given that the mast cell gate will inevitably collect some non-mast cells upon analysis of 
high total cell numbers (40,000 events), the percentage of skin mast cells expressing 
EYFP is probably close to 100%.  
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Fig. 2.10 Efficiency of Cre-mediated activation of EYFP reporter gene expression in mast cells. 
EYFP expression is demonstrated in cells from peritoneal lavage fluid and single cell suspension of 
skin of Mcpt5-Cre R26R-EYFP double positive mice. Peritoneal mast cells were identified as 
CD117 and FcεRIα and skin mast cells as CD117 and CD45 double positive cells. Mast cell 
populations were gated and EYFP fluorescence intensitiy was displayed in histogram plots. The 
green graph represents the Mcpt5-Cre/R26R-EYFP mouse, the red graph the Cre-negative but 
R26R-EYFP positive control animal (a littermate in most instances). Results are representative for 
seven (peritoneal mast cells) and five (skin mast cells) A-Mcpt5-Cre mice. 
 
 
 
 
Fig. 2.11 EYFP Reporter gene expression in peritoneal mast cells of male and female X-Mcpt5-
Cre R26R-EYFP double positive mice. EYFP fluorescence intensity of CD117+FcεRIα+ mast cells 
was displayed in histogram plots. The Green graph represents Mcpt5-Cre R26R-EYFP double 
positive mice, the red graph represents the Cre-negative but R26R-EYFP-positive controls.  
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A similar efficiency of Cre-mediated deletion in mast cells was observed in three male X-
Mcpt5-Cre R26R-EYFP double positive mice (98.5±0.6%, Fig. 2.11). The mast cell 
population in the skin was analyzed in three males and showed efficient activation of 
EYFP expression (46/58, 61/66 and 48/55 gated events, data not shown). In contrast to 
the males, in two female X-Mcpt5-Cre R26R-EYFP double positive mice analyzed, a 
reporter gene expression was only observed in 61% and 32% of peritoneal mast cells 
consistent with random X-chromosome inactivation (Fig. 2.11). 
2.1.4.2 Investigation of mast cell-specificity of Cre-mediated recombination 
Various hematopoietic non-mast cell populations were investigated for potential Cre-
mediated activation of EYFP expression. In peritoneal macrophage and B cell (n=3 for 
each, A-Mcpt5-Cre and X-Mcpt5-Cre) as well as in splenic basophil, eosinophil, 
neutrophil, dendritic cell, macrophage, B cell and T cell populations (n=3 for each, A-
Mcpt5-Cre and X-Mcpt5-Cre) no or very few EYFP positive cells could be detected (i.e. 
below 1%, Fig. 2.12). In addition, analysis of the non-hematopoietic fraction of skin cell 
suspensions (composed primarily of fibroblasts and keratinocytes) did not reveal Cre-
mediated activation of EYFP expression (Fig. 2.12).  
A low percentage of EYFP expressing cells was detected in the CD49b (α2-Integrin) 
positive compartment of the spleen in A-Mcpt5-Cre mice, stained with the anti-49b 
antibody clone DX5 (on average 3.67±1.88%, n=4). This monoclonal antibody stains 
natural killer (NK) cells as well as NK T cells (Arase et al., 2001). We further examined the 
NK and NK T cell populations in peripheral blood samples of one A-Mcpt5-Cre R26R-
EYFP double positive animal. As shown in Fig. 2.13, 8.96% of the CD49b+NKG2D+ 
NK cell subset, but only 1.29% of NK T cells, defined as CD49b+CD3+ cells, displayed 
EYFP reporter gene expression (Fig. 2.13, A and B). Only 0.78% of NKG2D single 
positive NK cells were EYFP positive (Fig. 2.13, B). In conclusion, a small fraction of the 
CD49b+NKG2D+ NK cells is the only hematopoietic cell population other than mast cells 
that delete loxP-flanked DNA.  
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Fig. 2.12 Absence of EYFP reporter gene expression in hematopoietic cells other than mast cells 
and in non-hematopoietic skin cells. EYFP expression was analyzed in hematopoietic cells from 
peritoneal lavage fluid and spleen cell suspensions of Mcpt5-Cre R26R-EYFP double positive 
mice. In order to enrich granulocytes, splenocytes were separated into lymphocyte and non-
lymphocyte fractions by MACS. Basophils were detected as CD49b and FcεRIα double positive 
cells. Macrophages, neutrophils, eosinophils, dendritic cells, B cells and T cells were stained using 
antibodies against F4/80, Gr-1, Siglec-F, CD11c, CD19 and CD3ε, respectively.  
EYFP fluorescence intensity of these populations and CD45-negative cells of the skin was 
displayed in histogram plots. The green graph represents Mcpt5-Cre R26R-EYFP double positive 
mice and the red graph Cre-negative but R26R-EYFP-positive controls (littermates in most 
instances). Results are representative for three A- and three X-Mcpt5-Cre mice. 
 
Fig. 2.13 Cre-mediated reporter gene expression in NK and NK T cells of one A-Mcpt5-Cre R26R-
EYFP double positive mouse. Peripheral blood samples were taken from the lateral tail vein of one 
animal and erythrocytes were lysed. NK cells and NK T cells were identified as CD49b (clone DX5) 
and NKG2D or CD49b and CD3ε double positive cells, respectively. (A) EYFP fluorescence 
intensity of these cell populations was displayed in histogram plots. The green graphs represent 
the A-Mcpt5-Cre R26R-EYFP double positive animal and the red graph the Cre-negative control. 
(B) The table displays the percentages of EYFP expressing cells among the indicated populations 
of the A-Mcpt5-Cre R26R-EYFP double positive animal. 
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Fig. 2.14 Cre-mediated activation of EYFP reporter gene expression in tg(CMV-Cre) R26R-EYFP 
double positive mice. (A) EYFP fluorescence of total cell populations of peritoneal lavage fluid, 
spleen, peripheral blood and skin was assessed by flow cytometry and displayed in histogram 
plots. The green graphs represent tg(CMV-Cre) R26R-EYFP double positive, the red graphs 
represent control mice. (B) Average percentage of EYFP expressing cells of total peritoneal, 
splenic, peripheral blood and skin cells. Macrophages, basophils, eosinophils, neutrophils, dendritic 
cells, B cells and T cells were stained with antibodies against F4/80, CD49b/FcεRIα, SiglecF, Gr-1, 
CD11c, CD19 and CD3ε, respectively. The EYFP expressing percentage of each cell population 
was assessed by flow cytometry. Results are representative of two double positive mice except for 
blood cells (n=1).  
 
In a control experiment we used mice with a germ line deletion of the stop element of the 
R26R-EYFP reporter obtained by crossing the reporter strain to the X-linked Cre-deleter 
strain tg(CMV-Cre) (Schwenk et al., 1995). Analysis of tg(CMV-Cre) R26R-EYFP double 
positive mice demonstrated that all non-mast cell populations analyzed for reporter gene 
expression in the Mcpt5-Cre mice can, in principle, express EYFP (Fig. 2.14, A and B). 
In contrast to six A-Mcpt5-Cre mice (described above), one Mcpt5-Cre transgenic animal 
displayed non-specific reporter gene expression in 15%-25% of all cell types analyzed 
including non-hematopoietic cells of the skin (data not shown). This animal was the 
progeny of a different F1 animal from the cross of the founder animal to the reporter 
strain. All littermates showed non-specific reporter gene expression to a variable extent 
(data not shown). This non-specific Cre-mediated recombination in cells other than mast 
cells was restricted to this substrain which was, therefore, not analyzed further. No non-
specific reporter gene expression could be detected (in all subsequent experiments) in the 
substrain that was finally designated as A-Mcpt5-Cre.  
As the A-Mcpt5-Cre line shows efficient and mast cell-specific Cre-mediated 
recombination and as this line has an advantage over the X-linked Cre line in terms of 
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% of EYFP expressing cells n
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breeding strategies and Cre-mediated deletion in female mice, this line will be used 
predominantly in the future for breeding with other floxed lines.  
 
2.1.4.3 Exclusion of Cre-mediated genotoxicity in Mcpt5-Cre mice  
In order to exclude a reduced viability of mast cells in Mcpt5-Cre mice due to Cre-
mediated genotoxic effects, the percentage of mast cells in peritoneal lavage fluid was 
compared in Mcpt5-Cre R26R-EYFP double positive and wild type animals. Numbers of 
peritoneal mast cells in double positive mice did not differ from those of wild type animals 
(Fig. 2.15, A).  
 
Fig. 2.15 Numbers and proliferative potential of peritoneal mast cells in Mcpt5-Cre transgenic mice. 
(A) Mast cells were quantified in percent of total peritoneal cells in peritoneal lavage fluid from 
control (n=9) and Mcpt5-Cre (seven A-Mcpt5-Cre and three male X-Mcpt5-Cre) mice. (B) 
Peritoneal cell-derived mast cells (PCMC) were generated from total peritoneal cells of one control 
and one A-Mcpt5-Cre R26R-EYFP double positive mouse by incubating these cells in medium 
supplemented with SCF-conditioned medium (Malbec et al. 2007). Cell numbers were quantified at 
each passage every 3-4 days by counting trypan blue excluding cells. (C) At passage seven, 
PCMCs were analyzed by flow cytometry by staining for CD117 and FcεRIα. CD117+FcεRIα+ cells 
were gated and analyzed for reporter gene expression (displayed in a histogram plot). The green 
graph represents the Mcpt5-Cre R26R-EYFP double positive mouse and the red graph the control 
animal.  
 
To assess whether the proliferative potential of mast cells in Mcpt5-Cre transgenic 
animals was reduced by genotoxic Cre effects, total peritoneal lavage cells of Mcpt5-Cre 
R26R-EYFP double positive and Cre-negative mice were cultured in presence of stem cell 
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factor (SCF) as described (Malbec et al., 2007). After 23 days, these cultures contained 
98% mast cells designated as PCMCs (peritoneal cell derived mast cells) as judged by 
expression of the CD117 and FcεRIα surface markers (Fig. 2.15, C). By this time, 
absolute cell numbers had increased more than 200-fold in both cultures (Fig. 2.15, B). 
Importantly, the mast cells grown from the Mcpt5-Cre R26R-EYFP mouse uniformly 
expressed EYFP ruling out an overgrowth of the culture by a (hypothetical) minor 
population of mast cells, which do not express Cre (Fig. 2.15, C). These results show that 
Mcpt5-Cre positive mast cells are viable like wild type mast cells, and that they are not 
growth retarded. Therefore, mast cells of Mcpt5-Cre transgenic mice do not seem to be 
significantly affected by Cre-mediated genotoxicity. 
2.1.5 Screening of Mcpt6-Cre transgenic mice for Cre-mediated 
recombination  
Seven of the Mcpt6-Cre founder lines that transmitted the transgene to the germline were 
mated to R26R-EYFP reporter mice and Mcpt6-Cre R26R-EYFP double positive offspring 
were obtained from five breedings and tested for Cre-mediated recombination by flow 
cytometry. Since the staining of mast cells with a new lot of the anti-FcεRIα antibody 
proved unreliable, in most of the following experiments mast cells were identified as 
CD117 and IgE positive cells. Given that, due to its high affinity for IgE, basically all FcεRI 
receptors are loaded with immunoglobulin E (Benoist and Mathis, 2002), cells which are 
positive for IgE can be considered as FcεRI+ and designated as FcεRI/IgE+.  
In two of the five lines, efficient Cre-mediated activation of EYFP expression was 
observed in CD117+FcεRIα/IgE+ peritoneal mast cells as well as in CD117+CD45+ skin 
mast cells (Fig. 2.16, A). As these lines were derived from the founder animals 526873 
and 526874 and as they displayed an autosomal pattern of transgene inheritance these 
two lines were designated as A73-Mcpt6-Cre and A74-Mcpt6-Cre. 95.92±0.96% and 
96.5±1.39% of CD117+FcεRIα+ peritoneal mast cells of the A73- and A74-Mcpt6-Cre line, 
respectively, displayed reporter gene expression (n=4 for both lines, Fig. 2.16, A). In one 
animal of the A73-Mcpt6-Cre line and two mice of the A74-Mcpt6-Cre line, the 
CD117+CD45+ skin mast cell population was analyzed for reporter gene expression. The 
majority of the few CD117+CD45+ cells gated was EYFP positive (51/59, 15/28 and 42/45 
gated events). Although a full length integration of the transgene could not be 
demonstrated for the A73-Mcpt6-Cre mice (Fig. 2.8, B), this line displayed almost identical 
efficiency of Cre-mediated recombination compared to the A74-Mcpt6-Cre line containing 
the full length transgene. This shows that the missing part of the transgene (of unknown 
size downstream of the Mcpt6-Cre sequence) was not important for transgene expression. 
In both Mcpt6-Cre lines, the expression of the Cre recombinase was restricted to mast 
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cells, since in two animals analyzed for each line reporter gene expression could be 
detected, if at all, in minimal numbers in hematopoietic cell populations other than mast 
cells (below 1%, Fig. 2.16, B and C). In contrast to the finding in Mcpt5-Cre/R26R-EYFP 
mice, peripheral blood CD49b+ cells were basically all EYFP negative (below 0.1%, Fig. 
2.16, B).  
 
 
Fig. 2.16 Efficiency and specificity of Cre-mediated activation of EYFP reporter gene expression in 
A73- and A74-Mcpt6-Cre mice. EYFP expression was analyzed by flow cytometry of cells from 
peritoneal lavage fluid and skin cell suspensions (A), peripheral blood samples (B) as well as 
spleen cell suspensions (C) of Mcpt6-Cre R26R-EYFP double positive animals. (A) Peritoneal mast 
cells were stained for CD117 and FcεRI bound IgE (n=4 for each Mcpt6-Cre line) and skin mast 
cells for CD117 and CD45 (n=1 for A73- and n=2 for A74-Mcpt6-Cre). Mast cell populations were 
gated and their EYFP fluorescence was displayed in histogram plots. (B) Basophils were identified 
as CD49b (clone DX5) and FcεRIα double positive cells in erythrocyte lysed blood samples. The 
basophil population as well as total CD49b+ cells were gated and displayed in histogram plots (n=2 
for A73-Mcpt6-Cre and n=1 for A74-Mcpt6-Cre). (C) Macrophages, eosinophils, neutrophils, 
dendritic cells, B cells and T cells were identified in total spleen cell suspensions as F4/80, Siglec-
F, Gr-1, CD11c, CD19 and CD3ε positive cells, respectively, (n=2 for each, A73- and A74-Mcpt6-
Cre). EYFP fluorescence of the respective cell populations was displayed in histogram plots. The 
green graphs represent Mcpt6-Cre R26R-EYFP double positive animals, the red graphs Cre-
negative but R26R-EYFP positive control animals (littermates in most instances).  
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A potential effect of Cre expression on the proliferative potential has not yet been 
determined for Mcpt6-Cre mice. However, both, A73- and A74-Mcpt6-Cre, displayed 
reduced mast cell numbers in the peritoneal cavity (0.8±0.38% mast cells of total 
peritoneal cells for the A73-Mcpt6-Cre line (n=4) and 0.73±0.29% for the A74-Mcpt6-Cre 
line (n=4) compared to 1.57±0.72% mast cells in control animals (n=6, Fig. 2.17). This 
result may be due to genotoxic effects of the Cre recombinase in mast cells of Mcpt6-Cre 
transgenic mice and will be analyzed further. 
 
 
Fig. 2.17 Number of peritoneal mast cells in Mcpt6-Cre mice. Mast cells were quantified as 
percent of total peritoneal cells in peritoneal lavage fluid from control (n=6), A73-Mcpt6-Cre (n=4) 
and A74-Mcpt6-Cre (n=4) mice.  
 
2.1.6 Test for Cre-mediated EYFP expression in BMMCs 
In vitro cultured bone marrow-derived mast cells (BMMC) are immature mast cells as 
judged by the proteoglycan and mast cell protease content of their granules (Lunderius et 
al., 2000). They contain chondroitin sulfate, but not heparin sulfate, as well as the mast 
cell proteases mMCP-5, -6 and CPA. The IL-3 dependent differentiation of bone marrow 
cells to BMMCs resulted in 91.9±1.84% of CD117+FcεRI+ cells after eight weeks of culture 
as shown in Fig. 2.18, A, for BMMCs derived from R26R-EYFP and A-Mcpt5-Cre, X-
Mcpt5-Cre, A73-Mcpt6-Cre, A74-Mcpt6-Cre and tg(CMV-Cre) double positive mice.  
Various studies demonstrated significant transcription of Mcpt5 and Mcpt6 in BMMCs by 
northern blot analysis (Gurish et al., 1992; Lunderius et al., 2000; McNeil et al., 1991; 
Reynolds et al., 1991) and mMCP-5 and -6 expression on the protein level (Eklund et al., 
1994; McNeil et al., 1992a; Wolters et al., 2001). However, only 7-35% of the 
CD117+FcεRI+ BMMCs derived from either Mcpt5-Cre or Mcpt6-Cre R26R-EYFP double 
positive mice display Cre-mediated activation of EYFP expression (Fig. 2.18, B and C). 
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Thus, in most of the cells the Mcpt5 and Mcpt6 promoters are either not active or active at 
such a low level that Cre expression is not sufficient for the deletion of the stop element. 
After twelve weeks in culture the percentage of EYFP expressing BMMCs was not 
significantly increased (8-41%, Fig. 2.18, C) demonstrating that neither Cre-expressing 
cells nor the EYFP-negative cells have a growth advantage. 
 
 
Fig. 2.18 EYFP reporter gene expression in bone marrow-derived mast cells (BMMC) derived from 
A- and X-Mcpt5-Cre, A73- and A74-Mcpt6-Cre and tg(CMV-Cre) R26R-EYFP double positive mice. 
Bone marrow cells were cultured in WEHI-3B conditioned medium. (A) After eight weeks (wk) in 
culture, cells were stained with antibodies against CD117 and FcεRIα and analyzed by flow 
cytometry. (B) CD117+FcεRIα+ cells of the indicated genotype (n=1 for all lines) were gated and 
displayed in histogram plots to show the fraction of EYFP expressing BMMCs. (C) The table 
specifies the percentages of EYFP expressing cells in the respective BMMC populations after eight 
and twelve weeks of culture. 
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In order to demonstrate that BMMCs can, in principle, express EYFP under the control of 
the ROSA26 promoter, the X-linked Cre-deleter strain tg(CMV-Cre) (Schwenk et al., 1995) 
was crossed with the R26R-EYFP strain. As displayed in the lower right histogram plot of 
Fig. 2.18 (B and C), EYFP expression could be detected in basically all CD117+FcεRI+ 
tg(CMV-Cre)/R26R-EYFP BMMCs after eight and twelve weeks of culture. 
 
2.1.7 Screening of Mcpt5-CreERT2 transgenic mice for Cre-
mediated recombination 
CreERT2 lines are characterized by constitutive expression of a CreERT2 fusion protein 
that is retained in the cytoplasm. Upon application of the estrogen analogon tamoxifen, 
the fusion protein translocates into the nucleus where it can mediate deletion of loxP-
flanked sequences. To assess whether peritoneal mast cells show Cre-mediated 
activation of EYFP expression upon tamoxifen induction, Mcpt5-CreERT2 R26R-EYFP 
double positive mice and Cre-negative littermates were orally treated with tamoxifen for 
five days using a feeding needle. Peritoneal lavage fluid cells were analyzed by flow 
cytometry three days or four weeks after the last tamoxifen application. In none of these 
lines, EYFP expression could be detected in mast cells (data not shown). To investigate 
whether the tamoxifen induction was unsuccessful or whether the expression of the fusion 
protein was ineffective, the frt site-flanked ERT2 element was removed using a mouse 
strain expressing an ubiquitously active Flp recombinase (hACTB::FLP mice (Dymecki, 
1996a)). In Mpct5-Cre(ERT2del) R26R-EYFP Flp-Deleter triple positive mice the Cre 
recombinase should be constitutively active without tamoxifen application. The efficiency 
of the ERT2 deletion was demonstrated by PCR on tail tip DNA (data not shown). 
Peritoneal mast cells were analyzed for reporter gene expression, but even after deletion 
of the ERT2 cassette no or only about 14 % of the mast cells showed Cre-mediated 
activation of EYFP expression (data not shown). Similar results were obtained for all four 
lines analyzed. From one line, we did not obtained triple transgenic animals. These results 
indicate that all five Mcpt5-CreERT2 lines are not functional, e.g. due to a defective 
transgene integration or an unfavorable integration site. New founder lines will be 
generated in the future.  
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2.2 A new model for inducible ablation of mast cells in 
adult mice 
The currently used mouse models for the investigation of mast cells, i.e. mast cell-
deficient mice, like the KitW/W-v and KitWsh/Wsh mutant lines, yielded valuable information but 
suffer from important limitations. Therefore, we established a new model for inducible 
mast cell-ablation by crossing A-Mcpt5-Cre mice to the iDTR strain (inducible diphtheria 
toxin receptor, (Buch et al., 2005)), which is characterized by the conditional expression of 
the high affinity simian diphtheria toxin receptor (DTR), i.e. the heparin-binding epidermal 
growth factor-like growth factor (HB-EGF). The receptor is necessary for the 
internalization of the toxin into the cell. Rodents usually are diphtheria toxin (DT) resistant 
because of the low affinity of the rodent HB-EGF to DT. In contrast, iDTR mice express 
the simian diphtheria toxin receptor under the control of the ubiquitously active ROSA26 
promoter provided a loxP-flanked stop element was removed by Cre-mediated 
recombination. Upon diphtheria toxin injection, all cells that express the DTR internalize 
the DT via its B subunit. Within the cell, the A subunit inactivates elongation factor 2 and 
thereby terminates protein synthesis and causes apoptotic death (Buch et al., 2005).  
2.2.1 Ablation of peritoneal and skin mast cells 
In order to test the efficiency of the ablation of peritoneal mast cells, A-Mcpt5-Cre iDTR 
double positive, Cre-negative iDTR single transgenic and wild type mice were treated with 
a single intraperitoneal (i.p.) injection of 25 ng DT/g bodyweight. 24 h later, peritoneal 
lavage fluid cells were analyzed for the presence of mast cells by flow cytometry. In the 
Cre-negative iDTR single positive as well as in wild type mice, normal numbers of 
CD117+FcεRIα+ cells could be detected (2.75±0.22% mast cells of total peritoneal cells, 
n=3) while in double positive mice only 0.035±0.01% mast cells were present reflecting 
successful ablation of 99.1±0.18% of CD117+FcεRIα+ cells (n=2, Fig. 2.19, A and B). 
Peritoneal macrophages, defined as F4/80+, and peritoneal B cells, defined as CD19+ 
cells, were not affected by DT treatment (Fig. 2.19, A and C). The results show that mast 
cells can be efficiently depleted in the peritoneal cavity with a single injection of the toxin.  
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Fig. 2.19 Efficiency of ablation of peritoneal mast cells. Mice were injected i.p. with a single dose of 
25 ng DT/g bodyweight. 24 h after the injection mice were sacrificed and peritoneal cells were 
isolated. (A) In peritoneal lavage fluid of wild type, iDTR single transgenic and A-Mcpt5-Cre iDTR 
double positive animals mast cells, B cells and macrophages were identified as CD117 and FcεRIα 
double and CD19 and F4/80 single positive cells, respectively, and analyzed by flow cytometry. (B) 
The average percent mast cells of total peritoneal cells in three control mice and two A-Mcpt5-Cre 
iDTR double positive mice are displayed. (C) Percent macrophages and B cells of total peritoneal 
cells in two control animals and one A-Mcpt5-Cre iDTR double positive mouse. 
 
The efficiency of mast cell depletion in the skin after DT injections was examined on either 
skin biopsies or skin samples from the back, abdomen or ear post mortem. In Giemsa 
stained paraffin sections mast cells appear dark purple due to the metachromatic staining 
of the mast cell granules. Mast cell numbers per mm2 were calculated by counting mast 
cells in the region between epidermis and panniculus carnosus and by software-supported 
determination of area size. DT treated Cre-negative iDTR positive littermates served as 
controls. Mast cell numbers in control mice were highly variable. Therefore, mast cell 
numbers in A-Mcpt5-Cre iDTR double positive mice were compared with a control 
collective representing mast cell numbers in back skin of ten Cre-negative mice 
(39.8±14.7 mast cells/mm2).  
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Fig. 2.20 Diphtheria toxin (DT) dosage finding experiments for depletion of skin mast cells in A-
Mcpt5-Cre iDTR double positive animals. Mice were treated with different DT dosages and number 
of DT injections. 4 mm biopsies (Bx) of the back skin from anesthetized animals or about 2 cm2 of 
back skin post mortem were taken three or seven days after the last DT injections. Mast cells were 
quantified per mm2 in Giemsa stained paraffin sections. The area between epidermis and 
panniculus carnosus was determined using Diskus 4.50 software (A) Scheme for the tested DT 
injection protocols. The corresponding average depletion efficiencies and animal numbers are 
listed. (B) Mast cell numbers per mm2 after injection of DT with the respective protocol were 
compared to mast cells per mm2 of a control collective (mast cell numbers in back skin of ten Cre-
negative control mice). 
 
24 h after a single injection of 25 ng DT/g bodyweight we found no reduction in mast cell 
numbers in the skin (data not shown). Interestingly, three days after a single injection, skin 
mast cells were reduced to 10.92±6.41 mast cells/mm2 (n=3, Fig. 2.20, A and B). In order 
to achieve efficient ablation of skin mast cells, different dosages, multiple injections and 
various injection intervals were tested. The different protocols are depicted in Fig. 2.20, A. 
The treatment with high doses, e.g. 3x 100ng/g (data not shown) or 4x 50ng/g bodyweight 
as well as frequent injections (7x 25 ng/g at daily intervals) turned out to be toxic or lethal 
for both, control and double positive mice. A reason for this toxic effect could be a 
contamination of the DT solution with endotoxins thereby causing a systemic inflammatory 
response. Also an effect mediated by the murine low affinity DTR cannot be excluded. 
Importantly, higher doses of DT resulted in complete elimination of skin mast cells (Fig. 
2.20, A and B), showing that, in principle, 100% of skin mast cells express Cre 
recombinase and undergo Cre-mediated deletion of the loxP-flanked allele. Given the 
toxicity of higher doses and frequent injections (daily intervals) and also the slow kinetics 
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of skin mast cell depletion, we decided to follow a regimen of four injections of 25 ng/g 
bodyweight at weekly intervals. In skin samples taken one week after the last injection, 
mast cell numbers were reduced to 2.28±2.02 mast cells/mm2 (n=7), i.e. with an average 
depletion efficiency of 94.27 % compared to the control collective (Fig. 2.20, A and B).  
As mentioned above, all animals, controls and double positive mice, treated with high DT 
dosages (50 – 100 ng/g bodyweight) showed severe clinical signs like lethargy, significant 
weight loss and hunch back over a period of one to two weeks until they finally died. In 
contrast, after four injections of 25 ng DT/g bodyweight at weekly intervals control and A-
Mcpt5-Cre iDTR double positive mice did not show any sign of disease. Nevertheless, 
some animals died within three days after the first injection. This problem occurred 
exclusively in A-Mcpt5-Cre iDTR double positive animals, 21.52% of which died (17 of 79 
double positive mice and 0 of 69 controls, Fig. 2.21).  
 
 
Fig. 2.21 Survival after the first injection of 
DT. A-Mcpt5-Cre iDTR double positive mice 
were either treated with DT alone or with DT 
together with the H1-antagonist pyrilamine 
(5µg/g bodyweight). The grey bar represents 
surviving and healthy DT treated animals. 
Black bar represents animals that died after 
the first DT injection within three days.  
 
 
This finding led to the assumption that mast cells might degranulate before dying by 
apoptosis resulting in high systemic levels of mast cell mediators leading to lethal 
anaphylaxis. Therefore, control and A-Mcpt5-Cre iDTR double positive mice were treated 
with DT following the same protocol but this time the H1-antagonist pyrilamine (5 µg/g 
bodyweight) was injected together with the first toxin injection. Among the animals treated 
with DT plus H1-antagonist, i.e. 21 controls (data not shown) and 23 Cre-positive mice 
(Fig. 2.21), only one (Cre-positive) mouse died indicating a significant reduction of lethality 
to 4.35%. This result suggests that histamine release was in fact the cause of the lethal 
effects of mast cell ablation and that this problem can be avoided by blocking histamine 
effects. Since the pyrilamine is injected only along with the first DT dosage and since mast 
cell depleted mice will be used for experiments only four weeks later, it can be assumed 
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that the H1-antagonist treatment will not affect the experiments. Despite the evidence for 
systemic mast cell mediator release, we never observed any sign of local inflammation on 
histological tissue analysis of DT-injected double positive mice (with or without H1-
antagonist treatment) (data not shown).  
As skin mast cell numbers vary between different locations, reduction of mast cell 
numbers (achieved by the final DT injection protocol) was also determined at other sites 
than back skin, i.e. abdomen and ear. Mast cell depletion in abdominal skin of A-Mcpt5-
Cre iDTR double positive mice was comparable to that in back skin with 1.34±1.16 
residual mast cells/mm2 (n=6) representing an average depletion efficiency of 96.58% 
compared to a control collective (39.2±14.16 mast cells/mm2, n=4, Fig. 2.22, A). Ear skin 
mast cell density of control mice was about 3-fold higher than in other skin regions 
(107±16.24 mast cells/mm2, n=4, Fig. 2.22, B) and depletion was least efficient in this 
location. Seven days after the last injection, 18.25±12.11 mast cells/mm2 remained (n=6) 
corresponding to an average depletion efficiency of 84.33% compared to the control (Fig. 
2.22, B). 
 
 
Fig. 2.22 Depletion of mast cells in abdominal skin, ear and peritoneal cavity by four injections of 
25 ng DT/g at weekly intervals. Animals were analyzed seven days after the last injection. (A) Mast 
cells were quantified in the area between epidermis and panniculus carnosus of belly skin of six A-
Mcpt5-Cre iDTR double positive and four Cre-negative control mice. (B) Mast cell numbers were 
determined in an area that represents the whole ear section of six double positive and four Cre-
negative mice. (C) Mast cells in peritoneal lavage fluid were stained for CD117 and FcεRI bound 
IgE and analyzed by flow cytometry.  
 
To further validate successful depletion of peritoneal mast cells using the final injection 
protocol, peritoneal lavage fluid cells were analyzed by flow cytometry seven days after 
the last injection. Seven A-Mcpt5-Cre iDTR double positive animals displayed an average 
depletion of 97% of CD117+FcεRIα/IgE+ mast cells corresponding to 0.06±0.05% mast 
cells of total peritoneal cells compared to 2.1% in control animals (n=13, Fig. 2.22, C).  
In order to assess whether the four injections of 25 ng DT/g bodyweight at weekly 
intervals affected hematopoietic cells other than mast cells, the percentages of CD49b+ 
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cells, eosinophils and basophils of total blood leukocytes (Fig. 2.23, A) and of T cells, B 
cells, neutrophils, macrophages and dendritic cells of total splenocytes (Fig. 2.23, B) were 
determined by flow cytometry. The results indicated that the DT treatment did not cause a 
reduction of these cell populations in A-Mcpt5-Cre iDTR double positive mice (n=3 for 
peripheral blood cells and n=2 for splenocytes) compared to control animals (n=3 for 
peripheral blood cells and one animal for splenocytes). Although a small fraction of 
CD49b+ cells were shown in A-Mcpt5-Cre R26R-EYFP double positive mice to express 
the Cre recombinase, a reduction of this cell population after DT treatment of A-Mcpt5-Cre 
iDTR mice was not detectable. The increased number of splenic neutrophils in double 
positive mice compared to the control (Fig. 2.23, B, right panel) has to be verified by 
analyzing more mice especially more DT-treated control animals.  
 
 
 
Fig. 2.23 DT does not affect hematopoietic cell populations other than mast cells. Control and A-
Mcpt5-Cre/iDTR mice were treated 4x with 25 ng DT/g bodyweight i.p. at weekly intervals. The 
percentages of each cell population of total blood leukocytes (A) and total splenocytes (B) were 
determined by flow cytometry after erythrocyte lysis. (A) In peripheral blood samples of A-Mcpt5-
Cre iDTR double positive mice (n=3) and Cre-negative controls (n=3) CD49+ cells, basophils and 
eosinophils were stained with anti-CD49b (clone DX5), DX5 and anti-IgE and anti-Siglec-F, 
respectively. (B) In spleen cell suspensions of one Cre-negative and two A-Mcpt5-Cre iDTR 
double positive mice T cells, B cells, neutrophils, macrophages and dendritic cells were stained 
with antibodies against CD3ε, CD19, Gr-1, F4/80 and CD11c, respectively.  
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In conclusion, the A-Mcpt5-Cre/iDTR system allows efficient ablation of mast cells in the 
peritoneal cavity and skin without affecting other cell populations. However, mast cell 
depletion in the skin occurs slowly and requires multiple i.p. injections compared to the 
complete depletion of peritoneal mast cells after a single injection.  
2.2.2 Depletion of gastrointestinal mast cells 
In mice two mast cell phenotypes can be distinguished, connective tissue type mast cells 
(CTMC) and mucosal mast cells (MMC). The CTMCs are located predominantly in the 
skin and peritoneal cavity but also in the connective tissue of most organs including the 
submucosal layers of the gastrointestinal tract and are characterized by storage of the 
proteoglycan heparin sulfate and the proteases mMCP-4, -5, -6 and MC-CPA. MMCs 
reside within epithelia of the gastrointestinal and respiratory tracts, i.e. above the 
basement membrane between the epithelial cells. Their granules contain the proteoglycan 
chonodroitin sulfate and mMCP-1 and -2. In order to test whether Cre recombinase is also 
expressed in the MMC subset, mast cell depletion was analyzed in the stomach. This 
organ was chosen because in C57BL/6 mice, hardly any MMCs can be found in the small 
intestine and colon while high numbers are usually encountered in the stomach. Paraffin 
sections were stained histochemically for the chloroacetate esterase activity using AS-D 
chloroacetate as a substrate. In the sections, mast cells can be recognized by their dark 
red stained granules. The stomach can be divided into the squamous portion 
characterized by squamous epithelium and the presence of CTMCs but not MMCs and 
the glandular portion that contains both, CTMCs in the submucosa and MMCs in the 
mucosal epithelium. Seven days after the last of four injections of 25 ng DT/g bodyweight 
at weekly intervals, the CTMCs were depleted efficiently in the squamous as well as in the 
glandular portion of the stomach. CTMC numbers were reduced to 1.46±0.65 mast 
cells/mm2 (n=3) corresponding a depletion efficiency of 94.2% compared to control mice 
(25.1±5.11 mast cells/mm2, n=2, Fig. 2.24, A (upper and middle panel) and B). In contrast, 
no significant reduction in MMC numbers could be detected in the mucosal layer 
(26.13±0.61 mast cells/mm2 in control animals (n=2) versus 20.63±5.2 mast cells/mm2 in 
A-Mcpt5-Cre iDTR double positive mice (n=3), Fig. 2.24, A (middle and lower panel) and 
B). These results indicate that under the control of the Mcpt5 promoter Cre recombinase 
is not expressed in mucosal mast cells or in progenitor cells that can give rise to MMCs. 
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Fig. 2.24 Depletion efficiency of connective tissue mast cells (CTMC) and mucosal mast cells 
(MMC) in the stomach. Mice were treated with four injections of 25 ng DT/g bodyweight at weekly 
intervals and were sacrificed seven days after the last injection. The stomach was washed with 
PBS and fixed with Carnoy’s solution. Paraffin sections were stained for chloroacetate esterase. 
(A) Squamous and glandular portion of either control mice or A-Mcpt5-Cre iDTR double positive 
mice are shown in 100-fold and 50-fold/200-fold magnification, respectively. Asterisks indicate the 
mucosal epithelium within the glandular portion of the stomach. Arrows indicate to chloroacetate 
esterase positive MMCs. Pictures were generated using a Leika DM 4000 B microscope. (B) 
CTMCs in the squamous and glandular portion and MMCs in the mucosal epithelium of the 
glandular portion were quantified as mast cells/mm2. Grey bars represent control mice (n=2), black 
bars represent A-Mcpt5-Cre iDTR double positive mice (n=3).  
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2.2.3 Effect of mast cell depletion on passive systemic 
anaphylaxis  
Anaphylaxis is a life threatening syndrome encompassing symptoms like bronchospasm, 
hypotension, laryngeal edema and hyperperistalsis. These clinical signs can be caused by 
the crosslinking of IgE antibodies bound to the high affinity IgE receptor (FcεRI) on mast 
cells and basophils which triggers the release of histamine, prostaglandins and 
leukotrienes (Kemp and Lockey, 2002). In order to test whether the ablation of connective 
tissue mast cells by DT injections also has an effect on a typical mast cell-mediated 
immune response, like anaphylaxis, the model of passive systemic anaphylaxis was 
applied to mast cell-depleted mice. In this model, the animals are first sensitized by 
injection of a monoclonal IgE antibody specific for the allergen dinitrophenyl (DNP). 24 h 
after sensitization, the mice are challenged with DNP coupled to human serum albumin 
(DNP-HSA). The transient drop of the body temperature is a widely used indicator of the 
intensity of the anaphylactic response. A-Mcpt5-Cre iDTR double positive mice and Cre-
negative controls, treated four times with 25 ng DT/g bodyweight at weekly intervals 
(without pyrilamine), were sensitized with IgE seven days after the last DT injection and 
were challenged 24 h later with either DNP-HSA or vehicle. The body temperature was 
measured using a rectal probe before and every ten minutes over a period of three hours 
after challenging. The Cre-negative controls which were challenged with DNP-HSA 
developed a severe anaphylactic response. Within 20 min the body temperature 
decreased by 5.3±0.57°C and reached a minimum after 40 min (reductio n of 6±1.1°C, Fig. 
2.25). On the contrary, mast cell-depleted mice displayed a reduced anaphylactic 
response. After a drop of the body temperature by 3.3±1.03°C at 20 min after challenging, 
the double positive mice quickly recovered (Fig. 2.25). While 60 minutes after DNP 
injection the temperature of controls was still low (33.7±1.55°C), the mast cell-depleted 
mice almost reached normal temperatures (37.5±0.52°C compared to 38 ±0.35°C before 
challenging). Depletion efficiency of mast cells was tested in the peritoneal cavity for six of 
eleven A-Mcpt5-Cre iDTR double positive mice. Hardly any peritoneal mast cells 
(0.035±0.03% of total peritoneal cells) could be detected in these mice reflecting an 
average depletion efficiency of 98.33%. Since sensitization as well as challenge was 
applied intraperitoneally, it was expected that peritoneal mast cells are the predominant 
effectors of this response. These results show that, although peritoneal mast cells were 
efficiently ablated, the mice still developed a minor anaphylactic response. This residual 
response may be due to the activation of residual connective tissue mast cells in other 
tissues, mucosal mast cells or basophils. 
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Fig. 2.25 Passive systemic anaphylaxis in mast cell depleted mice. A-Mcpt5-Cre iDTR double 
positive and Cre-negative control mice were injected i.p. four times with 25 ng DT/g bodyweight at 
weekly intervals. Seven days after the last injection, mice were sensitized i.p. with 12.5 µg anti-
DNP-IgE. 24 h later, mice were either challenged i.p. with 400 µg DNP-HSA or injected with vehicle 
(saline). The body temperature was measured using a rectal probe before and every ten minutes 
after challenge over a period of three hours. For each time point, the drop of body temperature is 
displayed in each group as the mean reduction of the average body temperature before challenge. 
Black circles represent control mice treated with vehicle, red squares challenged double positive, 
mast cell depleted mice and black triangles challenged control mice. Numbers of animals in each 
group are indicated.  
 
2.2.4 Repopulation of mast cells after DT-induced ablation 
Repopulation of peritoneal cavity and skin with mast cells was investigated by FACS 
analysis of peritoneal lavage fluid and metachromatic staining of sections from skin 
biopsies. DT-treated A-Mcpt5-Cre iDTR double positive mice and Cre-negative control 
animals were sacrificed one (n=3), seven (n=7), 14 (n=4), 21 (n=4), 28 (n=2), 42 (n=2), 56 
(n=3) and 84 (n=2) days after the last DT injection and peritoneal cells were isolated. The 
percentage of CD117+FcεRI/IgE+ mast cells of total peritoneal cells was compared to that 
of control mice (2.1±0.8% mast cells of total peritoneal cells, n=13, Fig. 2.26, A). 
Surprisingly, we did not observe a significant repopulation of the peritoneal cavity with 
mast cells within eight weeks after depletion. After an initial increase to 7% of control mast 
cell numbers three weeks after the last DT injection, the restoration of the peritoneal mast 
cell numbers seemed to stagnate and reached only 8% after 56 days. (Fig. 2.26, A). 
Between week eight and twelve, mast cells started to return gradually to 34% of control 
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mast cell numbers 84 days after the last DT injection. Even though animal numbers for 
each time point were very low, these results clearly demonstrate that mast cells 
repopulate the peritoneal cavity in significant numbers only twelve weeks after DT 
treatment. To further validate the data, more mice and later time points have to be 
analyzed.  
 
 
Fig. 2.26 Mast cell repopulation of the peritoneal cavity and skin after DT-induced mast cell 
ablation. (A) A-Mcpt5-Cre iDTR double positive and Cre-negative control mice were injected i.p. 
four times with 25 ng DT/g bodyweight at weekly intervals. Mice were sacrificed one (n=3), seven 
(n=7), 14 (n=4), 21 (n=4), 28 (n=2), 42 (n=2), 56 (n=3) and 84 (n=2) days after the last injection 
and peritoneal cells were isolated. Cells were analyzed for the presence of mast cells (defined as 
CD117+FcεRI/IgE+ cells) by flow cytometry. Mast cell numbers were displayed as percentages of 
total peritoneal cells and compared to those of control mice (n=13). Percentages in parentheses 
reflect percent mast cells of control mast cell numbers. (B) Numbers of skin mast cells were 
quantified as mast cells/mm2 in Giemsa stained paraffin sections of back skin from double positive 
animals treated with three i.p. injections of 35 ng DT/g bodyweight at weekly intervals. 4 mm punch 
biopsies from the back skin were taken on day seven, 22, 40, 56, 77 and 105 (n=5 for each time 
point except d77 with n=4) after the last DT injection. Mast cell numbers in sections of these 
biopsies were compared to the average mast cell number per mm2 of back skin of ten Cre-negative 
control animals. Percentages in parentheses reflect percent mast cells of control mast cell 
numbers.  
 
39,8
1,1 3,24
4,44
9,83
5,44 6,18
0
10
20
30
40
50
60
control d7 d22 d40 d56 d77 d105
m
as
t c
el
ls
/m
m
2
days after last injection
2,1
0,035 0,06 0,08 0,15 0,09 0,08 0,17
0,71
0,0
0,5
1,0
1,5
2,0
2,5
3,0
control d1 d7 d14 d21 d28 d42 d56 d84
%
 
m
as
t c
el
ls
 
o
f t
o
ta
l 
pe
rit
o
n
ea
l c
el
ls
days after last injection
A
B
peritoneal cavity
skin
(7%)(1.4%) (3%) (3.8%) (4.3%) (3.8%) (8%)
(34%)
(2.8%) (8%) (11%) (24.7%) (13.7%) (15%)
Results  54 
Similar observations were made in the skin. In order to test the repopulation of skin with 
mast cells, biopsies from back skin of DT-treated mice were taken at two to four week 
intervals. For this experiment, mice were used that had received three i.p. injections of 
35ng DT/g bodyweight at weekly intervals. Seven days after the last injection mast cell 
numbers were reduced to 1.1±1.76 mast cells/mm2 reflecting an average depletion 
efficiency of 97.2% (n=5, Fig. 2.26, B). Mast cell numbers slightly increased until eight 
weeks after the last DT injection to 9.83±3.94 mast cells/mm2. Thus, mast cell numbers 
were restored to 24.7% on average. For later time points we expected that the gradual 
increase in mast cell numbers would continue, but surprisingly, three weeks later (77 days 
after the last DT injection) mast cell numbers decreased again to 13.6% of control 
numbers (n=4, Fig. 2.26, B). Even 15 weeks after the last injection (d105, n=5) the mast 
cell numbers remained at the same level (15% of control numbers) demonstrating that the 
decrease of the mast cell numbers at time point d77 was not due to heterogeneity of mast 
cell numbers at different sites of the skin from which the biopsies were taken. Future 
experiments will demonstrate whether at later time points mast cell numbers recover to 
normal values or whether the induced ablation profoundly disturbed the steady state 
homeostasis of mast cell populations.  
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3 Discussion 
Mast cells are one of the most versatile cells of the body. They express an enormous 
spectrum of mediators of which distinct profiles are released dependent on the mode of mast 
cell activation. Mast cells have been demonstrated to be essential initiators of innate immune 
responses against pathogens and important modulators of adaptive immunity. Even 
immunosuppressive mast cell functions were shown. The currently used mouse models for 
the investigation of mast cell biology, i.e. the reconstitution of KitW/Wv or KitWsh/Wsh mice with in 
vitro differentiated mast cells derived from gene deficient mice, provided important 
information, but inherent technical problems limit experimentation and interpretation of the 
data. In addition, the availability of viable knock-out mice that can serve as a source of 
cultured mast cells for the reconstitution of mast cell-deficient mice is limited.  
This thesis reports the successful generation of mast cell-specific Cre transgenic mouse lines 
that allow inactivation of genes selectively in mast cells in vivo. Two lines express Cre under 
the control of the Mcpt5 promoter. The A-Mcpt5-Cre line is characterized by autosomal 
inheritance of the transgene, while the X-Mcpt5-Cre line shows X-linked inheritance 
(Scholten et al., 2008). Another two lines express Cre recombinase under the control of the 
Mcpt6 promoter. Application of these Mcpt6-Cre transgenic lines (A73- and A74-Mcpt6-Cre) 
might be restricted due to Cre-mediated genotoxic effects on mast cells in these lines. All 
lines uniformly express Cre recombinase in all connective tissue type mast cells (CTMC) in a 
highly mast cell-specific manner resulting in efficient deletion of loxP-flanked DNA. To 
examine the mast cell-specific functions of individual genes, a diverse spectrum of mouse 
lines carrying loxP-flanked genes is available for mast cell-specific Cre-mediated 
mutagenesis in vivo using the Mcpt5-Cre lines. The A-Mcpt5-Cre line was applied for the 
establishment of a new model for inducible mast-cell ablation in adult mice as demonstrated 
in this thesis. A significant reduction of the mast cell-mediated systemic anaphylactic 
response in mast cell-depleted animals demonstrated the usefulness of this model for mast 
cell research. Recently, another Cre line was published by Müsch et al. that reportedly 
expresses Cre recombinase under the control of a baboon chymase promoter in mucosal 
mast cells (MMC) of lung and intestine (Müsch et al., 2008). Thus, this strain might 
complement our system.  
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3.1 Novel transgenic strains for mast cell-specific Cre-
mediated mutagenesis in vivo 
3.1.1 Design and construction of the transgene 
To achieve mast cell-specific Cre-mediated deletion in vivo, Cre recombinase has to be 
expressed under the control of a mast cell-specific promoter. Ideally, a novel Cre-transgenic 
mouse would allow deletion of genes in all mast cells, i.e. CTMCs as well as MMCs. 
Promising candidate promoters were the promoters of mast cell protease genes which are 
abundantly expressed in mast cells while there is little evidence for expression in other cell 
types. In this thesis, Mcpt5 and Mcpt6 promoters were used for the generation of the 
transgenes. Both proteases, mMCP-5 and mMCP-6, are expressed in CTMCs and also in 
bone marrow derived mast cells (BMMC) as shown on transcriptional and translational levels 
(Gurish et al., 1992; Lunderius et al., 2000; Wolters et al., 2001). Other mast cell proteases 
could be excluded like e.g. mMCP-8, which is predominantly expressed in basophils 
(Lunderius and Hellman, 2001), mMCP-9, which can be detected in uterine mast cells (Hunt 
et al., 1997), or mMCP-1 and -2, which are predominantly expressed in MMCs (Pejler et al., 
2007). mMCP-4 is considered to be a terminal differentiation marker of CTMCs (Pejler et al., 
2007). Thus, Cre expression in a precursor that can differentiate into both, CTMCs and 
MMCs, seemed unlikely. In addition, mMCP-7 is not expressed in C57BL/6 mice at all due to 
a point mutation in this strain (Hunt et al., 1996). The mc-cpa promoter was not chosen in 
order to avoid Cre expression in related cell types that we reasoned may occur since the mc-
cpa is one of the first mast cell protease genes to be expressed during mast cell 
differentiation (Pejler et al., 2007).  
The construction of the transgene was facilitated by the advances in BAC recombineering. 
The advantage of BAC-based transgenes is that BAC vectors can accommodate large 
genomic DNA fragments which encompass the entire genomic sequence of a gene of 
interest (in this work Mcpt5 and Mcpt6) along with abundant flanking sequence containing all 
cis-acting regulatory elements with high probability. In addition, these large molecules, when 
randomly integrated into the genome, are less, if at all, prone to position effects at the 
integration site. To drive Cre expression under the control of the Mcpt5 or Mcpt6 promoter, 
only exon 1 of these genes was replaced by the Cre cassette avoiding deletion of possible 
regulatory elements located within the introns of these genes.  
Mcpt5 and Mcpt6 are both encoded in protease gene clusters, Mcpt5 within the chymase 
locus on chromosome 14 and Mcpt6 within the tryptase locus on chromosome 17 (Gurish et 
al., 1993; Wong et al., 2004) and are, therefore, flanked by several other genes, mostly 
protease genes, many of which were included in the BAC clones. Given that, most probably, 
multiple copies of the gene constructs integrate into the genome, it seemed advisable to 
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remove other genes from the BAC inserts as far as possible in order to avoid effects of 
altered gene dosage in the transgenic mice. Therefore, the BAC inserts were shortened. In 
case of the Mcpt5 containing BAC insert, all known open reading frames could be removed 
still leaving abundant upstream and downstream sequence flanking Mcpt5. In the Mcpt6 
BAC, two genes, Tpsg1 and Tpsab1, encoding for the membrane bound protease mTMT and 
for mMCP-7, respectively, were located in close proximity of the Mcpt6 gene and were, 
therefore, not eliminated. In case of the Tpsab1 gene, no gene dosage effects were expected 
as mMCP-7 is not expressed in C57BL/6 mice due to a point mutation (Hunt et al., 1996).  
The neighboring chymase and tryptase genes of the original BAC inserts are homologous to 
each other in variable extend (Gurish et al., 1993; Wong et al., 2004) which may increase the 
risk of undesired recombination events during the construction process. Therefore, 
homologous regions for modification of the BAC were carefully chosen to avoid unwanted 
recombination events and, after the last modification step, i.e. removal of the ERT2 cassette, 
it was essential to test the integrity of the BAC clones. The shortening of the BAC inserts 
precluded informative comparison of restriction digest patterns of the modified with those of 
the original BAC clones. Therefore, the integrity of the sequences upstream of the translation 
start of Mcpt5 and Mcpt6 was investigated with Southern blot analysis. Even though, the final 
constructs had undergone at least five modification steps, integrity of the BAC transgenes 
within the analyzed regions could be demonstrated. It seems likely that the risk for unwanted 
recombination had been minimized by the initial elimination of neighboring genes with a high 
grade of homology.  
3.1.2 The Mcpt5 and Mcpt6 promoters allow efficient Cre expression 
in mast cells 
The four new Cre transgenic lines demonstrated that the Mcpt5 and Mcpt6 promoters allow 
efficient and cell type-specific expression of Cre recombinase in mast cell since in Mcpt5-Cre 
and Mcpt6-Cre R26R-EYFP double positive mice, a Cre-mediated activation of reporter gene 
expression could be detected in dermal as well as in peritoneal mast cells. These results 
could be confirmed in the model for inducible ablation of mast cells in A-Mcpt5-Cre iDTR 
double positive mice. In these animals, peritoneal and dermal mast cells as well as CTMCs 
located in the submucosal layers of the stomach were efficiently depleted reflecting Cre 
expression in basically all CTMCs located at these anatomical sites. The detection of EYFP 
reporter gene expression in skin mast cells by flow cytometry was hampered by the low 
numbers of mast cells in the skin cell suspensions. However, in A-Mcpt5-Cre/iDTR mice 
treated with high dosages of diphtheria toxin (DT), it could be demonstrated that all skin mast 
cells are susceptible to DT-induced cell depletion and, therefore, must express Cre. In the X-
Mcpt5-Cre line, females showed Cre-mediated recombination in only about half of the mast 
Discussion  58 
cells most likely due to random inactivation of the X-chromosome carrying the transgene. 
Incomplete inactivation of particular genes may be advantageous if an attenuation of a 
severe phenotype is desired.  
Importantly, in Mcpt5-Cre iDTR double positive mice treated with DT, CTMCs of the stomach 
were efficiently depleted whereas the MMCs within the mucosal epithelium were still present. 
This result clearly demonstrates that the Mcpt5 promoter is not active in MMCs and neither in 
mast cell progenitors that can give rise to both, CTMCs and MMCs. This result was 
unexpected since Mcpt5 expression was demonstrated on the RNA and protein levels in 
BMMCs as well as on RNA level in BMCPs, a common precursor for basophils and mast 
cells, found in the spleen of adult mice (Arinobu et al., 2005). Both, BMMCs and BMCPs, 
were shown to give rise to CTMCs as well as MMCs in vivo (Arinobu et al., 2005; Nakano et 
al., 1985). Therefore, we expected to observe Cre-mediated recombination in both mast cell 
populations in Mcpt5-Cre mice. However, only a small portion of BMMCs showed Cre-
mediated activation of reporter gene expression in all four Cre lines (A- and X-Mcpt5-Cre as 
well as A73- and A74-Mcpt6-Cre) after eight weeks of culture. These results were supported 
by a report about expression and localization of mMCP-5 in secretory granules of BMMCs. 
The analysis of cytospins of an eight week old BMMC culture revealed mMCP-5 only in 
BMMCs carrying electron dense granules which could be detected only in a fraction of 
BMMCs (McNeil et al., 1992a). Various reports suggest that the classification of murine mast 
cells into two subpopulations, with CTMCs expressing the proteases mMCP-4, -5, -6 and 
MC-CPA and MMCs expressing mMCP-1 and -2, may be too static. Friend et al. could show 
that mast cells can change their protease expression pattern during infection with the 
helminth Trichinella spiralis. In addition to the mast cell populations expressing either mMCP-
5 or mMCP-1 and -2, these authors detected populations with a transitional phenotype 
displaying either mMCP-5 and mMCP-2 or mMCP-2 expression alone (Friend et al., 1996). 
Furthermore, the typical localization of these cell populations can deviate during immune 
responses. In a model for colon cancer that suggests an important role for mast cells in 
tumor formation, mMCP-6 but also mMCP-2 positive mast cells were found abundantly within 
the mucosal epithelium of the polyps in Rag-/- mice (animals devoid of T and B cells) 
(Gounaris et al., 2007). Whether these mMCP-6 expressing cells are MMCs with an altered 
protease pattern or CTMCs that moved into the epithelial layer was not determined. 
However, both examples, T. spiralis injection and polyp formation, show that protease 
expression is not necessarily restricted to a distinct mast cell population and that both, 
Mcpt5- and Mcpt6-Cre mice, may be useful also in the elucidation of mast cell functions 
during immune responses at the mucosal surfaces.   
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3.1.3 Cre-mediated deletion is restricted to mast cells  
Analysis of hematopoietic cells other than mast cells revealed that the Mcpt5 and Mcpt6 
promoters are highly specific for mast cells. When choosing these promoters, we were aware 
of the risk of non-mast cell-specific Cre expression in cell types that share a common 
precursor with mast cells. Until today it is controversially discussed whether committed mast 
cell progenitors (MCP) are directly derived from multipotential progenitors in the bone 
marrow (Chen et al., 2005) or whether they can originate from myeloid precursors (Arinobu 
et al., 2005). In the hands of Arinobu et al. the common myeloid progenitor (CMP) as well as 
the granulocyte/monocyte progenitor (GMP) could also differentiate to mast cells. The 
absence of Cre expression in cells of the myeloid lineage in Mcpt5- and Mcpt6-Cre mice 
argued against expression of mMCP-5 and -6 in CMPs or GMPs. Furthermore, Arinobu and 
coworkers detected a basophil/mast cell progenitor (BMCP) in the spleen. In culture, these 
cells, defined as Lin-c-Kit+FcγRII/IIIhiβ7hi, exclusively gave rise to committed MCP and 
basophil progenitor cells (BaP) which differentiated into mast cells and basophils, 
respectively. They found Mcpt1 and Mcpt5 mRNA in BMCPs as well as in MCPs suggesting 
that an expression of the Cre recombinase in these progenitor cells had to be expected in 
Mcpt5-Cre transgenic mice, in which case Cre-mediated deletion of loxP-flanked sequences 
would occur not only in mast cells but also in basophils. Interestingly, splenic basophils did 
not display any Cre-mediated activation of reporter gene expression. Additionally, in A-
Mcpt5-Cre iDTR double positive mice treated with DT basophils were still present in normal 
numbers. Therefore, the detection of Mcpt5 RNA in BMCPs might reflect a fraction of these 
cells that already is committed for mast cells or the activity of the Mcpt5 promoter is too low 
for successful Cre-mediated recombination. Given that BMCPs also can supply the intestine 
with MCPs which differentiate into MMCs, it is more likely that the Mcpt5 promoter is active at 
low level that is not able to drive Cre expression at levels necessary for Cre-mediated 
recombination.  
The only notable Cre expression outside the mast cell compartment was detected in NK cells 
of Mcpt5-Cre but not in Mcpt6-Cre mice. NK cells were identified either as CD49b/NKG2D 
double positive or NKG2D single positive cells. About 9% of the CD49b+NKG2D+ subset of 
NK cells displayed Cre-mediated recombination while in less than 1% of NKG2D single 
positive cells reporter gene expression could be detected. The CD49b+ NK cells represent a 
subset that is characterized by a high cytotoxic activity while CD49b is down regulated in 
proliferating NK cells (Arase et al., 2001). This suggests that mMCP-5 is up regulated in a 
fraction of activated NK cells.  
All mice designated as A-Mcpt5-Cre are progeny of a single F1 animal derived from the 
original founder. However, the progeny of another F1 animal displayed non-specific Cre-
mediated recombination in variable fractions of all non-mast cell populations analyzed. This 
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finding could reflect a chimerism of the founder animal. Two independent integrations might 
have occurred in the embryo in two different cells that both gave rise to germ cells. The 
additional transgene present in the unspecific substrain may have been subject to position 
effects that lead to ubiquitous expression of the transgene. In contrast, no unspecific reporter 
gene expression (except for the small fraction of the NK cell subset described above) could 
be detected in the substrain finally designated as A-Mcpt5-Cre.  
3.1.4 Absence of Cre-mediated genotoxicity in Mcpt5-Cre mice 
The Cre recombinase has been shown to mediate genotoxicity in some Cre transgenic or 
Cre knock in mice. Mammalian genomes contain cryptic or pseudo loxP sites which occur 
with an estimated frequency of 1.2 per megabase and which can serve as functional 
recognition sites for Cre (Schmidt-Supprian and Rajewsky, 2007). Permanent and high levels 
of Cre expression can, therefore, cause growth arrest or even cell death. Thus, the difficulty 
in Cre transgenic animals is to achieve Cre expression levels high enough for efficient Cre-
mediated deletion of loxP-flanked target genes but low enough to avoid Cre-mediated 
genotoxicity. Even though the protease mMCP-5 is abundantly expressed in mast cells, in 
Mcpt5-Cre mice we found no difference in mast cell numbers or proliferation of mast cells ex 
vivo in response to stem cell factor indicating that Cre-mediated genome damage is not a 
prominent feature of these mice. Two factors could contribute to this finding. First, the 
transgene contains a loxm2 site and, therefore, Cre-mediated recombination should reduce 
transgene copy number. This may result in initial high levels of Cre expression with 
subsequent reduction of Cre activity. Second, the analysis of the Mcpt5 promoter suggests a 
silencer located between 470 bp and 2200 bp upstream of the transcription start. The 
expression of a luciferace reporter gene in a plasmid containing only the first 470 bp of the 
promoter was 30-fold higher than in a plasmid containing 2200 bp of the promoter region 
(Morii et al., 1997). Thus, the presence of a silencer and the reduction of copy numbers after 
Cre expression may result in ideal Cre expression levels.  
In Mcpt6-Cre mice, the proliferative potential ex vivo has not been analyzed yet. However, 
the reduced frequency of mast cells in the peritoneal cavity of these mice could be due to 
Cre-mediated genotoxicity. Like the Mcpt5-Cre transgene, also the construct for the Mcpt6-
Cre mice contains a loxm2 site and one can, therefore, expect a similar reduction of copy 
numbers upon Cre expression as described above. The presence of a potential silencer 
element like in the Mcpt5 promoter is not known (Morii et al., 1996; Ogihara et al., 1999). In 
the case of significant Cre-mediated genotoxicity potential applications of the Mcpt6-Cre lines 
will be limited. However, DT-mediated mast cell ablation may be particularly efficient in these 
mice which will, therefore, be crossed to the iDTR strain.   
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3.1.5 Attempt to generate mice with inducible, mast cell-specific Cre 
activity 
In contrast to the mast cell-specific Cre lines with constitutively active Cre recombinase, no 
functional founder line for tamoxifen-inducible Cre recombinase activity could be identified.  
Since it is known that orally administered tamoxifen is metabolized in the liver to 4-OH-
tamoxifen (Kamal and Goetz, 2007) which has a high affinity to the CreERT2 domain (Feil et 
al., 1997), it was expected that tamoxifen treatment will result in Cre activity in mast cells. To 
rule out that the CreERT2 cassette was non-functional, e.g. due to disturbed folding of the Cre 
polypeptide in the presence of the ERT2 domain, we deleted the ERT2 cassette by Flp-
mediated recombination in vivo. However, also offspring from Mcpt5-CreERT2 R26R-EYFP 
Flp-deleter breedings did not show any or only very low reporter gene expression in 
peritoneal mast cells. Constitutive expression of Flp recombinase in the mice most likely 
results in a reduction of transgene copy numbers since frt sites of neighboring copies will 
recombine. This reduction of transgene copies may contribute to a low level of Cre 
expression. Thus, it is difficult to assess whether the inefficient Cre-mediated reporter gene 
activation was due to inefficient induction of Cre activity by tamoxifen application or whether 
the transgenes were not functional. Since after tamoxifen administration, significant reporter 
gene expression could not be detected in any of the animals, it is more likely that Cre 
expression from the transgenes was too low to drive tamoxifen-induced Cre-mediated 
recombination. This inefficiency could be due to the integration of truncated constructs or to 
position effects at the integration site. In conclusion all five Mcpt5-CreERT2 transgenic lines 
have been considered as non-functional and new founder lines will be generated.  
 
3.2 A new model for inducible ablation of mast cells in vivo 
The relevance of mast cells in innate as well as in adaptive immune responses has been 
investigated using mast cell-deficient KitW/Wv and KitWsh/Wsh mice in most in vivo studies. These 
models suffer inherent technical limitations as described above. Alternatively, inducible 
ablation of mast cells was achieved by the administration of antibodies directed against the 
c-Kit receptor which abrogated the survival signal mediated by SCF (Brandt et al., 2003; 
Gekara and Weiss, 2008). As c-Kit is also expressed on hematopoietic progenitor cells, other 
hematopoietic lineages are invariably affected especially by long-term administration of the 
anti-c-Kit antibody (Gekara and Weiss, 2008). Therefore, mast cell research would benefit 
considerably from new models of mast cell deficiency that are not dependent on 
compromised Kit function. The availability of a mouse strain for conditional expression, i.e. 
controlled by Cre-mediated recombination, of a diphtheria toxin receptor (DTR) under the 
control of the ROSA26 promoter (Buch et al., 2005) and of the novel mast cell-specific Cre 
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transgenic mouse lines generated in the setting of the present thesis, provided a possibility to 
inducibly ablate mast cells in adult mice without affecting other hematopoietic cell 
populations. In the second part of this thesis it could be demonstrated that in diphtheria toxin 
(DT) treated A-Mcpt5-Cre iDTR double positive mice, connective tissue type mast cells can 
be efficiently depleted. Interestingly, the recovery of the mast cell populations in the tissues 
was very slow. Thus, this system provides a useful tool for the investigation of mast cell 
functions even in long-term experiments.  
3.2.1 Efficient ablation of connective tissue mast cells in adult mice 
The DTR-based system for inducible ablation of cell populations has been successfully 
applied by other groups for depletion of hematopoietic cell populations like T cells, B cells 
(Buch et al., 2005), dendritic cells (Jung et al., 2002), Langerhans cells (Bennett et al., 2005) 
or regulatory T cells (Lahl et al., 2007). The regimens for the DT treatment differ depending 
on the target cell type. While efficient ablation of T or B cells required multiple administrations 
of DT, splenic dendritic cells as well as Langerhans cells were efficiently ablated within 24 h 
after a single DT injection. In A-Mcpt5-Cre iDTR double positive mice, close to 100% of 
peritoneal mast cells were depleted 24 h after a single DT injection, while skin mast cells 
were not affected at that time point. The depletion efficiencies obtained using the various 
injection protocols suggested that ablation of skin mast cells requires high doses of the toxin 
and that skin mast cells undergo DT induced apoptosis with a slow kinetic. The 
administration of high DT doses at short intervals caused clinical signs like lethargy, hunch 
back and substantial weight loss and finally resulted in lethality consistent with observation of 
Jung and coworkers (Jung et al., 2002). This lethality probably results from a systemic 
inflammatory response due to contamination of the DT solution by endotoxins or from DT 
effects mediated by the low affinity mouse DTR. While toxic and, therefore, not applicable for 
most experimental questions, the highly efficient ablation of even skin mast cells achieved by 
high DT doses showed that, in principle, all skin mast cells can be ablated demonstrating that 
close to 100% of mast cells in the skin express Cre recombinase under the control of the 
Mcpt5 promoter. In the ear pinna mast cell depletion was most difficult, but with high DT 
dosages basically all mast cells could be eliminated at this location (data not shown) ruling 
out the possibility that the mast cell population in the ears do not express Cre. Our final 
injection regimen with four injections of 25 ng DT/g bodyweight at weekly intervals resulted in 
efficient depletion of skin mast cells, but did not cause macroscopically evident disease. 
Whether skin mast cells are less sensitive to the toxin or whether toxin delivery into the skin 
is inefficient is not clear. The efficient depletion with high doses supports the assumption of 
pharmacokinetic problems. However, Bennett and coworkers were able to deplete 
Langerhans cells (that reside in the epidermis) with a single i.p. injection of 16 ng/g 
bodyweight within 24 h (Bennett et al., 2005). It is known that DT induces apoptosis in 
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proliferating as well as in non-proliferating cells (Saito et al., 2001) indicating that the resting 
phenotype of skin mast cells is not the reason for the slow depletion.  
With the final injection protocol, i.e. four times 25 ng/g bodyweight at weekly intervals, neither 
control nor double positive animals showed any macroscopic signs of slowly progressive 
disease observed after high dosage administration. However, some few and exclusively Cre-
positive animals died within three days after the first injection. This sporadic lethality was 
most likely due to release of mediators from the dying mast cells that caused anaphylaxis. 
This assumption was supported by a successful prevention of this problem by administration 
of the H1-antagonist pyrilamine together with the first DT injection. The H1-antagonist reliably 
prevented death after the initial DT application. Mast cell degranulation upon DT exposure in 
vivo will be verified in future experiments by testing for degranulation markers in peritoneal 
lavage fluid, like e.g. β-hexosaminidase. An interference of pyrilamine treatment with 
experimental results is not expected since experiments will in general be started about four 
weeks after the injection of the H1-antagonist along with the first DT administration. 
Moreover, pyrilamine has a short half life of less than 24 hours (Kelly and Slikker, 1987). 
Buch et al. raised the question whether repetitive DT injections induce a humoral response 
against the toxin. They demonstrated a moderate antibody response that was without 
neutralizing effect (Buch et al., 2005). Consistent with these results, we found that even the 
fourth DT injection three weeks after the first treatment further improved the depletion 
efficiency ruling out an antibody response with neutralizing effect in this regimen of DT 
application.  
In summary, the Mcpt5-Cre/iDTR system allows reliable depletion of CTMC without affecting 
other cell types and without significant toxicity when using a single dose of an H1-antagonist 
along with the first DT treatment. Thus, this model for inducible ablation of mast cells in adult 
mice provides a useful and versatile tool for the investigation of mast cell functions.  
3.2.2 Reduced anaphylactic response in mast cell-depleted animals 
Anaphylaxis is an acute, life-threatening allergic reaction most commonly triggered by 
antigen crosslinking of IgE bound to the high affinity IgE receptor (FcεRI) on mast cells and is 
characterized by a systemic release of mediators like histamine, leukotrienes and 
prostaglandins. In the model for IgE-mediated passive systemic anaphylaxis, mice are 
sensitized by injection of an IgE antibody directed against an allergen resulting in loading of 
FcεRI with antigen-specific IgE. Upon antigen encounter, FcεRI are crosslinked via IgE and 
trigger the degranulation of mast cells. In the mast cell depleted A-Mcpt5-Cre/iDTR 
transgenic mice, we observed a significantly impaired anaphylactic response as compared to 
controls. However, the anaphylactic response was not completely abolished. This was most 
likely not due to low efficiency of CTMC depletion because efficient ablation of peritoneal 
mast cells was demonstrated in those mice. This finding raised the question whether residual 
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mast cells in other tissues than the peritoneal cavity, foremost MMCs, and/or other cell types 
are the reason for the residual anaphylactic response.  
Choi et al. showed that mast cells were dispensable in a model of IgE-mediated active fatal 
anaphylaxis induced by penicillin V in KitW/Wv mice (Choi et al., 1998). Since FcεRI in the 
mouse is exclusively expressed on basophils and mast cells (Kawakami and Galli, 2002), 
basophils were most likely the mediators of the anaphylactic response in the model of Choi 
and coworkers. In contrast, in another model of anaphylaxis an anti-IgE monoclonal antibody 
(mAb) failed to induce anaphylaxis in mast cell-deficient mice (Strait et al., 2002). In the 
same study it was demonstrated that MMCs respond with degranulation to anti-IgE mAb as 
assessed by increased serum levels of mMCP-1. In conclusion, in DT treated A-Mcpt5-Cre 
iDTR double positive mice which are basically devoid of CTMCs but have normal MMC and 
basophil numbers it seems likely that both cell types contribute to the residual anaphylactic 
response. Our result clearly demonstrates that the selective depletion of CTMCs has a 
significant impact on the anaphylactic response and that basophils and MMCs are not 
sufficient to completely substitute CTMC functions in this model.   
3.2.3 Slow recovery of mast cell populations after induced ablation  
The iDTR/DT system has been used previously for the ablation of other hematopoietic cell 
populations like dendritic cells, Langerhans cells and macrophages. In these models the 
DTR was expressed under the control of the CD11c promoter (Jung et al., 2002), langerin 
promoter (Bennett et al., 2005; Kissenpfennig et al., 2005) or CD11b gene regulatory 
elements for macrophage specific DTR expression (Cailhier et al., 2005). The restoration of 
these cell types after DT-mediated ablation was found to occur within six days for splenic 
dendritic cells and about four days for peritoneal macrophages after a single DT injection. 
While Bennett et al. reported that Langerhans cells do not repopulate the epidermis during 
four weeks after a single injection of DT, Kissenpfennig et al., who independently generated 
another langerin-DTR strain, demonstrated that Langerhans cell depletion persisted for only 
six to seven days.  
We found that peritoneal mast cells did not repopulate the peritoneal cavity significantly 
before twelve weeks. Eight weeks after the last DT injection only 8% of normal mast cell 
numbers were found while after twelve weeks mast cell numbers reached 34% of normal.  
The restoration of skin mast cells was even slower than the repopulation of the peritoneal 
cavity. Mast cell numbers in the skin gradually increased until eight weeks after DT treatment 
to 25% of normal mast cell numbers. But, unexpectedly, at the following two time points, i.e. 
eleven and 15 weeks, mast cell numbers substantially decreased again to only 13-15% of 
normal numbers. The consistent results for the week eleven and 15 demonstrated that the 
decline after eight weeks was not due to heterogeneity of mast cell numbers at the different 
sites of back skin from which the biopsies were taken. The decline after day 56 may suggest 
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an exhaustion of progenitor cells in the skin. The source of progenitors for the mast cell 
repopulation may be the multipotent stem cells residing in the bulge region of hair follicles (in 
case of skin repopulation (Kumamoto et al., 2003)), bone marrow or spleen, anatomical sites 
demonstrated to be reservoirs for mast cell progenitors (Arinobu et al., 2005; Chen et al., 
2005; Pennock and Grencis, 2004). Upon infection of mice with either Schistosoma mansoni 
(Khalil et al., 1996) or Trichinella spiralis (Arinobu et al., 2005), an expansion of progenitors 
in the bone marrow and spleen has been detected. Whether an enlargement of these 
progenitor pools is also evident after induced mast cell depletion remains to be determined. 
The signals that are responsible for the recruitment of progenitors from these reservoirs are 
largely unknown. An important factor known to regulate mast cell numbers is SCF (Galli et 
al., 1994; Shelburne and Ryan, 2001). This is reflected in the absence of mast cells in the Kit 
receptor mutant (KitW/Wv and KitWsh/Wsh) or SCF mutant (Sl/Sld) mice. SCF is, therefore, a good 
candidate to locally act as a chemoattractant for mast cell precursors in the various tissues. 
In accordance with this concept, Tsai and coworkers demonstrated that the intradermal 
injection of SCF into mast cell-deficient Sl/Sld mice resulted in accumulation and proliferation 
of mast cells in the skin reflecting the recruitment, proliferation and/or maturation of mast cell 
progenitors (Tsai et al., 1991). In DT-treated mast cell-depleted mice the presence of SCF in 
the skin as well as the effects of recombinant SCF injected into the dermis has to be 
investigated in future experiments. Usually this growth factor is expressed in the skin as a 
transmembrane protein on keratinocytes that can be cleaved by mast cell chymases to its 
soluble form, which is as bioactive as the membrane bound form (Longley et al., 1997). 
Tomimori et al. demonstrated that the accumulation of mast cells in a model of dermatitis 
was abolished by application of chymase inhibitors and that the intradermal injection of a 
chymase resulted in an increased mast cell density (Tomimori et al., 2002b). Longley et al. 
and Tomimori et al., therefore, suggest that the release of chymases by mast cells 
represents a positive feedback loop in which increased amounts of soluble SCF boost mast 
cell proliferation and/or precursor recruitment and maturation and that this positive feedback 
might promote the pathogenesis for example of mastocytosis and various forms of 
inflammatory skin disease. Apart from the suggested pathological role of chymases, this 
mechanism may also play a role in the steady state homeostasis of mast cells in the skin. On 
the basis of these observations one can hypothesize that in DT-treated mice, a decline of 
released chymases might result in a reduction of soluble SCF that is necessary for the 
recruitment of progenitor cells.  
The induction of dermatitis in KitW/Wv mice by epicutaneous administration of phorbol 12-
myristate 13-acetate (PMA) results in the development of mature mast cells in the skin at the 
treated site in this mast cell-deficient strain but not in Sl/Sld mice (Gordon and Galli, 1990b) 
demonstrating again that SCF is essential for the recruitment and maturation of mast cell 
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progenitors. Mast cell development in KitW/Wv mice after induction of immune responses was 
also observed by other groups (Metz et al., 2007). Thus, it will be interesting to investigate 
whether repopulation of the skin and peritoneal cavity of DT-treated mast cell-depleted mice 
will be accelerated under inflammatory conditions. In future experiments using our Mcpt5-
Cre/iDTR system it will be of great importance to assess whether an accumulation of mast 
cells occurs at sites of inflammation in the mast cell-depleted mice. In that case the DT 
treatment could be intensified and prolonged or DT could also be applied locally since we 
have shown that local administration results in highly efficient ablation of mast cells (data not 
shown).  
Our new system for inducible ablation of mast cells represents a useful tool for the 
investigation of mast cell functions. The persistence of mast cell depletion makes the model 
suitable for long-term experiments. In addition, the A-Mcpt5-Cre/iDTR system should allow 
new insights into the mechanisms of steady state homeostasis of mast cell populations and 
mast cell homing to tissues in healthy mice and mast cell recruitment during immune 
responses.  
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4 Materials and Methods  
4.1 Chemicals and enzymes 
Unless otherwise specified, all standard chemicals were purchased from Roth (Karlsruhe), 
Merck Biosciences (Darmstadt), Serva (Heidelberg) or Sigma-Aldrich (München). 
Restriction endonucleases, Taq polymerase, Shrimp Alkaline Phosphatase (SAP), 
Exonuclease I and Proteinase K including the respective buffers were obtained from NEB 
(Frankfurt am Main) or Fermentas life sciences (St. Leon-Rot).  
4.2 Bacterial cell culture  
4.2.1 LB (Luria Broth) medium and agar 
1% peptone (w/v), 0.5% yeast extract (w/v), 1% NaCl (for high salt) or 0.5% NaCl (for low 
salt) (w/v), optional 1.5% Select Agar (w/v) (for LB agar plates, Invitrogen, Karlsruhe) in 
ddH2O 
4.2.2 Antibiotics 
All antibiotics were purchased from Sigma except zeocin (InvivoGen, Toulouse). 
antibiotic stock solutions 
final concentration for 
low copy vectors high copy vectors 
chloramphenicol  30 mg/ml in 100% ethanol 15 µg/ml 50 µg/ml 
ampicillin  100 mg/ml in ddH2O 50 µg/ml 100 µg/ml 
tetracycline 10 mg/ml in 75% ethanol 3 µg/ml 10 µg/ml 
kanamycin 30 mg/ml in ddH2O 15 µg/ml 50 µg/ml 
zeocin 100 µg/ml in ddH2O 25 µg/ml in low salt LB medium 
 
Table 4.1 Antibiotics applied for BAC modification and subcloning. The final concentration in LB 
medium as well as in LB agar plates is dependent on the copy number of the extra-chromosomal 
DNA except for zeocin that was always used in a concentration of 25 µg/ml. 
 
4.2.3 Escherichia coli (E. coli) strains 
E. coli strain genotype 
DH10B F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 endA1 araD139 
∆ (ara, leu)7697 galU galK λ- rpsL nupG /pMON14272 / pMON7124 
HS996 F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 deoR araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::IS2 
DH5α F- φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) gal- phoA supE44 λ- thi-1 gyrA96 relA1  
 
Table 4.2 E. coli strains used in this thesis as hosts for smaller plasmids or BAC vectors. DH10B 
were the BAC hosts for the clones purchased from the RZPD, HS996 was kindly provided by 
Youming Zhang (Gene Bridges) and DH5α were purchased from Invitrogen. 
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4.3 Oligonucleotides  
Table 4.3 Oligonucleotides used in this thesis were purchased from Metabion (Martinsried) 
 
No.  name sequence template 
Sequencing of Cre and genotyping of Mcpt5-Cre, Mcpt6-Cre and Mcpt5-CreERT2 mice 
P1 Mcpt5-CreUP 5'ACAGTGGTATTCCCGGGGAGTGT Mcpt5 promoter 
P2 Mcpt6-CreUP 5'AGACTCCTGGGATGAACCTGCCCT Mcpt6 promoter 
P3 CreSeq1b-DO 5'GTCAGTGCGTTCAAAGGCCA iCre 
P4 Mcpt5-Ex1-DO3 5'GCTTTGGTGCTGGAACCCAGGA Mcpt5 Exon1 
P5 Mcpt5-Ex1seq-DO 5'TGAGAAGGGCTATGAGTCCCA Mcpt5 Intron1 
P6 CreSeq1-UP 5'CCCTGGTGATGAGGAGAATC iCre 
P7 CreSeq2b-DO 5'CCATGTCCCTGGCAGCACCCA iCre 
P8 CreSeq2-UP 5'GCCTGATCTATGGTGCCAAGG iCre 
P9 CreSeq3b-DO 5'CCACAAAGCCTGGCACCCTCTTC ERT2 
P10 CreSeq3-UP 5'CCAGACCCTTCAGTGAAGCT ERT2 
P11 CreSeq4b-DO 5'CCTCCAGCAGCAGGTCATAGAG ERT2 
P12 CreSeq4-UP 5'CCCACATCAGGCACATGAGT ERT2 
P13 CreSeq5b-DO 5'GGATCTCCATTCGCCATTCAG SV40 PolyA 
P14 CreSeq5-UP 5'GCACATCCCCCTTTCGCCA SV40 PolyA 
Test for full length integration in Mcpt6-Cre founder mice 
P15 AmpTest-UP 5'GTGCGCGGAACCCCTATTTG ampicillin resistance 
cassette P16 AmpTest-DO 5'GGTCCTCCGATCGTTGTCAGAAG 
P17 ZeoTest-UP 5'GGAAGTTCGTGGACACGACCTC zeocin resistance 
cassette P18 ZeoTest-DO 5'GCACAGTCAAGGCCGAGAATG 
Genotyping of mouse strains other than Mcpt5- and Mcpt6-Cre mice 
P19 ROSA26-UP 5'CCAAAGTCGCTCTGAGTTGTTATC ROSA26 promoter 
P20 R26stopDO1 5'GCGAAGAGTTTGTCCTCAACC STOP cassette 
P21 ROSA26-DO2 5'GGAGCGGGAGAAATGGATATG wt ROSA26 locus 
P22 Flp-UP 5'CACTGATATTGTAAGTAGTTT Flp gene 
P23 Flp-DO 5'CTAGTGCGAAGTAGTGATCAG Flp gene 
P24 DelCre-UP 5'GAAAGTCGAGTAGGCGTGTACG CMV promoter 
P25 DelCre-DO 5'CGCATAACCAGTGAAACAGCAT nlsCre 
P26 iDTR-UP1 5'GGAAAGTCCGTGACTTGCAAGAG iDTR 
P27 iDTR-DO 5'TCAGTGGGAATTAGTCATGCC iDTR 
Sequencing of the promoter region of Mcpt5 and Mcpt6 genes 
P28 M5ProSeq1-UP 5'CATATTTGGGCCTTAGGCTTATTACTC 
Mcpt5 promoter 
P29 M5ProSeq1-DO 5'GGATGGTTAAGCAGAAAGGACCC 
P30 M5ProSeq2-UP 5'CCTGAAAGAGAAGAGATGGCATG 
P31 M5ProSeq2-DO 5'GCCAAGAGATATAAGCCAATGCTG 
P32 M5ProSeq3-UP 5'GCTCTGCATCGGTGAGAGCAAGC 
P33 M5ProSeq3-DO 5'CCCAACAGGCTTACAATGATGTAC 
P34 M5ProSeq4-UP 5'CCCAGTGTTCCAAGACATGAG 
P35 M5ProSeq4-DO 5'CCCCATCTGTTCTTCTGACAC 
P36 M5ProSeq5-UP 5'CCTTCCTAAAAATGTTTCCAGAGCTAC 
P37 M5ProSeq5-DO 5'CTTCTAACGGTCATGCTTAGGCAC 
P38 M5ProSeq6-UP 5'CTGCATGTGTCCCTCGCTGACC 
P39 M5ProSeq6-DO 5'GTGAAATACAAATCAGAGACAGGAGCG 
P40 M5ProSeq7-UP 5'CCTCTGCTAAGAAAAGACACCGCTC 
P41 M5ProSeq7-DO 5'CAGAAGGATGCCTGAGTTGGAC 
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P42 M6ProSeq1-UP 5'GCATTTCCTTGGGCATTTCACCGC 
Mcpt6 promoter 
P43 M6ProSeq1-DO 5'CATCTGGAAGCAGTGAGGAGCAC 
P44 M6ProSeq2-UP 5'GCTGATGAAATGCTCTATGAAGGG 
P45 M6ProSeq2-DO 5'GGAAAGGGGTATCTTCTGAGGG 
P46 M6ProSeq3-UP 5'CAGAATTCTTGGGAGTACTAGGAG 
P47 M6ProSeq3-DO 5'GAGGGGGGTGGGTATCAGAC 
P48 M6ProSeq4-UP 5'GCATCCAGCAGCCCTGAATTCTG 
P49 M6ProSeq4-DO 5'CCTGCATGCACCATTGAATCG 
P50 M6ProSeq5-UP 5'CTAGGCAGTCCTTGATCCGACC 
P51 M6ProSeq5-DO 5'GGCTGATAACCTCACTCTGAGTC 
P52 M6ProSeq6-UP 5'CCAGACCATGAGGTTGTGTGC 
P53 M6ProSeq6-DO 5'GTGTAGGACAGTGACTTAGCTATCC 
P54 M6ProSeq7-UP 5'GGCCTTGAGTGTTCAGCCAATGAG 
P55 M6ProSeq7-DO 5'GGGTCATTAGCTGTCATACAGTC 
Generation of the probes for Southern blot analysis 
P56 M5Probe1-UP 5'CTGGATAAGAGTTAGAAGTCTCAG 
insert DNA upstream 
of Mcpt5 
P57 M5Probe1-DO 5'GCCCTGCCTAGAGTCAGGTAATG 
P58 M5Probe2-UP 5'GCCCAGAGATGGTCCCACCCA 
P59 M5Probe2-DO 5'CCTGCCACTAGCTCCACAGGT 
P60 M5Probe3-UP 5'CGGTCTATTTCCCCACAGGCT 
P61 M5Probe3-DO 5'CCCTAACGTCCGTCCAATGGTC 
P62 M5Probe4-UP 5'CCCAGACATCCTGTACCTGGT 
P63 M5Probe4-DO 5'GGTTGTCCTCTGAGAGGCTCTAC 
P64 M5Probe5-UP 5'GGGCATAGTTTCCCTCCTTGTG 
P65 M5Probe5-DO 5'GCCCATGAACATACAAGAAGCC 
P66 M5Probe6-UP 5'GGCTGACTGTACGAATTGAAAGGC 
P67 M5Probe6-DO 5'CGGTTTGGATGGAGGTTGGTATC 
P68 M6Probe1-UP 5'CCCATCTGCTCAAGGCTCAGC 
insert DNA upstream 
of Mcpt6 
P69 M6Probe1-DO 5'CCAGTGAGAGTCCTGTGGACC 
P70 M6Probe2-UP 5'GGCTCCTATCAATTTGCTGTGCTC 
P71 M6Probe2-DO 5'CCTGGATGAGCGAATCCTGTG 
P72 M6Probe3-UP 5'GGGTTGAGCTGAGCGTATCTG 
P73 M6Probe3-DO 5'GCCTTTGTCATGGTGTCTCTTC 
P74 M6Probe4-UP 5'GGTCGTGCAGAGCACCAGGAAC 
P75 M6Probe4-DO 5'GCCAGCAATCTTGGTGAGTGTG 
P76 M6Probe5-UP 5'GGCACTCAGAACCATACCAGATTC 
P77 M6Probe5-DO 5'CCATGTTGAGGTGAGACTGTTAG 
P78 M6Probe6-UP 5'GCCAGGAGCCTTCTTGAGACC 
P79 M6Probe6-DO 5'GGCAGAGTTCAGAGATGCAACTGC 
  
 
 
4.4 Standard molecular biology methods 
4.4.1 Polymerase chain reaction and colony PCR 
The polymerase chain reaction (PCR) was used for various applications like the 
amplification of DNA cassettes for the insertion into BAC vectors, sequencing and 
genotyping. In a standard protocol 10-100 ng template DNA was amplified with 1x 
reaction buffer, 2 mM MgCl2, 200 nM each primer, 200 µM dNTP mix and 0.05 U/µl Taq-
Polymerase were used (Fermentas Life Sciences except primers). For most applications, 
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the template DNA was denatured at 95°C for 5 min fo llowed by 30-35 cycles of 45 sec at 
95°C, 1 min at the appropriate annealing temperatur e and 1 min per kb DNA to be 
amplified at synthesis temperature (72°C). Amplific ation was completed with a final 
synthesis step at 72°C for 7 min. The optimal annea ling temperature of the primers was 
estimated with the following formula: TA=59.9+0.41(GC%)-600/L (GC%, GC content in 
percent, L, total number of base pairs).  
Colony PCR was used to verify successful modifications of BAC vectors. Single bacterial 
cell colonies were resuspended in 5 µl ddH2O in PCR tubes and pre-incubated at 95°C for 
5 min to lyse the bacteria. 45 µl of the PCR mastermix were added, samples were mixed 
by tapping and further processed as described above.  
4.4.2 DNA sequencing 
The sequencing was commercially performed by Seqlab Sequencing Laboratories, 
Göttingen. 25 ng template DNA/100 bp (maximum 5 µl) was used for each sequencing 
reaction (usually gel purified PCR products). In case of unpurified PCR products used as 
templates, the samples were pretreated with 4 U SAP (Shrimp Alkaline Phosphatase) and 
10 U Exonuclease I, in order to remove primers and dNTPs. The samples were mixed, 
centrifuged briefly and incubated for 30 min at 37°C followed by inactivation of SAP and 
Exonuclease at 80°C for 30 min. 5 µl of the process ed PCR products and 20 pmol of 
primer were used for sequencing.  
4.4.3 Gel purification of DNA fragments 
PCR products or DNA restriction fragments were loaded on a 1% agarose gel and 
submitted to gel electrophoresis. The DNA fragment of interest was cut from the gel and 
extracted from the agarose matrix using the QIAEX II Gel Extraction Kit (Qiagen, Hilden) 
following the manufacturer’s instructions.  
4.4.4 Small and intermediate scale preparation of plasmid DNA 
The isolation of small amounts of plasmid DNA was performed according to Qiagen 
protocols and as described in section 4.5.4 for BAC DNA isolation using buffers P1 to P3.  
Higher amounts of plasmid DNA were isolated from bacterial cells using the Qiagen 
Plasmid Midi Kit following the manufacturer’s instructions. The purified plasmid DNA was 
dissolved in TE buffer pH 8.0 (10 mM TrisCl pH 8.0, 1 mM EDTA).  
4.4.5 Quantification of DNA 
The concentration of DNA was determined by measuring absorption at 260 nm and 
280 nm (A260 and A280). An A260 of 1 corresponds to a concentration of approximately 
50 µg/ml of double stranded DNA. The purity of the DNA can be assessed by calculating 
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the ratio of A260/A280 with 1.8 reflecting pure DNA. A ratio below or above 1.8 indicates 
protein or RNA contamination, respectively. Alternatively, DNA concentrations were 
estimated in an agarose gel after electrophoresis by comparing the band intensities with a 
standard.  
4.4.6 Restriction digest 
DNA was enzymatically cleaved by restriction endonucleases (NEB and Fermentas Life 
Sciences) using the appropriate enzyme buffers. Following the manufacturer’s 
instructions, 1 U was used to digest 1 µg of DNA at 37°C in most instances.  
4.4.7 Southern blot  
Southern blot analysis was performed according to standard procedures and bound 
probes were detected by chemoluminescence.  
4.4.7.1 Buffers 
Liquid Block: Delivered with the Gene Images Random Prime Labeling and CDP-Star 
Detection Kit (Amersham/GE-Healthcare, Munich). Aliquots were stored at -20°C. 
Denaturation and transfer buffer: 0.4 M NaOH, 0.6 M NaCl in ddH2O 
Neutralization buffer: 0.5 M TrisCl, 1 M NaCl in ddH2O, pH 7.2 
20x SSC: 0.3 M NaCitrate, 3 M NaCl in ddH2O, pH 7.0. 
Hybridization buffer: 5x SSC, 0.1% SDS (w/v), 5% Dextransulfate (w/v), 5% Liquid Block 
(v/v) in ddH2O, incubate 2 h at 65°C to facilitate the dissolvin g of the Dextransulfate. 
Buffer A: 100 mM TrisCl, 300 mM NaCl in ddH2O, pH 9.5 
Blocking buffer: Liquid Block 1:10 diluted in buffer A, 0.1% NaAzide (w/v)  
Anti-fluorescein AP conjugate solution: 0.5% BSA (w/v), AP conjugate (enclosed in the 
CDP-Star Detection Kit) 1:5000 in buffer A 
Wash buffer 1: 1x SSC, 0.1% SDS (w/v) in ddH2O 
Wash buffer 2: 0.5x SSC, 0.1% SDS (w/v) in ddH2O 
Wash buffer 3: buffer A with 0.3% Tween 20 (v/v, Serva) 
Substrate: CDP-Star detection reagent enclosed in the CDP-Star Detection Kit 
4.4.7.2 Blotting 
DNA was digested with restriction enzymes, loaded on a 0.7% agarose gel and submitted 
to gel electrophoresis in TAE buffer. The gel was cut to an appropriate size and 
photographed together with a ruler. In order to denature the DNA, the gel was incubated 
in denaturation/transfer buffer for 30 min. The DNA was transferred to the PoraBlot NY 
plus membrane ( Macherey-Nagel, Düren) by alkaline transfer by capillary force. For this 
purpose the gel was placed onto three sheets of pre-wetted Whatman paper (3 mm) the 
margins of which were connected to a reservoir of transfer buffer. The membrane was 
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placed on top of the gel followed by three additional pre-wetted sheets of Whatman paper 
and dry paper towels (at least 6 cm in height) topped by a weight. After over night blotting, 
the membrane was incubated in neutralization buffer for 5 min and subsequently dried at 
80°C for 2 h.  
4.4.7.3 Probe labeling 
Purified PCR products or restriction fragments to be used as probes were labeled with 
fluorescein coupled dCTPs using the Gene Images Random Prime Labeling Kit following 
the manufacturer’s instructions. Briefly, approximately 100 ng of template DNA was 
denatured in a volume of 20 µl at 99°C for 5 min an d placed on ice. A mastermix 
consisting of the dNTP mix (which included the labeled dCTPs), the primer mix for random 
priming and the Klenow fragment, was added to the denatured DNA and the sample was 
incubated for 1 h at 37°C. The reaction was stopped  by addition of EDTA (final 
concentration 20 mM). The probe was kept on ice or stored at -20°C prior to the 
hybridization.  
4.4.7.4 Hybridization and detection 
The hybridization buffer as well as the hybridization tubes were pre-heated at 65°C. The 
membrane was wetted in 5x SSC, placed into a hybridization tube and pre-incubated in 
hybridization buffer without probe at 63°C for 2 h in a hybridization oven, before freshly 
denatured probe was added. After overnight incubation at 63°C, the membrane was 
washed with wash buffer 1 and subsequently with wash buffer 2 each time for 15 min at 
65°C. To reduce unspecific binding of the AP conjug ate, the membrane was incubated for 
1 h in blocking buffer at RT. During the subsequent incubation of the membrane with anti-
fluorescein AP conjugate at RT for 1 h, the antibody bound to the fluorescein labeled 
dCTPs of the probes. The membrane was washed thrice with wash buffer 3, each step for 
15 min at RT. The substrate solution was pipetted onto the membrane and after 5 min, an 
Amersham HyperfilmTM was exposed for 15 min to 2 h. 
 
4.5 Molecular biology methods for modification of BAC 
vectors 
4.5.1 BAC clones 
BAC clones used in this thesis were part of the RPCI-23 mouse BAC library (library No. 
731 (Osoegawa et al., 2000)). Fragments of C57BL/6 genomic DNA, partially digested 
with EcoRI, were cloned into EcoRI sites of pBACe3.6 vector. For each clone, both ends 
of these inserts were sequenced generating “end sequences” which define the 
chromosomal location of the genomic fragment. The BAC clones indicated in Table 4.4 
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were purchased from the RZPD (Deutsches Ressourcenzentrum für Genomforschung 
GmbH, Berlin) and propagated in DH10B E. coli cells at 37°C in chloramphenicol 
conditioned medium. Glycerol stocks were generated by adding 300 µl of sterile glycerol 
to 900 µl of an over night culture. The mixture was frozen on dry ice and stocks were 
stored at -80°C. 
 
BAC clone  
(RZPD clone ID) 
chromosomal position of 
genomic inserts [bp] gene of interest synonyms 
RP23-284A14 
(RPCIB731A14284Q2) Chr. 14, 56471619 – 56678625  Mcpt5 Cma1 
RP23-240F3 
(RPCIB731F3240Q2) Chr. 17, 25433400 – 25606599  Mcpt6 Tpsb2 
Table 4.4 BAC clones from the mouse BAC library RPCI-23 used in this thesis  
 
4.5.2 BAC recombineering 
The modification of BAC vectors was performed by homologous recombination using the 
Red/ET recombination system (“ET-cloning”, patent-registered by Gene Bridges, 
Dresden). The Red/ET recombination system relies on the plasmid pRedET encoding the 
Redα/Redβ protein pair which mediates homologous recombination. In addition the 
plasmid carries the gene coding for the Redγ protein that prevents the RecBCD complex 
of the intrinsic recombination system of the BAC host from degrading linear DNA 
fragments. The genes for the Redαβγ proteins are organized in an operon under the 
control of the L-arabinose inducible pBAD-promoter. Therefore, transcription is respressed 
by an AraC dimer until L-arabinose binds to this repressor. The plasmid is a derivate of 
the thermo-sensitive, low copy pSC101 replicon (oriR101) and includes the RepA protein 
which is necessary for replication and distribution of the plasmid to the daughter cells. As 
RepA is temperature-sensitive, cells have to be propagated at 30°C while the expression 
of the Redαβγ proteins requires 37°C and L-arabinose. This has t he advantage that the 
expression of the recombinases can be limited to a short time window since the copy 
number of the plasmid decreases rapidly at 37°C, th ereby minimizing the occurrence of 
undesired additional recombination events.  
In principle, the BAC host is first transformed with the plasmid pRedET (which also 
encodes a tetracycline resistance) and propagated by 30°C. In a second step, the 
expression of Red α, β and γ is induced by addition of L-arabinose, the temperature is 
switched to 37°C and the BAC host is transformed wi th a PCR product encompassing the 
5’ and 3’ homology regions (HR) for the homologous recombination and DNA sequence to 
be integrated into the BAC. The homologous recombination event replaces the sequence 
of the BAC that is flanked by the HRs (Fig. 4.1).  
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Fig. 4.1 Principle of Red/ET recombination. The BAC host is transformed with the plasmid 
pRedET and propagated at 30°C. In a second step the  expression of the Red α, β and γ is induced 
by addition of L-arabinose and a temperature switch to 37°C. The PCR product containing 
homology regions (HR) is electroporated into the BAC host and product recombines with the BAC 
vector.  
 
4.5.2.1 Templates and sources of DNA cassettes 
The selectable markers, i.e. the ampicillin (amp), zeocin (zeo) and neomycin (Neo) 
resistance cassettes, were amplified from pBluescriptII KS+, psiRNA-hH1zeo (InvivoGen) 
and pR6K-PGK-gb2-Neo (Gene Bridges), respectively. The minimal vector for subcloning 
by homologous recombination was based on pACYC184 (NEB). The iCre sequence 
together with the frt-flanked estrogen binding domain was subcloned from the plasmid 
pCreERT2Amp, kindly provided by Giuseppe Testa, Milan.  
4.5.2.2 Primer design and generation of the PCR product containing the 
HRs 
Oligonucleotides containing the HR sequences were purchased from Metabion, 
Martinsried. The HRs were usually 50 bp homologous to a target of the vector to be 
modified. The design of the primers depended on the application of the BAC 
recombineering method. The replacement of BAC sequences by a DNA cassette 
required amplification of the cassette using primers that also contained the HR 5’ and 3’ 
of the BAC sequence to be replaced. In addition to the HRs, these primers can optionally 
contain restriction sites. Thus, from 5’ to 3’, the primers are composed of (1) the HR, (2) 
optional restriction site and (3) primer for the amplification of the selectable marker.  
In order to subclone DNA sequences from a vector by homologous recombination, a 
minimal vector that encompasses a resistance gene and an origin of replication was 
amplified from plasmid DNA. Note, that the forward primer for amplification of the minimal 
vector contained the HR 3’ of the cassette to be subcloned and the reverse primer the 5’ 
pRedET
BAC vector
BAC host
Step 1
30°C
HRHR
Step 2
1. + L-arabinose
2. + PCR product
37°C
modified BAC
HR HR
HR HR
homologous 
recombination
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HR, respectively. In this way, the minimal vector replaces the vector backbone and 
incorporates the desired DNA fragment (see also Fig. 2.3, section 0).  
For the generation of these PCR products, the plasmids used as templates were digested 
with restriction enzymes prior to amplification. About 1-5 µg plasmid DNA were incubated 
in 20-50 µl samples with restriction endonucleases that do not cleave within the part to be 
amplified. 1 µl of cleaved plasmid DNA was used as template without further processing. 
The resulting PCR product was precipitated with 2.5 volumes of 100% ethanol and 
0.1 volumes of 3 M NaAc pH 5.2 and washed twice with 70% ethanol. After resuspension 
of the air dried DNA pellet in ddH2O, the PCR product was used for electroporation into 
the BAC host. The cleavage of the plasmid DNA prior to PCR prevents the 
electroporation of circular template DNA and, thus, reduces the occurrence of false 
positive colonies containing the template plasmid only.  
4.5.2.3 BAC modification protocol 
BAC modification was largely done according to the manual of the “Quick and Easy BAC 
Modification Kit” (Gene Bridges, Dresden) with some modifications. All bacterial cell 
propagation steps during the BAC modification procedure were performed in selective LB 
medium in 1.5 ml microcentrifuge tubes with a punctured lid. The bacterial cells were 
incubated in a thermomixer (Eppendorf, Hamburg) at 1100 rpm. All electroporation steps 
were done using electroporation cuvettes (Bio-Rad, Munich) with a 1 mm gap and the 
Electroporator 2510 (Eppendorf, Hamburg). Optimal electroporation results were 
obtained at a voltage of 1350 V and a time constant of 5-6 ms. Before starting, ddH2O 
and electroporation cuvettes were chilled on ice and the benchtop centrifuge was cooled 
to 2°C. Fast handling of the bacteria and careful c ooling of each sample on ice whenever 
possible were prerequisites for successful electroporation. The following protocol 
includes the preparation of electro-competent cells.  
 
Step 1: electroporation of the pRedET plasmid 
− Inoculate 1 ml LB medium supplemented with the respective antibiotic (15 µg/ml 
chloramphenicol (Cm) in case of the BAC clones from the library RPCI-23) with one 
colony of the BAC host.  
− Cultivate cells overnight at 37°C. 
− Transfer 30 µl of the overnight culture into 1.4 ml LB-medium containing the same 
antibiotic and incubate at 37°C for 2 h.  
− Centrifuge for 30 sec at 11,000 rpm, discard supernatant by quickly inverting tube 
twice, resuspend pellet in 1 ml cold ddH2O by vortexing. 
− Repeat the previous step. 
− Centrifuge again and discard supernatant leaving a volume of about 40 µl in the 
tube.  
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− Add 1 µl pRedET (0.2 – 0.5 µg). 
− Mix briefly by pipetting up and down, transfer the cell/DNA mixture into a chilled 
cuvette and electroporate. 
− Ad 1 ml LB medium without antibiotic to the electroporated cells and transfer them 
back into the same microcentrifuge tube. 
− Incubate at 30°C for 70 min. 
− Plate 100 µl of the cells on LB agar plates containing Cm and tetracycline (Tet, 
3 µg/ml). 
− Incubate at 30°C overnight to 24 h. 
Step 2: L-arabinose induction and electroporation of the PCR product 
− Inoculate 1 ml LB medium containing Cm and Tet with one colony from the plate 
obtained in step 1 and incubate overnight at 30°C. 
− Inoculate two tubes with 1.4 ml LB-medium conditioned with Cm and Tet with 30 µl 
of the overnight culture and incubate 2 h at 30°C. 
− Add 20 µl 10% (w/v) L-arabinose (Sigma, in ddH2O, aliquots stored at -20°C) to one 
tube, incubate 40 min at 37°C. The second tube serv es as a negative control 
without induction of Red/ET recombination. 
− Electroporate the PCR product (0.1-0.2 µg in 1-2 µl) as described in step 1. 
− Plate cells harboring the modified BAC and uninduced control cells on LB agarose 
plates containing Cm and the appropriate antibiotic selecting for correctly 
recombined clones and incubate overnight at 37°C. T he ratio of colonies on the 
induced and uninduced plates should exceed 100:1. 
− Identify clones with correct recombination events by colony PCR.  
4.5.3 Cre- and Flp-mediated recombination in E. coli 
In order to remove loxP- or frt- flanked sequences from BAC vectors in E. coli, the BAC 
hosts were transformed with the expression vector 706-Cre or 706-Flp (Gene Bridges, 
Dresden). Transformation and further handling of the bacteria were done according to the 
manufacturer’s instructions. Briefly, the transformation was performed by electroporation 
as described above and successfully transformed bacteria selected for Tet resistance. 
Bacteria were streaked out on LB agar plates containing the appropriate antibiotics and 
were incubated for at least 24 h at 30°C. 2 ml LB m edium samples were inoculated with 
single colonies and incubated 2-3 h at 30°C and ove rnight at 37°C. The temperature 
switch to 37°C induced the expression of the Cre or  Flp recombinase. To test for deletion 
of the loxP- or frt-flanked sequence, PCR was performed on 1 µl of the bacterial culture 
following the protocol for the colony PCR. To be sure that the 2 ml bacterial cultures were 
each derived from a single colony, BAC DNA was isolated according to the small scale 
preparation protocol for BAC DNA (section 4.5.4) and re-transformed into DH10B cells by 
electroporation.  
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4.5.4 Small scale preparation of BAC DNA 
2 ml overnight cultures were prepared in 2 ml Eppendorf tubes with a punctured lid and 
incubated in a thermomixer at 37°C and 1100 rpm. Af ter centrifugation at 11000 rpm the 
pellet was resuspended in 200 µl buffer P1 (50 mM TrisCl pH 8.0, 10 mM EDTA, 
100 µg/ml RNase A (Sigma)). Bacterial cells were lysed by adding 200 µl of buffer P2 
(200 mM NaOH, 1% SDS (w/v)), carefully inverting the tube and incubating at room 
temperature (RT) for 5 min. 200 µl of buffer P3 (3 M KAc, pH 5.5) were added, samples 
were gently mixed by inverting and centrifuged at 11000 rpm for 5 min. The supernatant 
was transferred into 1.5 ml microcentrifuge tubes and DNA was precipitated by adding 0.7 
volumes of isopropanol. The samples were mixed by inverting (but not vortexing in order 
to avoid shearing of the large DNA molecules). DNA was centrifuged and washed once 
with 70% ethanol, dried briefly and dissolved in TE buffer.  
4.5.5 Purification of BAC DNA for pronucleus injection 
The isolation and purification of BAC DNA suitable for pronucleus injection were done as 
described by Sparwasser et al. (Sparwasser et al., 2004) with modifications as detailed in 
the following.  
4.5.5.1 Buffers and reagents 
All buffers were prepared in ddH2O unless otherwise specified and, if possible, 
autoclaved. All buffers and reagents were exclusively prepared and used for the BAC 
purification. (*: Buffers freshly prepared prior each BAC DNA preparation) 
Solution I: 10 mM EDTA, pH 8.0 
Solution II*: 0.2 M NaOH, 1% SDS (w/v) (prepare 1% SDS solution and then add slowly 
NaOH) 
Solution III*: 1.9 M KAc, adjusted to pH 5.5 with glacial acetic acid, pre-cooled on ice 
(use 7.5 M KAc for fresh preparation of solution III)  
Resuspension buffer I: 10 mM TrisCl pH 8.0, 50 mM EDTA, pre-heated to 37°C 
Resuspension buffer II: 50 mM TrisCl pH 8.0, 50 mM EDTA  
1xTAE: 40 mM TrisCl, 20 mM NaAc, 1 mM EDTA  
Injection buffer: 10 mM TrisCl pH 7.5, 0.1 mM EDTA, 100 mM NaCl (autoclaved and 
further purified by filtration through a 0.2 µm filter) 
TE buffer: 10 mM TrisCl pH 8.0, 1 mM EDTA  
Reagents: 7.5 M KAc, 10% SDS (w/v), glacial acetic acid, isopropanol, RNase A 
(10 mg/ml) , phenol/chloroform/isoamylalcohol 25:24:1 (Fluka, Ulm), chloroform 
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4.5.5.2 Maxi preparation of BAC DNA 
− Pellet bacterial cells of a 250 ml over night culture at 6.000 g and 4°C for 15 min. 
− Resuspend pellet in 20 ml Solution I, incubate 5 min at RT. 
− Carefully add 40 ml of Solution II, mix gently by swirling the bottle for 5 sec, incubate 
5 min at RT. 
− Carefully add 30 ml Solution III, mix gently by swirling the bottle, incubate 15 min on 
ice. 
− Centrifuge at 6000 g for 20 min at 4°C and filter supernatant through a gauze swab 
into a clean bottle. 
− Centrifuge again at 6000 g for 20 min at 4°C and t ransfer supernatant into a clean 
bottle through a 70 µm cell strainer. 
− Add 45 ml isopropanol and pour the mixture into a clean bottle allowing the phases 
to mix. 
− Centrifuge at 6000 g for 15 min at 4°C, discard su pernatant and aspirate remaining 
liquid using a water-jet vacuum pump. Air-dry the pellet briefly. 
− Resuspend DNA pellet in 9 ml pre-heated resuspension buffer I by swirling gently. 
− Pour DNA containing solution into a 30 ml capped centrifuge tube and add 4.5 ml of 
7.5 M KAc, mix by inverting the tube gently (precipitate should form). Place the tube 
at -80°C for 30 min. 
− Thaw at RT and centrifuge at 4000 g in swinging buckets for 10 min at 4°C. While 
spinning, prepare another 30 ml tube with 27 ml 100% ethanol. Pour the supernatant 
onto the ethanol and mix gently by inverting the tube in order to precipitate the DNA.  
− Centrifuge at 4000 g for 10 min, discard the supernatant, aspirate excess 
supernatant with the water-jet vacuum pump and briefly air-dry the pellet.  
− Resuspend DNA in 700 µl resuspension buffer II and add 10 µl RNase A, incubate 
for 1 h at 37°C. 
− Transfer the DNA solution to a 1.5 ml microcentrifuge tube and add 700 µl 
phenol/chloroform/isoamylalcohol 25:24:1, mix gently until phases are mixed, 
centrifuge 5 min and transfer the aqueous phase into a clean tube. 
− Repeat the previous step. 
− Repeat previous step but this time extract with pure chloroform.  
− Transfer the aqueous phase into a clean tube and precipitate with 700 µl 
isopropanol, mix gently, centrifuge for 20 min and discard the supernatant.  
− Wash DNA pellet with 500 µl 70% ethanol, centrifuge for 5 min. Discard the 
supernatant and briefly air-dry the pellet. 
− Dissolve BAC DNA in 50-100 µl TE pH 8.0 or ddH2O (for enzymatic digest). 
 
4.5.5.3 Separation of the BAC insert from the vector backbone 
In order to separate the BAC insert from the vector backbone, the BAC DNA was 
submitted to NotI digest (for Mcpt5-Cre and Mcpt5-CreERT2) or AscI/BstBI double digest 
(for Mcpt6-Cre). For each construct, two digests were prepared, one 200 µl sample for the 
pronucleus injection containing the total BAC DNA yield of one maxi preparation and one 
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100 µl sample containing DNA of a second maxi preparation for indicator lanes (see 
below). Both samples were prepared with 1x reaction buffer, 1x BSA, RNase A (final 
concentration 10 µg/ml) and enzyme in excess and incubated over night at 37°C.  
The gel electrophoresis was performed under ethidium bromide free conditions using a 
0.6% (w/v) agarose gel. The total 200 µl sample was loaded into two slots. 20 and 40 µl of 
the 100 µl sample were loaded into the two adjacent slots on each site of the lanes of 
interest serving as indicator lanes. Electrophoresis was performed at 5 V/cm for about 4 h 
at 4°C. Afterwards, the indicator lanes were separa ted from the lanes containing the DNA 
for pronucleus injection and were stained with ethidium bromide. To protect the DNA from 
the UV light, the unstained gel was placed onto a sterile aluminum foil strip on a UV 
transilluminator with the indicator lanes on both sites allowing the excision of the BAC 
insert DNA from the unstained gel.  
4.5.5.4 Electroelution 
The Elutrap® Electroelution System (Whatman) was used to extract the BAC insert DNA 
from the agarose gel slice. The electroelution device was assembled following the 
manufacturer’s instructions and placed into the same chamber used for the 
electrophoresis described in the previous section. The electrophoresis chamber was 
sealed with tape left and right of the Elutrap® device to avoid leakage current. The gel 
slice was placed into the large compartment of the device and the chamber as well as the 
Elutrap® device was filled with TAE buffer. A voltage of 6 V/cm for 4.5 h at 4°C was 
applied. Thereby, the insert DNA passed the BT2 membrane but not the BT1 membrane 
and, thus, was trapped in the small compartment between both membranes, called the 
trap (Fig. 4.2). Before recovering the DNA from the trap, the current was inverted for 
20 sec to mobilize DNA that may have adhered to the BT1 membrane. The pure DNA was 
recovered from the trap by pipetting.  
 
Fig. 4.2 Elutrap® Electroelution System (Whatman). In principle, the DNA is extracted from an 
agarose gel piece placed in the large compartment by a current directed through the Elutrap 
device in the indicated direction. While the BT2 membrane is permeable for DNA the BT1 
membrane is not, thus, the DNA is collected in the small compartment between the BT2 and BT1 
membrane (trap).  
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4.5.5.5 Drop dialysis 
In order to exchange the TAE buffer against the buffer required for pronucleus injection, 
the recovered DNA from the electroelution was submitted to drop dialysis. For this 
purpose, a MF-Millipore membrane filter with 25 nm pore size (#VSWP 02500, Millipore, 
Schwalbach) was placed onto 30 ml injection buffer in a 10 cm cell culture dish. 100 µl of 
DNA in TAE buffer were pipetted on top of the filter and the dish was capped tightly. After 
30 min the drop now containing purified BAC insert DNA dissolved in injection buffer was 
removed from the filter.   
4.5.5.6 Pulsed-field gel electrophoresis 
The isolated BAC insert DNA was tested for its integrity und purity by pulsed-field gel 
electrophoresis (PFGE) using the CHEF-DR III variable angle system (Bio-Rad, 
München). The PFGE was performed in 0.5x TBE (45 mM Tris-borate, 1 mM EDTA). A 
1% PeqGold Pulsed-Field agarose gel (Peqlab, Erlangen) placed in the middle of the 
hexagonal chamber was loaded with DNA. The Mid Range PFG Marker I  embedded in 
agarose (Peqlab) was used as a size standard. The PFGE was performed with an initial 
switch time of 0.2 sec, a final switch time of 25 sec, 6 V/cm for 16 h and at a buffer 
temperature of 12°C. Afterwards, the gel was staine d with 0.5 µg/ml ethidium bromide in 
ddH2O for 20 min. Excess ethidium bromide was removed by washing with ddH2O for 10-
20 min.  
4.5.6 Generation of transgenic mice by pronucleus injection 
The pronucleus injection of purified BAC DNA into fertilized C57BL/6 oocytes was done by 
Ronald Naumann, Transgenic Core Facility, MPI of Molecular Cell Biology and Genetics, 
Dresden. The injected oocytes were transferred into pseudopregnant foster mice. 
Transgenic offspring were identified by PCR using genomic tail DNA as template.  
 
4.6 Mice 
4.6.1 Mouse strains  
All mice were on the C57BL/6 background and crossed exclusively to C57BL/6 mice. 
Beside the newly generated Mcpt5-Cre and Mcpt6-Cre strains, the following mouse lines 
were used in this thesis: R26R-EYFP Cre excision reporter (Srinivas et al., 2001), 
tg(CMV-Cre) that mediates a germline deletion of loxP-flanked DNA (Schwenk et al., 
1995), transgenic hACTB::FLP ubiquitously expressing the Flp recombinase (Dymecki, 
1996a) and ROSA26-iDTR (Buch et al., 2005). Mice were kept under specific pathogen 
free (SPF) conditions and all experiments were done according to institutional guidelines.  
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4.6.2 Genotyping 
4.6.2.1 Isolation of genomic tail DNA 
Mouse tail tips, about 0.5 cm in length, were incubated overnight at 55°C rocking in 500 µl 
lysis buffer (200 mM TrisCl, 100 mM NaCl, 1% SDS (w/v), 50 mM EDTA) supplemented 
with 100 µg Proteinase K (Fermentas Life Sciences). Undigested material was 
sedimented by centrifugation and the supernatant was poured into a fresh 1.5 ml 
microcentrifuge tube containing 500 µl isopropanol. The samples were mixed by inverting 
the tubes several times. The precipitated DNA was pelleted by centrifugation and washed 
once with 70% ethanol. The air dried DNA pellet was dissolved in TE buffer by incubating 
at 55°C shaking for at least 2 h.  
4.6.2.2 Genotyping protocols 
Mice were genotyped by PCR using the standard PCR program (see section 4.4.1) with 
varying annealing temperatures (TA) and cycle numbers. Primers used for genotyping are 
listed in Table 4.3. 
PCR strain primer PCR product TA and cycle number 
Mcpt5-Cre Mcpt5-Cre P1/P3/P4 wt: 224 bp Mcpt5-Cre: 554 bp TA=57°C, 30 cycles 
Mcpt6-Cre Mcpt6-Cre P2/P3 Mcpt6-Cre: 553 bp TA=63°C, 12 cycles  TA=58°C, 18 cycles 
Mcpt5-
CreERT2 
Mcpt5-
CreERT2 P12/P5 
Mcpt5-CreERT2: 
1097bp 
TA=63°C, 12 cycles  
TA=58°C, 18 cycles 
ROSA26-
STOP 
R26R-EYFP 
ROSA26-iDTR P19/P20/P21 
wt:600 bp 
R26-STOP: 300 bp 
TA=54°C, 12 cycles  
TA=51°C, 18 cycles 
iDTRspez ROSA26-iDTR P26/P27 iDTR: 450 bp TA=56°C, 12 cycles  TA=52°C, 18 cycles 
FlpDel ACTB::FLP P22/23 FlpDel: 725 bp TA=54°C, 12 cycles  TA=51°C, 18 cycles 
DelCre tg(CMV-Cre) P24/25 DelCre: 600 bp TA=58°C, 35 cycles 
 
Table 4.5 Protocols for genotyping of the indicated mouse strains by PCR, the corresponding 
primer sequences are listed in Table 4.3 under the respective primer numbers.  
 
Note that in transgenic mice, it is not possible to distinguish between heterozygous and 
homozygous mice by PCR. Therefore, transgenic mice were never crossed to each other. 
In case of the Mcpt5-Cre typing, a third primer (P4) was used that amplified together with 
the upstream primer (P1) a product representing the wt Mcpt5 locus. This PCR product, 
which should always be present, served as an internal control of that PCR. 
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4.6.3 Procedures of animal experimentation 
4.6.3.1 Administration of tamoxifen  
CreERT2 positive mice were treated orally with tamoxifen (free base, Sigma) since it is 
known that tamoxifen is metabolized in the liver to 4-OH-tamoxifen (Kamal and Goetz, 
2007) that binds with high affinity to the ERT2 domain (Feil et al., 1997). 400 mg of 
tamoxifen  were suspended in 400 µl 100% ethanol, mixed by vortexing. 19.6 ml 
sunflower oil (Sigma) were subsequently added to this mixture resulting in a 20 mg/ml 
tamoxifen suspension. To dissolve the tamoxifen in the oil/ethanol mixture, the 
suspension was vortexed for 5 min and subsequently sonicated. Single use aliquots were 
stored at -20°C and thawed at 56°C. The mice were t reated with 2 mg tamoxifen for five 
consecutive days by gastric intubation using a feeding needle (1.2 x 4 mm, Heiland, 
Hamburg). 100 µl tamoxifen were injected directly into the stomach by introducing the 
feeding needle through the esophagus. The tamoxifen was kept shaking at 56°C until 
injected.  
4.6.3.2 Administration of diphtheria toxin  
The 1 mg/ml stock solution of the diphtheria toxin (DT, Sigma) in pyrogen free ddH2O was 
stored in 6 µl aliquots at -80°C. Fresh aliquots we re thawed on ice for each treatment. The 
working concentration was 5 µg/ml. Thus, the 6 µl-aliquots were diluted 1:200 with 1.2 ml 
sterile PBS. Mice were injected intraperitoneally (i.p.) with 25-100 ng DT/g bodyweight 
with varying numbers of injections and treatment intervals. One injection protocol included 
the application of the H1-antagonist pyrilamine (pyrilamine maleate salt, Sigma) together 
with the DT. For this purpose 12 µl of a 100 mg/ml pyrilamine stock solution was added to 
the 1.2 ml DT working solution resulting in a dose of 5 µg/g bodyweight for the H1-
antagonist.  
4.6.3.3 Back skin biopsies 
Mice were anesthetized by i.p. injection of a Rompun (Bayer HealthCare)/Ketanest 
(Pfizer) solution (5% Rompum (v/v) and 10% Ketanest (v/v) in sterile isotonic saline). 10 µl 
of this solution per g bodyweight were injected. The mice were shaved and a skin fold was 
lifted from the back and fixed with two fingers on a sterile pad. One biopsy was taken at 
the edge of the skin fold using a 4 mm biopsy punch (Stiefel, Wächtersbach).   
4.6.3.4 Passive systemic anaphylaxis  
In the model of passive systemic anaphylaxis, mice were first sensitized with IgE directed 
against an allergen thereby loading the high affinity IgE receptor (FcεRI) on mast cells and 
basophils with allergen-specific IgE. Later, the mice were challenged with the respective 
allergen. For sensitization 12.5 µg mouse anti-DNP-IgE (clone SPE-7, Sigma) were 
injected i.p.. 24 h later, mice were challenged by i.p. injection of 400 µg DNP-HSA 
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(Sigma). The intensity of the anaphylactic response was assessed by measuring the drop 
of the body temperature every 10 min over a period of 3 h using the thermometer Bio-TK 
9882 (Bioseb, France) and the rectal probe BRET3.  
 
4.7 Cell culture 
4.7.1 Cell culture media and reagents 
Penicillin/Streptomycin:  100 U/ml penicillin, 0.1 mg/ml streptomycin (final 
concentrations, Biochrom AG, Berlin) 
L-Glutamine: 2 mM final concentration (Biochrom AG) 
Complete DMEM: DMEM medium (Gibco) supplemented with 10% FBS (Biochrom AG), 
50 µM β-mercaptoethanol, L-glutamine, penicillin/streptomycin  
WEHI-3B conditioned medium: Supernatant of IL-3 producing WEHI-3B cells purchased 
from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig). 
The medium was prepared by culturing 1x105 WEHI-3B cells in complete IMDM 
containing 10% FBS, 25 µM β-mercaptoethanol, L-glutamine and penicillin/ streptomycin 
for 3-4 days until cell density reached about 1x106 cells/ml. Cells were carefully mobilized 
from the culture dish bottom using a cell scraper, centrifuged and the supernatant was 
collected. 50 ml aliquots were stored at -20°C.  
Complete Opti-MEM: Opti-MEM (Invitrogen, Karlsruhe) supplemented with 10% FBS and 
penicillin/streptomycin 
SCF containing medium: Supernatant of murine SCF secreting CHO transfectants 
(generated by S. Lyman, Immunex, Seattle, and kindly provided by P. Dubreuil, Marseille). 
The CHO transfectants were cultivated in DMEM supplemented with 10% FBS, L-
glutamine, penicillin/streptomycin, 1 mM sodium pyruvate and splitted 1:10 every 2 days 
in 10 cm dishes. For collecting the supernatant, cells were seeded on 15 cm dishes and 
grown to confluency. 72 to 96 h later SCF containing supernatant was harvested. 50 ml 
aliquots were stored at -20°C.  
1x PBS: 10 mM Na2HPO4, 1.5 mM KH2PO4; 2.6 mM KCl, 136 mM NaCl, pH 7.4 
4.7.2 Cultivation of BMMCs 
Femur and tibia of both limbs from one mouse were removed under sterile conditions and 
flushed with complete DMEM using a 24 gauge needle. The bone marrow cells (BMC) 
were filtered through 70 µm and 40 µm cell strainers, subsequently centrifuged at 1200 
rpm for 5 min and washed twice with PBS. In order to lyse erythrocytes, the cell pellet was 
resuspended in erythrocyte lysis buffer (155 mM NH₄Cl, 10 mM KHCO₃, 1 µM EDTA, 
pH 7.3) and incubated for 5 min at RT. Cells were centrifuged, washed with PBS and the 
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pellet was resuspended in complete DMEM supplemented with 20% WEHI-3B 
conditioned medium. BMCs were cultured in a 50 ml culture flask at 37°C and 5% CO 2. 
Floating cells were transferred in a clean flask with fresh medium twice a week until no 
adherent cells were left. Thereafter, cells were fed by replacing half of the volume of the 
medium by fresh complete DMEM supplemented with WEHI-3B conditioned medium. 
After four to eight weeks, the culture should consist of more than 90% BMMCs which are 
identified flow cytometrically by means of their cell surface markers CD117 and FcεRIα 
(see section 4.8).  
4.7.3 Cultivation of PCMCs 
Peritoneal cell derived mast cells (PCMC) were generated as recently described by 
Malbec and coworkers (Malbec et al., 2007). Peritoneal cells were isolated under sterile 
conditions by peritoneal lavage using RPMI medium without supplements. Cells were 
sedimented at 1200 rpm for 5 min. The pellet was resuspended in 1 ml complete Opti-
MEM freshly supplemented with 4% SCF containing medium. The cells were seeded at a 
density of 1x106/ml complete Opti-MEM with 4% SCF containing medium into tissue 
culture dishes of appropriate size. 24 h later, non-adherent cells were removed and fresh 
medium was added to the adherent cells. In subsequent passages all cells were collected 
by transferring non-adherent and trypsinized adherent cells in the same Falcon tube. Cells 
were centrifuged, resuspended in fresh complete Opti-MEM with SCF and seeded at a 
density of 3x105/ml.  
 
4.8 Flow cytometry  
4.8.1 Buffers and reagents 
FACS buffer: 1x PBS, 0.5% (w/v) BSA (Serva), 2mM EDTA in ddH2O 
Collagenase IV (Worthington Biochemical Corp., Lakewood, NJ): 2 mg/ml in PBS, freshly 
prepared before use 
Propidium iodide (Sigma): 1mg/ml stock solution in ddH2O, working dilution 1:100, final 
concentration 0.5 µg/ml 
BD Pharm Lyse (BD biosciences): Erythrocyte lysis buffer, 1:10 diluted in ddH2O 
PBS: see section 4.7.1 
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4.8.2 Antibodies for flow cytometry 
specificity target cells host/isotype clone dye 
final 
dilution 
commercial 
source 
CD117 mast cells Rat IgG2b κ 2B8 APC 1:500 eBiosciences 
CD19 B cells Rat IgG2a κ 1D3 PE 1:100 BD-Pharmingen 
CD3ε T cells Armenian hamster IgG1κ 145-2C11 PE 1:100 BD-Pharmingen 
CD45 hematopoietic 
cells Rat IgG2b κ 30-F11 PE 1:100 BD-Pharmingen 
CD49b basophils/  NK cells Rat IgM κ DX5 APC 1:100 eBiosciences 
F4/80 macrophages Rat IgG2a κ BM8 PE 1:100 eBiosciences 
FcεRIα mast cells/ basophils 
Armenian 
hamster IgG MAR-1 PE 1:300 eBiosciences 
Gr-1 neutrophils Rat IgG2b κ RB6-8C5 PE 1:10 Miltenyi Biotec 
IgE mast cells/ basophils Rat IgG1 κ 23G3 PE 1:20 eBiosciences 
NKG2D NK cells Rat IgG1 κ CX5 PE 1:40 eBiosciences 
Siglec-F eosinophils Rat IgG2a κ E50-2440 PE 1:100 BD-Pharmingen 
       
Table 4.6 Monoclonal antibodies conjugated either with phycoerythrin (PE) or allophycocyanin 
(APC) used for flow cytometry. Stock concentrations of all antibodies were 0.2 mg/ml except of 
anti-IgE (0.1 mg/ml) and anti-Gr-1 (not specified).  
 
4.8.3 FACS staining 
The hematopoietic cells in the cell suspensions (described below) were identified by 
staining for cell surface markers. Unspecific binding of antibodies to Fc receptors via their 
invariable part of the heavy chain was avoided by blocking with anti-CD16/32 
(eBioscience) directed against the FcγIII and the FcγII receptor, respectively. 
Subsequently, cells were incubated with the antibodies listed in Table 4.6 in 50-100 µl 
FACS buffer for 30 min on ice. After two washing steps propidium iodide was added (final 
concentration 0.5 µg/ml) for the detection of dead cells. The samples were analyzed in a 
BD FACS Calibur equipped with a 488 nm and 633 nm laser.  
4.8.4 Single cell suspensions  
4.8.4.1 Peritoneal lavage 
Mice were sacrificed, the skin was removed from the peritoneum as far as possible and 
the peritoneal cavity was flushed with 4-7 ml cold FACS buffer. Cells were sedimented 
and the pellet resuspended in 1 ml FACS buffer.  
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4.8.4.2 Skin cell suspension 
Both ears and 1-2 cm2 of back skin were excised from shaved adult mice. The fat was 
removed from the back skin and both, ears and back skin, were minced thoroughly using 
two scalpels. The tissue mush from one mouse was suspended in 20 ml Collagenase IV 
(2 mg/ml). The suspension was aliquoted into 2 ml microcentrifuge tubes which were 
incubated for 1 h at 37°C and 1400 rpm in a thermom ixer. During this incubation, the 
tissue suspensions were mixed twice with a Pasteur pipette. The suspensions were 
poured over a 70 µm cell strainer and centrifuged at 300 g for 10 min at 4°C. The cell 
pellet was resuspended in 10 ml FACS buffer and poured over a 40 µm and subsequently 
over a 30 µm strainer. Cells were finally centrifuged at 250 g for 5 min at 4°C and 
resuspended in 2 ml FACS buffer.  
4.8.4.3 Spleen cell suspension 
The spleen was removed from the animal, smashed in a Petri dish containing DMEM 
medium using a plunger of a 2 ml syringe and rubbed through a 70 µm cell strainer. The 
Petri dish and the cell strainer were washed once and the resulting suspension was 
centrifuged. The cell pellet was resuspended and incubated for 5 min at RT in 8 ml 1:10 
dilution of BD Pharm Lyse solution in order to lyse erythrocytes. After additional 
centrifugation, cells were resuspended in 5 ml FACS buffer and finally filtered through a 
40 µm strainer.  
4.8.4.4 Enrichment of splenic granulocytes  
About 80% of spleen cells are B and T cells. Thus, granulocytes, in particular the 
basophils represent a rare population in this organ (about 0.04% of total spleen cells). In 
order to enrich granulocytes, spleen cell suspensions were separated into lymphocyte and 
non-lymphocyte fractions by magnetic activated cell sorting (MACS). T and B cells were 
labeled with anti-CD3ε-Biotin/anti-Biotin MicroBeads and anti-CD19 MicroBeads (Miltenyi 
Biotec, Bergisch Gladbach), respectively, and extracted from a total spleen cell 
suspension using LS columns (Miltenyi Biotec) following the manufacturer’s instructions. 
Briefly, the cells from one spleen (see section 4.8.4.3) were transferred into a FACS tube, 
centrifuged and resuspended in FACS buffer in the appropriate staining volume. The anti-
CD3ε antibody was added at a dilution of 1:25. Cells were incubated for 10 min at 4°C and 
washed once with FACS buffer. CD19 and anti-Biotin MicroBeads (1:10 and 1:5 final 
dilutions, respectively) were added to the cells in a total volume of 100 µl per 107 cells. 
After an incubation of 15 min at 4°C, cells were wa shed once and resuspended in 1 ml 
FACS buffer. The LS column was equilibrated with 3 ml of degassed FACS buffer. Cells 
were applied onto the column which was placed in a magnet and washed twice. The flow 
through was collected as the non-lymphocyte fraction. The T and B cells were recovered 
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after removing the column from the magnet by flushing it firmly with 5 ml FACS buffer 
using a plunger.  
 
4.9 Histology 
Skin samples were fixed in formalin over night and embedded in paraffin. 6 µm sections 
were stained with Giemsa following standard protocols. Mast cells were identified in 
Giemsa stained sections by means of their dark purple cytoplasmic granules. As the 
granules of mucosal mast cells, in contrast to those of connective tissue mast cells, are 
sensitive to formalin fixation, samples from the gastrointestinal tract were washed with 
PBS, fixed for 1 h in Carnoy’s solution (ethanol/Chloroform/ glacial acetic acid 6:3:1) and 
transferred to 100% ethanol and then to xylol for at least 2 h (each step). The tissue was 
embedded in paraffin and sections were stained with naphthol AS-D chloroacetate (CAE 
staining) serving as substrate for the chloroacetate esterase present in cytoplasmic 
granules of neutrophils and mast cells. In sections of the stomach mast cells appeared 
dark red and were localized between epithelial cells while neutrophils appeared pink and 
could be distinguished by their segmented nuclei.  
Mast cells were quantified as cells/mm2 by software supported determination of the area 
in which mast cells were counted (DISKUS software 4.50, Hilgers – Technisches Büro, 
Königswinter)  
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5 Abbreviations  
Ac acetate 
Amp ampicillin 
APC allophycocyanin 
BAC bacterial artificial chromosome 
BaP basophil progenitor 
BMC bone marrow cell 
BMCP basophil/mast cell progenitor 
BMMC bone marrow derived mast cells 
bp base pair 
BSA  bovine serum albumin 
Cm chloramphenicol 
CMP common myeloid progenitor 
Cre  causes recombination 
CTMC connective tissue mast cells 
d day 
dCTP desoxycytidine triphosphate 
ddH2O bidistilled water 
DMEM Dulbecco’s modified Eagle medium 
DNA desoxyribonucleic acid  
dNTP desoxyribonucleoside triphosphate 
DT diphtheria toxin 
DTR diphtheria toxin receptor 
E. coli Escherichia coli 
EDTA ethylene diamine tetraacetate 
ER estrogen receptor ligand binding domain 
EYFP enhanced yellow fluorescent protein 
FACS fluorescent activated cell sorting 
FBS fetal bovine serum 
g gravitational acceleration, 9.81 ms-1 
GMP granulocyte/monocyte progenitor 
h hours 
i.p. intraperitoneal 
Ig immunoglobulin 
IL interleukin 
kb kilobases  
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loxP locus of crossing (X)-over of P1 
LT leukotriene 
MACS magnetic activated cell sorting 
MCP mast cell progenitor 
MMC mucosal mast cells 
mRNA messenger ribonucleic acid 
Neo neomycin 
PAMP pathogen associated molecular pattern 
PBS phosphate buffered saline 
PCMC peritoneal cell derived mast cell 
PCR polymerase chain reaction 
PE phycoerythrin 
PG prostaglandine 
PMA phorbol 12-myristate 13-acetate 
rpm rounds per minute 
RT room temperature 
SDS sodium dodecylsulfate 
Sl steel locus 
SPF specific pathogen free 
SSC standard saline citrate buffer 
TA annealing temperature 
TE Tris-EDTA 
Tet tetracycline 
TLR toll-like receptor 
TNFα tumor necrosis factor α 
Tris Tris-(hydroxymethyl-)aminomethan 
U unit 
v/v volume per volume 
W white spotting locus 
w/v weight per volume 
wt wild type 
Zeo zeocin 
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